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Abstract
Parkinson’s disease is a highly prevalent neurodegenerative disorder. Several genes 
have been shown to be associated with familial Parkinson’s disease and they usually 
lead to Parkinson’s disease due to the presence of mutations that affect protein function. 
It has been suggested that variations in the expression of the wild type genes may also 
lead to Parkinson’s disease. The causes of idiopathic Parkinson’s disease remain 
unknown. Several factors may contribute to its onset, including: susceptibility genes, 
environmental stress and aging.
This study aimed to characterize the influence of oxidative stresses on the regulation of 
genes associated with Parkinson’s disease. The effects of oxidative stress on a- 
synuclein, parkin and PINK1 were investigated in a cell culture model. Both a - 
synuclein and parkin were similarly up-regulated when cells were exposed to stresses 
such as dopamine and l-methyl-4-phenylpyridinium (MPP+). In constrast, PINK1 
levels were up-regulated only by MPP+, and were down-regulated in both dopamine 
and MG 132 treatments. This work confirmed and extended previous reports that 
oxidative stresses are implicated in Parkinson’s disease, and also revealed the 
complexity of the regulation by these stresses.
A further study into the regulation of a-synuclein showed a novel interaction between 
the a-synuclein promoter and an Early Growth Response transcription factor family 
member in oxidative stress conditions. Moreover, this work demonstrated that several 
other neuronally expressed transcription factors influenced the regulation of a - 
synuclein, such as the product of the Parkinson’s disease associated gene, Nurrl. The 
decreased expression of this gene increased a-synuclein transcription. This is of 
interest, as variations in the levels of either of these genes can cause Parkinson’s disease 
and such an interaction was novel. This work further demonstrated that the POU family 
trancription factor, Bm3a, was involved in this pathway. Bm3a appeared to function 
antagonistically to Nurrl in a-synuclein regulation.
In addition to studies of gene regulation, mutational and/or protein analysis were 
performed on Nurrl and PINK1. Studies of PINK 1 protein established the functional 
importance of cleavage of precursor PINK1 and also provided a better estimation of the 
location of the cleavage site. These genes are more recent discoveries compared to a - 
synuclein and parkin, thus, such studies will give important insights into their 
Parkinson’s disease properties.
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Chapter I: Introduction
1.1 Parkinson’s disease  background
1.1.1 History of Parkinson’s disease
Parkinson’s disease symptomology was initially described as abnormal movement or 
gait (Goetz et al., 2001; Parkinson, 2002), having been first clinically characterized in 
1817 by James Parkinson in his paper entitled ‘An essay on the shaking palsy’ 
(Parkinson, 2002). Parkinson’s disease was further studied by Jean-Martin Charcot at 
the Salpetriere hospital in Paris in 1887 (Federoff et al., 2003; Goetz, 1987). He was the 
first to separate Parkinson’s disease into discrete symptoms, e.g. differentiating 
bradykinesia from rigidity and emphasizing that muscle strength was well preserved in 
the disease (Federoff et al., 2003; Goetz, 1987). Remarkably, not only was Charcot the 
first to also recognize and use the feature of Parkinson’s disease, micrographia, which 
involves small, cramped handwriting and/or the progression to continually smaller 
handwriting, for diagnosis. He also discovered the therapeutic benefits of belladonna 
alkaloids and rye-based products prior to the recognition that Parkinson’s disease was 
due to dopaminergic/cholinergic imbalance (Federoff et al., 2003; Goetz, 1987).
The most complete pathologic analysis of Parkinson’s disease and the clear delineation 
of the brainstem lesions were performed by Greenfield and Bosanquet at the National 
Hospital, Queen Square, London (Goetz et al., 2001; Greenfield and Bosanquet, 1953). 
William Gowers was the first to suggest a possible genetic predisposition to the 
development of Parkinson’s disease, reporting that 15% of patients had a family history 
of the disease (Gowers, 1886-1888).
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1.1.2 Parkinson’s disease characteristics
Parkinson’s disease is the second most common neurodegenerative disorder after 
Alzheimer’s disease. It is characterized clinically by symptoms like tremor, rigidity, 
postural instability and bradykinesia (slowness of movement). Other symptoms may 
also accompany the above abnormalities. These include autonomic dysfunction, 
depression, and a general slowing of intellectual processes. In some cases, disorders 
such as constipation (Abbott et al., 2001; Ashraf et al., 1997) and rapid eye movement 
sleep behavior disorder also emerge as early symptoms of Parkinson’s disease (Olson et 
al., 2000).
Parkinson’s disease is also pathologically characterised by the presence of Lewy bodies 
and neurites in various regions of the nervous system. Lewy bodies are eosinophilic 
cytoplasmic inclusions which have a fibrillar structure and a dense core, surrounded by 
a halo. They are often also associated with Lewy neurites, which are just proteinaceous 
formations found in neurones. They are found in regions such as substantia nigra, 
cerebral cortex, locus ceruleus, hypothalamus, nucleus basalis of Maynert, cranial motor 
nuclei, as well as loss o f dopaminergic neurons in the substantia nigra pas compacta 
(Braak et al., 2003a; Braak et al., 2003b). Loss of neuromelanin pigment from the 
substantia nigra and locus coeruleus and the presence of Lewy bodies in cells from 
various regions of the brain, especially in the surviving neurons in the substantia nigra 
pars compacta, are the typical features in Parkinson’s disease (Braak et al., 2003a; 
Braak et al., 2003b).
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1.1.3 Epidemiology of Parkinson’s disease
Parkinson's disease affects a larger proportion of males compared to females (approx. 
1.5:1.0 ratio) (Dluzen and McDermott, 2000). Whether this phenomenon might be due 
to exposure in the workplace, sex-linked variability or a protective effect of oestrogen is 
not known. The average age of onset of Parkinson’s disease is between 60 and 80 years, 
and about 1% of the general population above the age of 65 are affected (Tanner, 1992). 
However, rare familial forms of Parkinson’s disease, which account for less than 10% 
of the Parkinson’s disease cases, may also occur, with a more variable age of onset 
depending on the mode of inheritance, but generally at a younger average age of below 
45 (Dawson and Dawson, 2003).
The cause of Parkinson’s disease is still unknown, but many factors have been shown to 
contribute to the development of Parkinson’s disease. These factors (Fig. 1.1) include, 
aging, environmental factors, oxidative stress, and genetic factors (Betarbet et al., 
2005). Some factors have also been reported to show protective effects reducing 
incidence of the disease. These include cigarette smoking, alcohol and caffeine intake 
(Grandinetti et al., 1994; Mayeux et al., 1994; Schoenberg et al., 1988). However, the 
evidence for their protective effect is weak and the mechanism is also not clear (Allam 
et al., 2004). Environmental toxins have been shown to be the most reproducible risk 
factor for Parkinson’s disease (Lai et al., 2002). Many studies have reported a higher 
risk of Parkinson’s disease in those who have lived in rural communities from an early 
age in Europe or North America (Lai et al., 2002). Possible candidates have included 
pesticides or herbicides that were used heavily by these communities after the Second 
World War (Lai et al., 2002). The latest school of thought in the development of late- 
onset idiopathic Parkinson’s disease involves the interaction between multiple
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predisposing genes and environmental factors (Elbaz et al., 2007), with oxidative 
stresses being of particular importance.
1.1.3.a Oxidative Stress in Parkinson’s Disease
The brain has a higher metabolic rate, yet a seemingly lower capacity for regeneration 
compared to other organs in the body, thus making it especially susceptible to the 
damaging effects of oxidative stress caused by reactive oxygen species (ROS), which 
are metabolic by-products of oxygen metabolism (Sayre et al., 2008). In addition, the 
specific vulnerability of dopaminergic neurons to damage by oxidative stresses in 
Parkinson’s disease may be attributed to their production of dopamine, which are highly 
prone to auto-oxidation. Furthermore, the metabolism of dopamine produces toxic 
metabolites (Stokes et al., 1999) and can generate reactive oxygen species (Maguire- 
Zeiss et al., 2005).
Evidence of oxidative damage has been found within the brain regions where specific 
neurodegeneration occurs in various neurodegenerative diseases, for example 
Parkinson’s disease, Alzheimer’s disease and Amyotrophic lateral sclerosis. For 
example, a-synuclein molecules with nitrated (protein nitration is a marker of protein 
oxidation) tyrosine residues have been found to accumulate in Lewy bodies in 
Parkinson’s disease and other synucleopathies, as revealed by postmortem studies 
(Giasson et al., 2000; Good et al., 1998). However, whether this is a cause of the disease 
or just a result of other defects is not yet known.
Although environmental stress, in particular oxidative stresses, are strongly believed to 
contribute to Parkinson’s disease, no specific agent has yet been shown to be involved.
6
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Several mitochondrial and proteasomal toxins such as MPTP, rotenone, MG 132 and 
dopamine are known to recreate many features of Parkinson’s disease in experimental 
models. However, the role of such toxins in Parkinson’s disease patients continues to be 
controversial and these toxins remain only as useful experimental models of the disease.
1.2 Mendelian genetics of Parkinson’s 
disease
The possibility of genetic predisposition to the development of Parkinson’s disease was 
first proposed by William Gowers. He reported that 15% of patients had a family 
history of the disease, and that this suggested genetics as an important factor in the 
development of Parkinson’s disease (Gowers, 1886-1888). However, little attention was 
given to the genetics of Parkinson’s disease until the discovery of Lewy bodies and the 
role of a-synuclein in the disease a century later, which will be discussed in further 
detail later in section 1.2.1. One o f the reasons for the lack of interest was due to the 
occurance of post-encephalitic parkinsonism following the influenza pandemic in 1918. 
The confusion of this syndrome with Parkinson’s disease caused many reaserachers to 
look for a viral aetiology in Parkinson’s disease (Lakke et al., 1977). In addition, early 
twin studies also failed to show increased concordance in identical twins compared to 
non-identical twins, thus further dismissing the role of genetics in Parkinson’s disease 
(Eldridge and Ince, 1984).
Linkage and positional cloning studies have since led to the identification of six genes 
and four other genetic loci associated with familial Parkinson’s disease. There is strong 
genetic evidence supporting a causal role for the following genes in familial Parkinson’s
7
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disease: a-synuclein (PARK1; PARK4) (Polymeropoulos et al., 1997), parkin (PARK2) 
(Kitada et al., 1998), Phosphatase and tensin homologue (PTEN)-Induced Putative 
Kinase 1 (PINK1; PARK6) (Valente et al., 2004b), serine protease Omi/HtrA2 (Strauss 
et al., 2005), DJ-1 (PARK7) (Bonifati et al., 2003), Leucine Rich Repeat Kinase 2 
(LRRK2;/V4AKS) (Paisan-Ruiz et al., 2004; Zimprich et al., 2004) and more recently, 
ATP13A2 (PARK9) (Ramirez et al., 2006; Williams et al., 2005) (Table 1.1).
There is also some evidence that mutations in Nuclear Receptor 4A2 (NR4A2/Nurrl) 
(Le et al., 2003), synphilin-1 (Wakabayashi et al., 2000) and ubiquitin C-terminal 
hydrolase LI (UCH-L1 \PARK5) (Lincoln et al., 1999) may also contribute to 
Parkinson’s disease (Table. 1.1). However, the rarity of disease causing mutations in 
these genes has raised questions about their importance and relevance to Parkinson’s 
disease. Although familial Parkinson’s disease, caused by specific genetic defects, 
produces only minority of Parkinson’s disease cases (<10%), study of these genetic 
defects may reveal key factors and abnormalities in the protein pathways and gene 
regulation, which are likely to be involved in the more common sporadic forms of 
Parkinson’s disease.
The discovery of these genes has produced startling insights into the pathogenesis of 
Parkinson’s disease with better understanding of the key factors and abnormalities in 
the protein pathways that lead to neurodegeneration in Parkinson’s disease. Dysfunction 
in two major pathways has been implicated by the nature of these genes namely: 
impairment in the ubiquitin-dependent proteasomal pathway and mitochondrial 
dysfunction and oxidative stress. More recently, increasing evidence suggests that 
dysfunction in another degradative pathway -  autophagy, may contribute to the
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pathogenesis of Parkinson’s disease. Each of these genes can be categorized into these 
pathways according to their function; this is described in more detail.
Locus Location Gene Inheritance Function Neu ro pathology Age of Onset
PARK]/
4 4q21 a-synuclein
Autosomal
dominant
Involved in
synaptic
function
Lewy bodies, 
Lewy neurites; 
variable glial 
inclusion, tau 
inclusion and 
amyloid plaque 
pathology
Early 
& late 
onset
PARK2 6q25-27 parkin Autosomalrecessive E3 Ligase
Variable Lewy 
body pathology
Early
onset
PARK3 2pl3 unknown Autosomaldominant Unknown
Lewy body 
pathology
Late
onset
PARK5 4pl4 UCH-L1 Autosomaldominant
Ubiquitin 
hydrolase and 
ligase
unknown Earlyonset
PARK6 1 p35-36 PINK1 Autosomalrecessive
Mitochondrial
kinase unknown
Early 
& late 
onset
PARK7 lp36 DJ-1 Autosomalrpppccivp
Involved in 
oxidative stress unknown Earlyonset
Late
onsetPARK8 12p 11
LRRK2
(dardarin)
IvvwMVC
Autosomal
dominant
response 
Protein kinase
Variable Lewy 
body and tau 
inclusion 
pathology
PARK9 lp36 ATP13A2 Autosomalrecessive
Possible ion 
pump unknown
Early
onset
PARK10 lp32 unknown
Genetic susceptibility locus determined by genome wide 
linkage study o f 51 Icelandic families with 1 or more family 
members with typical PD
PARKU 2q unknown
Genetic susceptibility locus by genome linkage in multiplex 
US PD families
Transcription 
factor involved
2q22-23 Nurrl/NR4A2
Autosomal
dominant
in
differentiation 
& maintenance 
of dopaminergic 
neurons
Lewy body 
pathology
Late
onset
l
Un­
mapped Htr2A/ Omi unknown
Serine protease 
and/or involved 
in stress 
response
unknown Lateonset
Table 1.1 Mendelian Parkinson’s disease-associated genes
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Autosom al Dom inant Parkinson’s disease
Autosomal dominant Parkinson's disease results from gain of function mutations that 
lead to the clinical manifestation o f Parkinsonism.
1.2.1 a-synuclein
1.2.l.a History
The amino acid sequence of synuclein was first reported in 1988 by (Maroteaux et al., 
1988), from the electric lobe of the Pacific electric ray (Torpedo califomica). It was so 
named syn(synapse)-nuclein(nucleus) due to its distribution on some regions of the 
nuclear membrane and high concentrations in presynaptic terminals of the nervous 
system, but not the peripheral tissue. In 1993, (Ueda et al., 1993) also reported on a 
similar protein which they then named “non-amyloid-P-component precursor” (NACP) 
due to the localization of NAC in amyloid plaques from Alzheimer's disease brains. 
Two homologous proteins were then subsequently identified by Jakes et al. (1994). The 
first was identical to NACP and was found to be a presynaptic protein with a 
perinuclear localisation, as such, it was later named as a-synuclein (Iwai et al., 1995; 
Jakes et al., 1994). The second, being homologous to a-synuclein, was named (3- 
synuclein. A third member of the synuclein family was later identified in a high- 
throughput direct differential-cDNA-sequencing screen for breast cancer markers and 
named y-synuclein (George, 2002). All three synucleins are homologous and are found 
to be expressed in various regions of the brain. However, only a-synuclein has been
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implicated in diseases such as Alzheimers’ and Parkinson’s disease (George, 2002; Iwai 
et al., 1995; Lavedan, 1998; Lavedan et al., 1998; Nakajo et al., 1994).
Homo sapiens a-synuclein was mapped onto chromosome 4q21.q23 and was found to 
consist of seven exons but only five coding regions (exons 2-6). Alternative splicing has 
been observed for exons 4 and 6, but different protein isoforms have not yet been found.
1.2.1.b a-synuclein in Parkinson’s Disease
1.2.1 .b.i a-synuclein in Lewy bodies
a-synuclein was found to play an important role in Parkinson’s disease when Spillantini 
discovered full length a-synuclein in Lewy bodies taken from postmortem brain tissue 
of sporadic Parkinson’s disease patients in 1997 (Spillantini et al., 1997). This followed 
the discovery of a-synuclein mutations in several rare families with inherited 
Parkinson’s disease (Polymeropoulos et al., 1997). This suggested a link between a- 
synuclein pathology and Parkinson’s disease pathogenesis. Despite skepticism, this link 
was further reinforced when studies revealed that the predominant protein in Lewy 
bodies and Lewy neurites is fibrillar a-synuclein in both sporadic and familial 
Parkinson’s disease (Baba et al., 1998; Mezey et al., 1998; Spillantini et al., 1997; 
Wakabayashi et al., 1997). The aggregation of a-synuclein to form these Lewy bodies 
and neurites is now thought to be the crucial step in the pathogenesis of Parkinson’s 
disease. Such aggregation of a-synuclein is thought to stem from misfolded 
intermediates which may result when levels of the protein exceed the normal range 
present (Wood et al., 1999). These misfolded intermediates were found to self-aggregate 
and form stable (3-sheet oligomers or protofibrils (Li et al., 2002; Wood et al., 1999),
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which are then capable of acting as a nucleus for a-synuclein aggregation and the 
formation of Lewy bodies.
1.2.1 .b.ii Structure & Cellular role of a-synuclein
The a-synuclein protein consists of 3 domains. The N-terminal repeat domain (residues 
1-65), is highly conserved and consists of six copies of imperfect 1 laa repeat, which are 
variations of the KTKEGV consensus sequence (Fig. 1.2). This domain is unordered in 
solution but may assume a double a-helical conformation, separated by a short break, 
which resembles lipid binding domains of class A2 apolipoproteins (Chandra et al., 
2003; Davidson et al., 1998). The assembly into amphipathic a-helixes occurs when a- 
synuclein binds to negatively charged phospholipids, suggesting that it might normally 
be membrane associated (Eliezer et al., 2001; Uversky and Fink, 2002).
The central domain of a-synuclein (residues 66-95) is hydrophobic and is also better 
known as non-Ap component o f plaque (NAC) found in amyloid plaques in 
Alzheimer’s disease (Ueda et al., 1993). This region is also relatively conserved 
between species and is required for a-synuclein to undergo a conformational change 
from random coils to p-sheet as well as form Ap-like protofibrils and fibrils (el-Agnaf 
and Irvine, 2002; Giasson et al., 2001).
The carboxyl-terminal domain (residues 96-140) is negatively charged and composed 
mainly of acidic amino acids (George, 2002). The domain is not conserved between 
species and is highly variable both in size and sequence (Lavedan, 1998). This acidic 
domain, between residues 125-140, has been shown via deletion mutants to display a 
chaperone-like-activity (Kim et al., 2002; Park et al., 2002). Several phosphorylation
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Figure.1.2 Structure of a-synuclein protein
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sites have also been identified in the C-terminal domain. These include, Tyr-125, -133, - 
136 and Ser-129. The phosphorylation of the tyrosine sites by p72syk and other tyrosine 
kinases, which have similar specificity, have been shown, in vitro, to cause a-synuclein 
to lose its ability to form oligomers (Negro et al., 2002). It is not known, however, if 
this modification would attenuate a-synuclein’s chaperone-like-activity.
a-synuclein has also been shown to be serine-phosphorylated by casein kinase-1, casein 
kinase-2 and G-protein-coupled receptor protein kinases (Okochi et al., 2000; Pronin et 
al., 2000). The phosphorylation at this position (Ser-129) changes the charge 
distribution and hydrophobicity of a-synuclein which then leads to promotion of 
fibrillation and oligomerisation (Fujiwara et al., 2002; McLean and Hyman, 2002). This 
can be seen in the abundance of extensively Ser-129 phosphorylated a-synuclein in 
Lewy Bodies. Other modifications, such as glycosylation and nitration, may also occur 
to the serine and tyrosine sites (in particular Tyr-125) present (Takahashi et al., 2002). 
These modifications have also been reported to affect its aggregation and targeting for 
proteasomal degradation. One such example is that shown by Shimura et al., whereby 
an O-glycosylated form of a-synuclein (aSp22) was found to be a substrate for 
ubiquitination by parkin (Shimura et al., 2001).
1.2.1 .b.iii Mutations in a-synuclein
Other than for its presence in Lewy bodies, a-synuclein’s association with Parkinson’s 
disease was also shown in the discovery of mutations in the a-synuclein gene in several 
families affected with familial Parkinson’s disease. The first mutation to be reported 
was that from a large Italian-American kindred (the Contursi family) and from three 
unrelated families of Greek origin (Polymeropoulos et al., 1997). The mutation was
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found to be a G-to-A transition at position 157, in exon 4, of the coding region of a- 
synuclein. This mutation caused the alanine residue at position 53 to change to a 
threonine (A53T). Despite the mutation causing the families to suffer from an 
autosomal dominant form of Parkinson’s disease, its role was unclear as the threonine at 
position 53 was naturally found in the rodent homologue, synuclein-1, and the zebra 
finch homologue, and the frequency of such a mutation was very low (Goedert, 2001; 
Vaughan et al., 1998).
However, further evidence was soon provided when (Kruger et al., 1998) identified a 
second mutation in exon 3 of the a-synuclein gene in an unrelated German family. This 
mutation is a G-to-C transition at position 88 which changes alanine to proline at 
position 30 (A30P). Unlike the first mutation, this mutation was not found normally in 
other species examined.
A third mutation was also recently discovered which caused a substitution of glutamate 
to lysine residue at position 46 (E46K). This mutation was found to cause familial 
Parkinson’s disease and dementia with Lewy bodies in the Spanish kindred (Zarranz et 
al., 2004)
All the above mentioned point mutations in the a-synuclein gene occurred in the highly 
conserved N-terminal region of the a-synuclein protein, which displays the 
characteristic imperfect repeats of consensus sequence KTKEGV, and these mutations 
are thought to increase the probability of the mutated a-synuclein protein to be in the 
coiled state, and thus more likely to aggregate to form Lewy bodies.
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1.2.1.b.iv Amplification of the a-synuclein gene
Amplification of the a-synuclein gene was recently found to also co-segregate with 
Parkinson’s disease with Lewy bodies. Amplification of the gene includes duplication 
(Chartier-Harlin et al., 2004; Ibanez et al., 2004a) and triplication (Farrer et al., 2004; 
Singleton et al., 2003) of the a-synuclein locus. These findings suggested that increased 
expression of a-synuclein was sufficient, possibly, to cause aggregation and thus lead to 
Parkinson’s disease. Nonetheless, other researchers were quick to point out that 
overexpression of a-synuclein was extremely rare in Parkinson’s disease patients 
(Gispert et al., 2005; Hofer et al., 2005), and that studies involving the overexpression 
of a-synuclein in mice also revealed that other mechanisms were needed for 
aggregation to occur (Martin-Clemente et al., 2004).
1.2.1 .b.v Polymorphisms of the a-synuclein promoter
As both mutation and amplification of the a-synuclein gene have been shown to be rare 
occurrences and have been excluded in the majority of Parkinson’s disease cases, other 
modifications to the a-synuclein gene have also been considered as possible factors 
contributing to Parkinson’s disease. Certain polymorphisms of the a-synuclein 5’ non­
coding region have been shown to be associated with sporadic Parkinson’s disease even 
in patients who do not express a mutated protein or have increased copy number of the 
gene (Chiba-Falek and Nussbaum, 2001; Kruger et al., 1999; Mizuta et al., 2002; Ross 
et al., 2007; Tan et al., 2004a; Tan et al., 2000; Xia et al., 1996). Such allelic variations 
have been found to occur mostly in the NACP-Repl repeat site of basic repeat 
sequence, (TQ ^T^TQ ^TA j^C A )*, located ~ 10kb upstream of a-synuclein gene 
translational start. The most common variation between Rep 1 alleles was the number of 
dinucleotide repeats. Even alleles o f the same size showed variability in the number of
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dinucleotide repeats, (TC)/o-//(T)XTC)«.//(TA)7-9(CA)/o-7/(the numerical subscript being 
the possible number of repeats), i.e. the total number of nucleotides remains the same, 
but variation in repetition may occur for each type of dinucleotide repeat (Farrer et al., 
2001b). Non-repetitive sites also displayed variation in the form of single nucleotide 
polymorphisms (SNPs). These allelic variations were found to affect the levels of a- 
synuclein expression (Chiba-Falek and Nussbaum, 2001).
Although there are reports claiming otherwise, (Izumi et al., 2001; Khan et al., 2001; 
Mellick et al., 2005; Parsian et al., 1998; Spadafora et al., 2003; Tan et al., 2003), with 
an overview of the reports pertaining to studies in oxidative stress, studies on the 
amplification of the a-synuclein locus as well as polymorphisms on the a-synuclein 
promoter, we believe it is quite convincing that even subtle changes in a-synuclein 
expression may lead to Parkinson’s disease pathogenesis.
1.2.1 .b.vi Oxidative Stress & a-synuclein
Although oxidative stresses had been shown to be important in the genesis of 
Parkinson’s disease, it was not clear how they were involved. Only when evidence, both 
in vitro and in vivo, was presented showing that oxidative stress promotes the formation 
of a-synuclein aggregates and inclusions, did the importance of its interaction with a- 
synuclein in Parkinson’s disease become clearer.
The MPTP (l-methyl-4-phenyl-1.2.3.6-tetrahydropyridine) model has been used by 
many to decipher the interactions between environmental agents and genetic factors 
which result in selective neurodegeneration. MPTP is a mitochondrial complex 1 
inhibitor and is selectively taken up into dopaminergic neurons via the dopamine
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transporter leading to severe oxidative damage and neuronal degeneration resulting in 
Parkinsonism in rodents, primates and humans (Javitch et al., 1985; Javitch and Snyder, 
1984; Ramsay et al., 1986; Shimura et al., 2001).
In some of the earlier reports on the involvement of MPTP in Parkinson’s disease, Vila 
et al. (2000) and Przedborski et al. (2001) demonstrated that chronic treatment of mice 
with MPTP selectively upregulated a-synuclein in the midbrain and resulted in tyrosine 
nitration modification of the protein and subsequently aggregation (Przedborski et al., 
2001; Vila et al., 2000). There was also evidence of a-synuclein up-regulation and 
aggregation in substantia nigra in MPTP treated non-human primate models (Kowall et 
al., 2000; Purisai et al., 2005). This was further supported by studies which indicated 
that not only were the disease causing mutant, A30P transgenic mice, especially 
sensitive to MPTP toxicity (Nieto et al., 2006), a-synuclein null mice also showed 
resistance to MPTP-induced neurodegeneration (Dauer et al., 2002; Klivenyi et al., 
2006; Schluter et al., 2003) when compared to their control littermates of similar genetic 
background.
Several other toxins were also used to support the hypothesis that environmental factors 
work in concert with genetic factors to result in Parkinson’s disease. Rotenone, a 
commonly used pesticide, was found to upregulate and aggregate a-synuclein (Betarbet 
et al., 2006; Sherer et al., 2002; Sherer et al., 2003). Paraquat, another commonly used 
herbicide, was found to induce fibrillation and aggregation of a-synuclein in mice 
(Manning-Bog et al., 2002).
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Dopamine, in addition, may be the major contributor of oxidative stress since it can be 
generated endogenously by the substantia nigral neurons (Barzilai et al., 2001; Sherer et 
al., 2002). The exposure to intra-cellular dopamine may lead to mitochondrial 
dysfunction and impaired proteolysis via its reactive metabolites, H2O2, 
dihydroxyphenylacetic acid and dopamine-quinones, or directly due to its oxidative 
nature (Khan et al., 2001; Kruger et al., 1998; Pearson et al., 2001; Stokes et al., 1999).
The main hypothesis involving dopamine dependent oxidative stress revolved around 
the defective storage of dopamine in synaptic vesicles which then, due to the increase in 
pH in the cytoplasm, results in its auto-oxidation and generation of reactive oxidative 
species (ROS) (Bamham et al., 2004). Such leakage of dopamine may be initiated by 
the perforation of the vesicular membranes by a-synuclein (3-sheeted oligomers 
(Lotharius and Brundin, 2002a; Lotharius and Brundin, 2002b; Voiles and Lansbury,
2003), which form when there is an increase in a-synuclein above manageable cell load, 
or when there is aberrant, misfolded mutated a-synuclein.
There has also been evidence showing that a-synuclein interacts with another 
presynaptic dopaminergic protein, dopamine transporter (DAT) (Lee et al., 2001). This 
interaction causes the recruitment of DAT to the membrane, which subsequently results 
in an accelerated uptake of dopamine. Due to the direct interaction between a- 
synuclein, DAT and dopamine, any mutation or changes in expression in a-synuclein 
could lead to an accumulation of dopamine in the cell and thus give rise to intracellular 
oxidative stress.
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Through studies on mutations in a-synuclein and amplifications of the gene locus, both 
of which lead to familial Parkinson’s disease, it is clear that a-synuclein plays an 
important role in the development of the disease. However, since such abberations are 
rare, yet the abundance of aggregated a-synuclein in Lewy bodies, present even in 
sporadic Parkinson’s disease patients whom carry neither mutations nor amplifications 
of the a-synuclein locus, other reasonings have been sought to explain the role of a- 
synuclein. The most convincing theory to date suggests that minute changes in levels of 
a-synuclein could, in long term, lead to Parkinson’s disease. Such increases in a- 
synuclein could be due to polymorphisms of the gene, or brought about by external 
stimuli, for example, environmental toxins or oxidative stresses. The excess a-synuclein 
would lead to its misfolding and aggregation, which could subsequently lead to cell 
death due to its toxicity or through the perforation of dopamine containing vesicles, 
leading to the leakage of oxidative dopamine. In such a case, selective death of 
dopaminergic neurons would occur resulting in Parkinson’s disease.
1.2.2 LRRK2/dardarin (PARK 8)
1,2.2.a Structure of LRRK2
LRRK2 (leucine-rich repeat kinase 2) is a large multidomain protein (Fig. 1.3), 
comprising of residues predicted to adopt the configuration of armadillo repeats and 
ankyrin repeats (Mata et al., 2006), a leucine-rich repeat (LRR) domain, a Roc (Ras of 
complex proteins) GTPase domain and C-terminal of Roc (COR) domain (Bosgraaf and 
Van Haastert, 2003), a kinase domain of the tyrosine kinase-like (TKL) subfamily 
(Manning et al., 2002) and a C-terminal WD40 domain (Mata et al., 2006).
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Figure. 1.3 Schematic diagram of LRRK2 domains organisation.
The positions of putative pathogenic amino acid substitutions are in magenta and amino acid 
substitutions segregating with Parkinson’s disease are shown in green. Abbreviations: ANK, armadillo 
and ankyrin repeats; LRR, leucine-rich repeat domain; Roc, Ras of complex proteins GTPase; COR, C- 
terminal of Roc domain.
(adapted from Mata et al., 2006)
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Armadillo repeats, ankyrin repeats and leucine-rich repeats have been shown, in 
general, to form the underlying structure of a specific protein-binding interface. In 
contrast to other more typical protein-protein interaction domains, these repeats do not 
recognize any specific amino acid sequence or structure. Instead, they form an 
elongated surface of varying size depending on the number of repeats. Specificity for 
protein partners is determined by variations in adaptive surface residues (Mosavi et al.,
2004).
The LRRK2 Roc domain is a Ras-related GTPase found to be able to form a strong 
dimer with other Roc domain containing proteins. It is believed that following the 
binding of GTP, a significant conformation change occurs in the domain which may 
then be conveyed to the C-terminal LRRK2 kinase domain through the COR domain 
either directly or indirectly as a molecular hinge, leading to the dimerization of the 
kinase domain and subsequently its autophosphorylation and activation (Deng et al., 
2008).
The LRRK2 WD40 domain consists of seven WD40 repeats which forms a circular 
propeller-like structure with a central pore (Mata et al., 2006). These WD40 repeats are 
short ~40 amino acid motifs, often terminating in a Trp-Asp (W-D) dipeptide. The 
resulting seven-propeller configuration provides potential binding surfaces for proteins 
and/or small ligands, which may bind either stably or reversibly (Smith et al., 1999b).
The presence of multiple protein interaction and catalytic domains in LRRK2 highlights 
its cellular importance and postulates its role as a hub for signalling and interaction 
between various proteins.
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1.2.2.b LRRK2 in Parkinson’s Disease
1.2.2.b.i Mutations in LRRK2
Mutations in LRRK2 have been found in a large number of Parkinson’s disease patients 
(Fig. 1.3). Most of these mutations are dominant, e.g. G2019, II122V, R1441C, as only 
one copy of the mutated gene is sufficient to cause the disease (Abou-Sleiman et al., 
2006b; Zimprich et al., 2004). The G2019S mutation in particular was detected in 5-6% 
of autosomal dominant familial Parkinson’s disease and 1-2% of sporadic cases (Abou- 
Sleiman et al., 2006b). This prevalence was found to be even higher for specific 
populations such as Ashkenazi Jews and North African Arabs (Abou-Sleiman et al., 
2006b).
Pathogenic mutations scatter throughout all functional domains of LRRK2 (Fig. 1.3) 
(Mata et al., 2005; Taylor et al., 2006). However, the predominance of the G2019S 
mutation in Parkinson’s disease patients has led to it becoming the main focal point of 
research into LRRK2’s role in Parkinson’s disease (Gilks et al., 2005). The LRRK2 
G2019S mutation is situated in a highly conserved DYG motif of the kinase domain. 
This mutation results in an increase in the kinase activity of LRRK2, thus implicating a 
gain of function in its pathogenic mechanism (Thomas and Beal, 2007). Furthermore, 
the lack of deletions or truncations of LRRK2, as well as the autosomal dominant 
pattern of inheritance, also point towards a gain-of-function pathology.
Several studies showed that the kinase activity of the mutant LRRK2 was responsible 
for neuronal toxicity, and that this, in turn, was likely dependent on the activity of its 
GTPase Roc domain, N-terminal to the kinase domain (Thomas and Beal, 2007). 
Studies involving mutations in the Roc domain showed that the binding of GTP to this
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domain regulates the kinase activity of LRRK2 as well as its phosphorylation by other 
kinases (Ito et al., 2007). As described earlier in section 1.2.2.a., the binding of GTP to 
the Roc domain results in a significant conformation change in the domain which may 
then be conveyed to the kinase domain through the COR domain, leading to the 
dimerization of the kinase domain and its autophosphorylation and activation. This 
explains why mutations in the Roc domain such as R1441C and 1137IV, led to aberrant 
kinase activity (Deng et al., 2008). In fact, these mutations resulted in a decrease in GTP 
hydrolysis, leading to a prolonged GTP-mediated activation of the kinase, further 
supporting the gain-of-function pathology hypothesis (Deng et al., 2008).
1.2.2.b.ii Cellular role of LRRK2
The cellular function of LRRK2 is still mainly unknown. It has been shown to be 
essentially a cytoplasmic protein that may associate with intracellular membranes, such 
as the outer mitochondria membrane, Golgi apparatus and endoplasmic reticulum, and it 
is capable of interacting with another Parkinson's disease associated gene, parkin 
(described in detail in section 1.2.5) (Thomas and Beal, 2007). Moreover, parkin 
appears to promote aggregates enriched with ubiquitinated LRRK2 (Thomas and Beal, 
2007). Although LRRK2 is not found to interact with either a-synuclein or tau, the 
identification of a-synuclein-positive Lewy body pathology or tau-positive 
neurofibrillary tangle pathology in LRRK2 patients suggests a possible common role of 
LRRK2 in the processing of these two proteins (Rajput et al., 2006; Ross and Farrer, 
2005; Zimprich et al., 2004).
More recently, LRRK2 was shown to phosphorylate actin binding proteins, moesin as 
well as ezrin and radixin, at a previously known phosphorylation site encompassing 
Thr558 (Jaleel et al., 2007). The phosphorylation of this site regulated the binding of
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moesin to actin. The GTPase, COR and kinase domains as well as the WD40 motif and 
C-terminal tail of LRRK2 were all found to be essential for this phosphorylation (Jaleel 
et al., 2007). In addition, there is also some speculation that LRRK2 might play a role in 
vesicular trafficking, as many Rho proteins, which also contain the Roc GTPase 
domain, have been found to regulate vesicular trafficking, but experimental evidence is 
still awaited (Abeliovich and Beal, 2006).
1.2.3 Nurr 1 (NR4A2)
1.2.3.a Structure & cellular role of Nurrl
Nurrl (NR4A2) is a transcription factor which belongs to the orphan nuclear receptor 
superfamily. It was first identified from a mouse brain cDNA library and was localized 
onto human chromosome 2q22-q23 (Law et al., 1992; Mages et al., 1994). The Nurrl 
gene contains 8 exons and 7 introns, and encodes for a 598 amino acid long protein 
which contains a DNA binding domain, a ligand binding domain and a variable region 
(Ichinose et al., 1999; Torii et al., 1999; Wang et al., 2003).
The transcriptional activity of Nurrl is thought to be performed by binding to NGFI-B 
response element (DNA sequence that is recognised by Nerve Growth Factor induced 
protein B (NGFI-B) DNA binding domain) on the DNA or by binding to Nurr77 
response element (DNA sequence that is recognised by Nurr77 DNA binding domain) 
in a homodimer conformation. It has been found to regulate the expression of genes 
such as tyrosine hydroxylase, the dopamine transporter, and vesicular monoamine
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transporter-2 and is required for the differentiation and maintenance of nigral 
dopaminergic neurons (Law et al., 1992; Sacchetti et al., 2001; Sakurada et al., 1999).
1.2.3.b Nurrl in Parkinson’s disease 
1 2.3.b.i Oxidative stress & Nurrl
Homozygous Nurrl knock-out mice have been found to fail to develop midbrain 
dopaminergic neurons, a perinatal lethal phenotype. Moreover, Nurrl heterozygote 
knock-out mice have reduced brain dopamine and suffer from locomotor deficits in 
response to neurotoxins such as MPTP and normal ageing (Jiang et al., 2005; 
Zetterstrom et al., 1997). Since a reduction of Nurrl in the adult brain may increase the 
vulnerability of dopaminergic neurons to stress - Nurrl may also play a role in the 
pathogenesis of Parkinson’s disease (Eells et al., 2002; Le et al., 1999).
1 2.3.b.ii Mutations in Nurrl
In 2003, Le et al reported two mutations (-291Tdel and -245T/G) in the 5’-untranslated 
region (UTR) of Nurrl in families with autosomal dominant Parkinson’s disease. These 
mutations were shown to decrease Nurrl expression levels in vitro and in lymphocytes 
of Nurrl positive Parkinson’s disease patients. Since the initial report at least ten 
follow-up studies in Parkinson’s disease have revealed only three additional mutations 
(-253C/T, -223C/T, and Serl25Cys) indicating that Nurrl mutations are rare (Grimes et 
al., 2006; Hering et al., 2004; Ibanez et al., 2004b; Karamohamed et al., 2005; Levecque 
et al., 2004; Nichols et al., 2004; Rawal et al., 2002; Tan et al., 2004b; Wellenbrock et 
al., 2003; Zimprich et al., 2003). The rarity of disease causing Nurrl mutations together 
with little in vivo functional data for Nurrl pathogenicity has raised questions about the 
importance and relevance of Nurrl to Parkinson’s disease.
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1.2.4 UCH-L1
1.2.4.a Cellular role of UCH-L1
Ubiquitin carboxy-terminal hydrolase-Ll (UCH-L1) is a de-ubiquitinating enzyme 
involved in the ubiquitin proteasome system (UPS) that hydrolyses the C-terminal of 
ubiquitin to generate ubiquitin monomers that can be reutilized to target proteins for 
clearance by the proteasome (Mouradian, 2002).
1.2.4.b UCH-L1 in Parkinson’s disease
Leroy et al. (Leroy et al., 1998) identified, in a sequencing project involving 72 families 
with Parkinson’s disease, a single missense mutation (Ile93Met) in the UCH-L1 gene in 
two German siblings. In both patients the clinical syndrome was typical for Parkinson’s 
disease. The significance of these finding is however uncertain, as no other families 
with mutations in this gene have been found to date (Harhangi et al., 1999; Lincoln et 
al., 1999). A common coding polymorphism (Serl8Tyr) in the UCH-L1 gene has been 
identified. This variant was reported to be inversely associated with Parkinson’s disease 
in a dose-dependent manner (Maraganore et al., 1999). This is supported by a recent 
meta-analysis of 11 published studies (Maraganore et al., 2004).
UCH-L1 is one of the most abundant proteins in the brain and immunofluorescence 
studies of Lewy bodies are positive for UCH-L1 protein, which implicates it either 
directly or indirectly with the development of Parkinson’s disease (Lowe et al., 1990). 
With UCH-L1 also functionally involved in the ubiquitin-dependent proteolytic
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pathway; it could potentially be a good candidate gene for Parkinson’s disease (Gosal et 
al., 2006).
Autosom al Recessive Parkinson’s disease
Autosomal recessive Parkinson’s disease occurs when both alleles of a gene are mutated 
resulting in the clinical manifestation of Parkinsonism. DJ-1, parkin, PINK1 and 
ATP13A2 are all associated with early onset autosomal recessive Parkinson’s disease 
and, interestingly, are also all linked to mitochondrial function.
1.2.5 Parkin (PARK 2)
1.2.5.a Cellular role of Parkin
Parkin is a 465 amino acid long protein containing two really interesting new gene 
(RING) finger domains separated by an IBR (in-between-ring) domain at the carboxyl 
terminal and an UBL (ubiquitin-like) domain at the amino terminal (Sakata et al., 2003; 
Shimura et al., 2000). It has been identified as an E3 ubiquitin-protein ligase, and plays 
a role in the ubiquitin proteasome system (UPS), by recruiting E2 components e.g. 
synphilin and facilitating the transfer of ubiquitin to damaged or misfolded target 
substrates (Fig. 1.4). These polyubiquitylated subtrates are then targeted to the 26S 
proteasome complex where they are degraded (Shimura et al., 2001; Upadhya and 
Hegde, 2003; Yang et al., 2006).
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Figure. 1.4 Role of Parkin in ubiquitin proteasomal system
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1.2.5.b Parkin in Parkinson’s Disease 
1 2.5.b.i Mutations in parkin
(Kitada et al., 1998) were the first group to find mutations in the parkin gene in 
Japanese autosomal recessive juvenile Parkinson's disease (ARJP) families. Parkin was 
then found to be the most common cause of early onset cases of ARJP, accounting for 
almost 50% of the cases (Abbas et al., 1999; Lucking et al., 2000).
In contrast to other Parkinson's disease cases, Lewy bodies are generally not present in 
parkin related Parkinson’s disease. A variety of homozygous and compound 
heterozygous mutations causing gene rearrangements and mis-sense mutations in the 
parkin gene have been found (Abbas et al., 1999; Lucking CB, 2000 ). Of these, mis- 
sense mutations were mainly found within the parkin C-terminus, RING1 domain. Most 
of these mutations were found to either impair its binding to putative substrates or 
render its ligase activity defective, thus resulting in loss-of-function (Imai and 
Takahashi, 2004; von Coelln et al., 2004). This loss-of-function mechanism normally 
leads to neurodegeneration and results in Parkinson’s disease with a lack of Lewy 
bodies (Farrer et al., 2001a; Shimura et al., 1999). However, Lewy body pathology was 
found in one patient with compound heterozygous parkin mutations (Farrer et al., 
2001b; Shimura et al., 1999). This suggested that some parkin mutants may still retain 
some ubiquitin-ligase activity, thus enabling the formation of Lewy bodies (Hattori and 
Mizuno, 2004).
1.2.5.b.ii Oxidative stress & parkin
There is accumulating evidence that parkin may play a role in maintaining 
mitochondrial function and preventing oxidative stress (Shen and Cookson, 2004).
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Parkin knock-out mice develop mitochondrial deficits (Palacino et al., 2004) and parkin 
knock-down in cell lines renders cells more vulnerable to oxidative stress (MacCormac 
et al., 2004). Parkin's ubiquitin ligase activity is also modified by nitric oxide mediated 
oxidative stress. Various groups have reported that the reactive metabolite of dopamine, 
dopamine quinone may decrease the solubility of endogenous parkin by covalently 
binding to cysteine residues of parkin (LaVoie et al., 2005; Tan et al., 2004b; Yao et al.,
2004). This results in the loss of parkin's activity. Furthermore, they found increased 
insoluble parkin in the caudate nucleus of Parkinson's disease patients (LaVoie et al.,
2005). Our group have also previously shown that endogenous parkin localizes to 
aggregates following exposure to dopamine in neuroblastoma cells (Valente et al., 
2004a).
The protective function of parkin and its additional role in the mitochondria, apart from 
being involved in the ubiquitin proteasomal system, was further established when it was 
found to function in the same pathway, but downstream, of another Parkinson's disease 
associated gene, PINK1 (PTEN-induced kinase 1). PINK1 is also a protective protein 
which resides mainly in the mitochondria. This is discussed in further detail below.
1.2.6 PINK1 (PTEN-induced kinase 1; PARK 6)
1.2.6.a Structure of PINK1
PINK1 (PTEN-induced kinase 1) was first identified in cancer cell expression profile 
experiments and was shown to be transcriptionally activated by PTEN, thus its name 
PTEN-induced kinase 1 (Abou-Sleiman et al., 2006b). PINK1 is an 8 exon gene which
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encodes for a 581 amino acid long protein. Via sequence comparisons with other 
proteins, it was found to consist of an N-terminal mitochondrial targeting motif, a C- 
terminal autoregulatory domain and a highly-conserved serine/threonine kinase domain 
(Abou-Sleiman et al., 2006b; Valente et al., 2004a). Recently, this has been 
corroborated using a baculovirus-infected insect cell system showing that PINK1 
preferentially phosphorylates serine/threonine residues on basic substrates compared to 
acidic substrates, and does not target tyrosine residues (Sim et al., 2006). This 
phosphorylation was further shown to be auto-regulated by PINK1 C-terminal domain 
(Sim et al., 2006).
1.2.6.b Mutations in PINK1
Mutations in PINK1 were first discovered in three large consanguineous families with 
autosomal recessive juvenile parkinsonism (ARJP) -  one Spanish, two Italian (Valente 
et al., 2004a). More mutations of the PINK1 gene have subsequently been found (Abou- 
Sleiman et al., 2006b). These mutations are recessive as only homozygous mutation, i.e. 
mutation on both copies of the gene, would lead to the disease.
The discovery that PINK1 mutations are mostly distributed around the kinase domain 
(Abou-Sleiman et al., 2006b; Kubo et al., 2006; Valente et al., 2004a), has led to 
assumptions that the disruption of kinase activity is the most probable disease 
mechanism. Some studies, using the measure of mitochondrial membrane potentials, 
have been performed which suggest that the loss of PINK 1 function adversely affects 
mitochondrial function and thereby also increases cellular susceptibility to stress (Abou- 
Sleiman et al., 2006a; Valente et al., 2004a). However, more definitive studies have not 
yet been performed to support this hypothesis.
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1.2.6.C PINK1 substrates & interactions
Over-expression of PINK1 has been shown to protect neuronal cells against 
mitochondrial and oxidative stresses such as MPTP, staurosporine and rotenone (Deng 
et al., 2005; Haque et al., 2008; Petit et al., 2005). TRAP1 (TNF receptor-associated 
protein 1, also known as heat shock protein 75) was identified as a substrate of PINK 1. 
Omi/HtrA2 was also found to interact with PINK1. TRAP1 and Omi/HtrA2 are both 
associated with the protection of mitochondria against cell death via apoptosis (Plun- 
Favreau et al., 2007; Pridgeon et al., 2007). This supports the cytoprotective role of 
PINK1.
1.2.6.c.i TRAP1 substrate of PINK1
TRAPl is a mitochondrial molecular chaperone associated with an anti-apoptotic 
function preventing oxidative-stress-induced mitochondrial cytochrome c release. This 
protective function was found to be dependent on TRAPl’s phosphorylation by PINK1 
(Pridgeon et al., 2007). Pathogenic PINK1 mutations such as G309D, L347P and 
W437X were shown to have an impaired ability to phosphorylate TRAPl (Pridgeon et 
al., 2007).
1.2.6.c.ii Omi/HtrA2 substrate of PINK1
Omi/HtrA2 is a serine protease from the GLGF (glycine-leucine-glycine-phenylalanine; 
also known as PDZ or DHR, Dig homologous region) domain containing family (Walsh 
et al., 2003). The GLGF domain is a common structural domain of 80-90 amino-acids 
found in the signaling proteins and helps anchor transmembrane proteins to the 
cytoskeleton and hold together signaling complexes (Ponting, 1997). It also contains a 
N-terminal mitochondrial-targeting domain as well as a reaper-like motif (Walsh et al., 
2003). The reaper-like motif is a N-terminal motif first identified in the drosophila
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protein, Reaper. This motif have been shown to disrupt inhibitor of apoptosis (IAP)- 
caspase complexes, displacing active caspases (Martins, 2002).
Omi-HtrA2 was thought to reside normally in the mitochondrial intermembrane space 
and when released to the cytosol during apoptosis, relieved caspase inhibition by 
binding to inhibitor of apoptosis proteins (IAPs), thereby stimulating apoptosis (Strauss 
et al., 2005). Omi/HtrA2 was first linked with Parkinson's disease when knockout mice 
showed parkinsonian phenotypes (Martins et al., 2004). Following this, a heterozygous 
mutation at Gly399 was found in four sporadic Parkinson's disease German patients and 
an Alal41 polymorphism which showed increased risk to Parkinson's disease further 
reinforcing its association with Parkinson's disease (Strauss et al., 2005).
Contrary to previous evidence of Omi/HtrA2 being pro-apoptotic, these loss-of-function 
mutations indicated that the deregulation of the protease activity of Omi/HtrA2 
increased the susceptibility of cells to stress, most probably through mitochondria 
dysfunction. Although genetic proof of a role for this gene in Parkinson's disease has 
not been unequivocally established, it was shown that phosphorylation of Omi/HtrA2 
during stress, modulated its proteolytic activity and that this phosphorylation was 
dependent upon PINK1 (Plun-Favreau et al., 2007).
Omi/HtrA2 was found to be phosphorylated by the p38 pathway during stress, in the 
presence of PINK1. In support of this relationship, brains of Parkinson’s disease 
patients with PINK1 mutations were found to have less phosphorylated Omi/HtrA2 
compared to idiopathic patients (Plun-Favreau et al., 2007). The p38 pathway involves 
p38 mitogen-activated protein kinases (MAPK). These kinases are responsive to various
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stress stimuli such as inflammatory cytokines, ultraviolet irradiation and osmotic shock, 
and are involved in cell differentiation and apoptosis. Following activation by 
phosphorylation, p38 MAPK in turn phosphorylates and activates other proteins 
including various transcription factors such as ATF-2, Mac and MEF2 (Pearson et al., 
2001).
It was postulated that upon p38 pathway activation due to stress, PINK1 was involved 
in the phosphorylation of Omi/HtrA2, which then increased its protease activity and 
thus provided mitochondrial protection. The direct interaction between PINK1 and 
Omi/HtrA2, however, was not shown (Plun-Favreau et al., 2007).
It is still unclear whether Omi/HtrA2 is indeed anti-apoptotic or not. Although Omi- 
HtrA2 contains the reaper-like motif and should promote apoptosis by lifting caspase 
inhibition, all molecular studies of Omi-HtrA2 done in the context of Parkinson's 
disease have proven otherwise. More research would be required before the cellular role 
of Omi-HtrA2 can be unequivocally established.
1.2.6.c.iii Parkin is downstream of PINK1
The association of PINK1 and its interacting proteins with the mitochondria 
strengthened the hypothesis that mitochondrial dysfunction may play a role in 
Parkinson's disease pathogenesis. This hypothesis was supported by postmortem studies 
showing mitochondrial impairment and oxidative damage (Beal, 2003). Nonetheless, 
despite the evidence, the mitochondrial dysfunction hypothesis has, until recently, been 
overshadowed by another theory based upon a-synuclein and parkin, which focused on 
protein aggregation and proteasomal dysfunction (Jenner and Olanow, 1998).
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More recently, it was found that the phenotypes in PINK1 loss-of-function mutations in 
Drosophila could be rescued by using transgenic expression of parkin. This implied that 
parkin and PINK1 may act in a common pathway, showing that the two theories 
described above might, in fact, act together in the pathogenesis of Parkinson's disease 
(Tan and Dawson, 2006; Yang et al., 2006).
Both PINK1 and parkin mutant Drosophila models have similar phenotypes -  male 
sterility, muscle and dopaminergic neuronal degeneration and increased sensitivity to 
oxidative stresses. Furthermore, double knockouts of both genes resulted in an identical 
phenotype to the single mutants suggesting a linear pathway between them (Tan and 
Dawson, 2006; Yang et al., 2006). Parkin has been suggested to act downstream from 
PINK1 in this pathway as parkin could rescue PINK1 knock-out phenotypes but not 
vice versa (as mentioned earlier). Interestingly, over-expressing parkin could restore 
normal mitochondrial morphology, DNA and protein content, but did not alleviate the 
PINK1 mutant Drosophila from its sensitivity to stressors, suggesting that the pathway 
involving PINK1 and parkin may only be involved in the maintenance of mitochondrial 
integrity (Yang et al., 2006).
The relevance of the observations in the Drosophila model to Parkinson’s disease was 
much debated, especially when PINK1 knock-out mice failed to display any 
nigrostriatal neurodegeneration (Kitada et al., 2007). Nonetheless, Exner et al. 
subsequently demonstrated, using human cell lines including primary cell lines from 
patients with two different PINK1 mutations, that PINK1 knockout or mutation resulted 
in mitochondrial morphology abnormalities that could only be reverted by enhanced 
expression of parkin or the re-introduction of wild type PINK1 (Exner et al., 2007).
36
Chapter I: Introduction
Following this discovery that PINK1 and parkin act through the same pathway, it would 
be especially interesting to identify substrates that, when phosphorylated by PINK1 in 
the mitochondria, lead to the recruitment or activation of parkin, which predominantly 
resides in the cytoplasm.
1.2.7 DJ-1 (PARK 7)
DJ-1 is a member of the THiJ/PfpI/DJl superfamily, a diverse family of proteins 
involved in various functions such as RNA-protein interaction regulation, chaperone 
activity, thiamine biosynthesis, Ras-related signal transduction and protease activity 
(Quigley et al., 2004; Wilson et al., 2004). They share the THiJ domain, which 
constitutes an overall a /p  structure, the function of which is unclear (Lee et al., 2003).
Parkinson’s disease causing DJ-1 mutations are rare and account for only about 1-2% of 
early onset autosomal recessive Parkinson’s disease cases. Its cellular and subcellular 
localization is unclear, but it has been shown to be enriched in the brain and peripheral 
tissues and is primarily cytoplasmically localized, with a small pool associated with the 
mitochondria (Zhang et al., 2005).
DJ-1 is thought to be involved in the oxidative stress response by acting as a redox- 
dependent chaperone (Zhou et al., 2006). It is capable of such a role due to the presence 
of several cysteine residues which undergo an acidic shift in pl-value when exposed to 
reactive oxidative species (ROS), thus potentially mopping them up (Abou-Sleiman et 
al., 2006b; Kubo et al., 2006). However, as the quenching ability of DJ-1 is modest, it is 
suspected that other pathways are involved, of which much evidence points towards the
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involvement of regulation of apoptosis via the phosphoinositide-3 kinase (P13-K) -  
AKT pathway (Abou-Sleiman et al., 2006b; Wood-Kaczmar et al., 2006). This 
hypothesis is supported by evidence showing that RNAi knockdown of DJ-1 a  in 
Drosophila increased its sensitivity to oxidative stress which was reduced with 
increased PI3K/Akt signaling capacity (Wood-Kaczmar et al., 2006). However, the 
mechanism of interaction between DJ-1 and the PI3K/Akt pathway remains unknown.
1.2.8 ATP13A2 (PARK 9)
ATP13A2 encodes for a member of the Ps-ATPases of the P-type ATPase superfamily. 
P-type ATPases generally makes use of ATP to maintain an ion gradient across the cell 
membrane. As each step in this process is reversible, they in turn use the membrane 
potential to produce ATP (Kuhlbrandt, 2004). The substrate specificities and functions 
of the Ps-ATPases are still relatively unknown, but due to their close homology to Pi- 
and P4-ATPases, they are most probably ion pumps. It has been shown that ATP13A2 is 
expressed in most tissues in mice, but is especially abundant in the brain (Schultheis et 
al., 2004).
Mutations in ATP13A2 have been identified recently as the underlying cause of an 
autosomal recessive form of early onset parkinsonism with pyramidal degeneration and 
dementia, Kufor-Rakeb syndrome (KRS) (Ramirez et al., 2006; Williams et al., 2005). 
Little is known about how these loss-of-function mutations lead to the genesis of this 
parkinsonian syndrome and whether there is any interaction between this protein and 
the other Parkinson’s disease associated genes. However, in vitro models have shown 
that, while wild-type ATP13A2 is localized to the lysosomes, the mutated proteins were 
retained in the endoplasmic reticulum and degraded by the proteasome (Ramirez et al.,
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2006), it is suspected that, an overload of such retained proteins may thus lead to 
neurodegeneration as seen in KRS due to proteasomal dysfunction.
Another theory is that, such loss of functional ATP13A2 from the lysosomes may lead 
to lysosomal dysfunction which may, in turn, impair cellular autophagy, which is the 
process of degradation of intracellular components via the lysosome. There is, currently, 
increasing evidence in the importance of autophagy impairment in Parkinson’s disease 
(Rubinsztein et al., 2005).
In view of the ample evidence supporting the importance of a genetic role in 
Parkinson’s disease, in particular the hereditary form of the disease, it is plausible that 
the genes described above may still be important in the idiopathic form of Parkinson’s 
disease. This may occur through the deregulation of the normal, wild-type gene. This 
deregulation may result due to various reasons, including exposure to toxins. 
Nevertheless, a major part of this process is carried out via gene regulation by 
transcription factors. As such, we will discuss, in the following sections, the regulation 
of genes and possible transcription factors involved.
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1.3 Regulation of Genes
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Figure. 1.5 Central dogma of molecular biology
Adapted from http://en.wikipedia.org/
Gene expression is the process by which inheritable information from a gene, such as 
the DNA sequence, is made into a functional gene product, such as protein or RNA. 
Several steps in the gene expression process may be modulated, including the 
transcription step and the post-translational modification o f a protein. Gene regulation 
gives the cell control over structure and function, and is the basis for cellular 
differentiation, morphogenesis and the versatility and adaptability o f any organism. 
Gene regulation may also serve as a substrate for evolutionary change, since control of 
the timing, location, and amount o f gene expression can have a profound effect on the 
functions (actions) o f the gene in the organism (Alberts et al., 2008; Karp, 2007).
Any step o f gene expression may be regulated, from the DNA-RNA transcription step 
to post-translational modification o f a protein. The following is a list o f stages where 
gene expression is regulated:
• Epigenome (Chemical and structural modification of DNA or chromatin)
• Transcription
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• Post-transcriptional modification e.g. splicing
• RNA transport (nuclear sequestration, nuclear export, sequestration in processing 
bodies)
• mRNA degradation
• Translation
• Post-translational modifications
Although potentially every step, as shown above, involved in the expression of a gene 
may be regulated, for most genes, the initiation of RNA transcription is the most 
important point of control. This is because, only transcriptional regulation ensures that 
the cell will not synthesize superfluous intermediates (Alberts et al., 2008; Karp, 2007).
1.3.1 Transcriptional Regulation
Transcription involves the synthesis of RNA from a DNA template by RNA polymerase 
(RNA pol). In eukaryotic transcription, there are three classes of RNA polymerases: I, II 
and III, catalyzing the transcription of genes encoding different classes of RNA. RNA 
pol I transcribes pre-rRNA 45S, which matures into 28S, 18S and 5.8S rRNAs. RNA 
pol III synthesizes tRNAs, 5S rRNA and other small RNAs found in the nucleus and 
cytosol. Only RNA pol II is involved in the transcription of protein coding genes and 
hence functions in the production of mRNA. As RNA pol II is not able to bind the DNA 
directly, other proteins bind to the DNA to form the pre-initiation complex prior to 
RNA pol II recruitment. Transcription then initiates with RNA pol II directing 3’- 
hydroxylation of the RNA chain on a ribonucleoside triphosphate, leading to extension 
of the chain in a 5’—>3’direction (Alberts et al., 2008; Karp, 2007).
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Transcription is regulated by the binding of proteins (transcription factors) to cis- 
regulatory DNA response elements (Ptashne, 1988). Several types of cis-acting 
elements have been defined including promoters, enhancers, upstream promoter 
elements and response elements. Transcription factors can be divided into two main 
groups, namely general transcription factors that form the pre-initiation complex and 
gene specific transcription factors which act to either stimulate or repress the assembly 
of the pre-initiation complex.
1.3.1.a Regulation by Transcription Factors
General transcription factors are sufficient for low levels of accurate transcription 
initiated by RNA pol II from core promoters, many of which contain the TATA box or 
initiator sequence, Py2CAPy5 (Roeder, 1996). However, general transcription factors are 
common to all RNA pol II transcribed genes, independent of cell type. As such, gene 
specific transcription factors are essential for the activation and repression of specific 
genes to ensure a tightly controlled temporal and/or tissue specific expression.
Transcription factors bind to promoter elements or enhancers to influence the initiation 
of transcription by recruiting chromatin modifiers and/or members of the pre-initiation 
complex. For example, assembly of general transcription factor TFIID into the pre­
initiation complex is a rate limiting step and is stimulated by the presence of 
transcriptional activators that bind to other general transcription factors such as TATA 
box binding protein (TBP) or specific TBP associated factor (TAF) subunits. SP1 is one 
such transcriptional activator. It interacts with dTAFl 10 and facilitates the pre-initiation 
complex assembly (Roeder, 1996). Alternatively, some activators may recruit factors
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that modulate chromatin structure to make the promoter and enhancer elements more 
accessible.
Conversely, transcriptional repressors may act to prevent activators from binding to 
their DNA binding sites via competition or formation of non-DNA binding protein- 
protein complexes with activators. In addition, inhibitors may interact with activators 
and block their activation domain in a phenomenon known as quenching. Direct 
inhibition may also occur by transcriptional repressors binding to their DNA elements 
in promoters and making contacts with the general transcription factors that hinders the 
formation of the pre-initiation complex (Latchman, 2008). One such example is the Eve 
(Drosophila even skipped) protein which functions by preventing the association of 
TFIID with the promoter TATA box element (McKay et al., 1999).
Additionally, some transcription factors bind co-activators or co-repressors that in turn 
interact with the basal apparatus. These co-activators and co-repressors themselves do 
not bind DNA but their specificity is conferred by their ability to associate with DNA 
binding transcription factors.
1.3.1.b Regulation of Transcription Factors
To allow for precise temporal and spatial regulation of transcription, the activity of gene 
specific transcription factors has to be regulated. This may be achieved in several ways. 
Some transcription factors may have restricted distribution and are only synthesized in 
certain tissues or at a specific time. This is typical of factors involved in the regulation 
of development (Alberts et al., 2008). Other transcription factors may require the
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presence of tissue-specific co-factors before they are able to regulate transcription 
(Alberts et al., 2008).
Alternatively, some transcription factors may be activated under certain conditions, such 
as an extracellular stimulus, by protein modifications in the form of phosphorylation, 
acetylation and/or ubiquitination. For example, NFkB is sequestered in the cytoplasm 
by binding to IkB. Extracellular stimuli such as stress, cytokines and free radicals cause 
the phosphorylation and ubiquitination of IkB. This releases NFkB and allows it to 
localise to the nucleus and active target genes (Karin and Ben-Neriah, 2000). Some 
factors may also be regulated by binding to a ligand. For example, steroid and thyroid 
hormones enter cells and combine with intracellular receptors to form active 
transcription factors (Beato and Klug, 2000).
The activation or synthesis of gene specific transcription factors in response to various 
spatial or temporal stimuli as well as the combinatorial control by various transcription 
factors allows the establishment of a vastly complex pattern of gene expression required 
in every organism for normal development and function.
1.3.l.c Types of Transcription Factors
In general, transcription factors bind to DNA as homodimers or heterodimers and 
recognize DNA through one of the more common structural motifs: zinc finger, leucine 
zipper, helix-loop-helix and helix-tum-helix.
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1.3.1 .c.i Zinc finger motif
The zinc finger motif is present in the largest class of mammalian transcription factors. 
Two common zinc finger motifs exist. The first type (Cys2His2) involves a zinc ion 
which holds an a-helix and a p-sheet together, coordinated through two histidines and 
two cysteines residues respectively (Alberts et al., 2008). Proteins that contain this motif 
share extensive homology (90% identical or conserved residues) throughout each zinc 
finger DNA-binding domain (Luscombe et al., 2000).
The second type of zinc finger motif (multicysteine: C4 or C6) is similar to helix-tum- 
helix motif, in which two a-helices are held together by zinc ions (Alberts et al., 2008). 
Although the two types of zinc finger motifs are structurally different, they both require 
zinc for part of their structure and they both use an a-helix to recognise and bind to 
DNA. Both EGR (contain Cys2His2 zinc finger motif) and Nuclear Receptor proteins 
(contain multicysteine, C4, zinc finger motif), to be described later, belong to this group 
of transcription factors.
1.3.1 .c.ii Leucine zipper motif
The leucine zipper motif gets its name because leucine residues occur every seventh 
amino acid along a stretch of a-helix. As an a-helix turns every 3.5 residues, this places 
all the leucine residues on one side of the a-helix. Unlike the zinc finger proteins, the 
leucine zipper proteins can only bind DNA in dimers. One a-helix from each monomer 
is held together by hydrophobic interactions between the leucine residues to form a 
short coiled-coil conformation. Just beyond the dimerization interface, the two a-helices 
separate to form the DNA binding domain (Alberts et al., 2008).
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1.3.1 .c.iii Helix-loop-helix motif
The helix-loop-helix motif is characterized by a shorter a-helix separated to a longer 
one by an intervening loop. Transcription factors with this motif, like those with leucine 
zipper motif, can only bind DNA when dimerised. However, transcription factors with 
the helix-loop-helix motif may bind to DNA as homodimers or heterodimers. This 
allows for a higher diversity in regulatory factors present. In addition, some helix-loop- 
helix transcription factors lack the a-helical extension required for DNA binding. 
Nonetheless, they can still dimerize with another full-length helix-loop-helix 
transcription factor. This heterodimer is unable to bind DNA tightly as only half of the 
necessary contacts for DNA binding are present (Karp, 2007).
1.3.1 .c.iv Helix-turn-helix motif
Finally, another very common motif, the helix-tum-helix is composed of two a-helices 
connected by a short extended chain of amino acids. The two helices are held at a fixed 
angle through interactions between the two helices. The C-terminal helix recognises and 
binds to consensus sequences on the DNA. Outside the helix-tum-helix motif, the 
structure varies drastically between different transcription factors. The POU-domain 
transcription factors which will be described later belong to this class of transcription 
factors (Alberts et al., 2008).
To further illustrate the importance of gene regulation in general and in Parkinson’s 
disease, the following sections will discuss in detail a few transcription factors, from 
different families, which are of relevance to this thesis.
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1.3.2 EGR sub-family of Transcription factors
Immediate early genes are the first gene targets activated by the diverse intracellular 
signaling systems relaying events and stimuli at the cell surface to the nucleus. This is 
essential to enable coupling of short-term, cell-surface events to the long-term, 
coordinated changes in gene expression that give rise to the required alteration in cell 
function (Beckmann and Wilce, 1997). The Early growth response (EGR) family of 
genes consists of inducible transcription factors belonging to a subclass of the 
immediate early genes. They respond rapidly to various stimuli and neuro-transmission 
by mediating a cascade of altered gene expression (Fig 1.6) (Beckmann and Wilce, 
1997).
1.3.2.a EGR protein structures & domains
The EGR family of transcription factors include EGR1 (also known as NGFI-A, krox- 
24, zi£268 and TIS8), EGR2 (also known as krox-20), EGR3 (also known as PILOT) 
and EGR4 (also known as NGFI-C and pAT133) (Beckmann and Wilce, 1997). EGR 
transcription factors belong to the Cys2His2 class of zinc finger motif-containing 
proteins and contain three zinc fingers each. The three zinc fingers recognize a nine 
base-pair sequence of DNA, with each finger spanning three nucleotides (O'Donovan et 
al., 1999).
All four members of the EGR family recognize the same consensus sequence 
GCG(G/T)GGGCG (Cao et al., 1990; Chavrier et al., 1988; Christy and Nathans, 
1989a; Crosby et al., 1991; Lemaire et al., 1990; Patwardhan et al., 1991). Although the 
consensus binding motif of Spl is related to, and may overlap, the EGR consensus site,
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Figure. 1.6 Gene Regulatory Network of TF family EGR in human
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Note:
Ellipses are ‘transcription factors (TFs)' Boxes are genes.
Hexagons are the clustered genes. The number of the genes is shown inside.
Red lines indicate the protein-DNA binding is known.
Only official gene symbols are used in the network.
Listing of the gene clusters (TFs are underlined):
16—►EGR 1: POU4F1. CSF2, CSF3, IL1B, IL12A, NAB1, NAB2, NGFB, OSM, MAPK1, MAPK3, MAPK4, MAPK8, MAPK11, CXCL12, 
CUL5.
5—EGR1 + EGR3 + EGR2: CHRM1, CHRM2, CHRM3, CHRM4, CHRM5.
EGR 1—88: CEBPB, ELK1, AR. JUN. MYB. NFKB1. PPARG. BCL2. RELA. TP53. WT1. CDK5, CDKN2A, CHGA, CHRNA7, COL1A2, 
COL2A1, CRABP2, ZFP90, CTNNB1, ACE, DUSP4, EIF4EBP1, ABCA2, F3, FCER2, FGFR3, FLT1, FLT3, FN1, ALOX5, GCG, ANKRD1, 
HGF, HSD11B2, APOA1, IFNG, IGF2, IL2RB, IL3, IMPDH2, LHB, LTB, MAOB, ACHE, MMP14, ATP2A2, SERPINE1, PCSK2, PDGFB, 
PECAM1, PLAU, POR, PDGFC, PSEN2, PTEN, BAX, RBI, CCND1, RET, SLC1A4, SLC5A5, SOD1, SOD2, SRY, VAMP2, SYN1, SYN2, 
TGFBR2, THBS1, TIMP1, TIMP2, TIMP3, TPO, VEGF, VEGFB, PTP4A1, TFPI2, FOSL1, EPX, CAT, CCKBR, CD9, CD 19, CD28, GDF15, 
PTGES, CD44.
Figure courtesy of http://rulai.cshl.edu/TRED/GRN/EGR.htm
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it was not found to compete for binding to DNA with EGR1 or EGR2 proteins 
(Chavrier et al., 1990; Christy and Nathans, 1989a).
Apart from eight other short regions of homology, the different EGR proteins are not 
homologous outside the DNA-binding zinc finger domain (Fig. 1.7) (Crosby et al., 
1992). It is not clear why these eight homologous regions are present, however, 
evolutionary maintenance of these regions suggests they have critical functions which 
may include interactions with other proteins involved in transcription (Crosby et al., 
1992). Three of these eight homologous regions found in EGR1, EGR2, and EGR3 are 
not found in EGR4. Hence, although EGR4 may bind to the same consensus site, the 
consequences of its interaction may be unique (Crosby et al., 1992).
Additional to the zinc finger DNA-binding domain, EGR proteins also have 
transcriptional activation and repression domains, nuclear localisation signal domain 
and acidic, basic regions as well as large regions rich in proline, alanine, serine and 
threonine residues in their N-terminal region (Fig 1.7) (Beckmann and Wilce, 1997; 
O'Donovan et al., 2000).
The transcriptional activation domains allow EGR proteins to activate target gene 
transcription. The repression domains, on the other hand, have only been found to 
interact with repressor proteins which repress EGR transcriptional activity. This was not 
noted in the case of EGR3. Activation and repression domains of EGR4 have yet to be 
characterized. The basic regions have been shown to aid in EGR transcriptional factor 
nuclear localisation and the large regions rich in proline, alanine, serine and threonine
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Figure. 1.7 Schematic diagram of structural and functional regions of EGR transcription factors.
The pink boxes represent the 8 regions of homology between the different EGR proteins. EGR4 only contain 
5 of the 8 homology regions. ‘A’ represent activation domains while ‘R1’ represent the region whereby NAB1 
or 2 interact. The red asterisk and line represent the location of splicing observed in EGR2 and 3.
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residues may serve for post-translational modifications to occur (Knapska and 
Kaczmarek, 2004).
1.3.2.b Basal brain expression profiles of EGR genes
All the EGR genes are highly expressed in the brain. In addition, EGR1 is also 
expressed in various regions of the body, in particular cancer cells; EGR2 is mainly 
found in Schwann cells, while both EGR3 and EGR4 are expressed in T-lymphocytes. 
As our interests lie in neurons in the brain, expression and function in other regions 
would not be further discussed.
High levels of EGR1, EGR3 and EGR4 are found in layers II and IV of the cerebral 
cortex (Beckmann and Wilce, 1997). Enrichment of EGR2 was found mainly in layers 
II and III of the cerebral cortex. All EGR proteins show high expression in the 
hippocampus, particularly in the CA1-3 subfields, and also in the striatum (Beckmann 
and Wilce, 1997). The continual expression of inducible EGR in these areas of the brain 
in the absence of intentional stimulation could be due to constitutive expression, or 
basal expression to ongoing, physiologically normal input from synapses or neuroactive 
hormones (Herdegen and Leah, 1998).
1 .3 .2 .C  EGR1
The EGR family was first linked to the nervous system when EGR1 was identified in a 
screening experiment aimed to detect early response genes induced by nerve growth 
factor (NGF) (Milbrandt, 1987). EGR1 was later shown to be induced by 
neurotransmitters or depolarization, thus indicating that it is not just involved in 
differentiating neurons but mature neurons as well (Sheng and Greenberg, 1990). Since
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then, EGR1 has also shown to be induced, in various regions of the brain, by different 
pharmalogical stimulations (shown in detail in Table 1.2).
EGR1 is mainly implicated in neuronal plasticity. Numerous studies have been 
performed to examine the function of EGR 1 in the sensory cortex, in response to visual 
and sensory stimulations (Kaczmarek and Chaudhuri, 1997; Knapska and Kaczmarek, 
2004); in the hippocampus, in response to various seizure stimuli (Gall et al., 1990); in 
long-term potentiation (Worley et al., 1993) and especially in learning (Knapska and 
Kaczmarek, 2004). EGR1 knock-out mice have been observed to have impaired long­
term potentiation following tetanic stimulation (Jones et al., 2001; Wei et al., 2000) and 
learning studies showed impaired acquisition and severe deficits in long-term spatial 
memory (Jones et al., 2001). Of particular relevance to Parkinson’s disease, EGR1 was 
shown to be induced when D1 dopamine receptors were stimulated in the striatum, 
where excitatory amino acid afferents from cerebral cortex and dopamine afferents from 
the substantia nigra synapse on common projection neurons (Keefe and Gerfen, 1996).
Spatial expression patterns of EGR1 mRNA correspond tightly with its protein level, 
indicating that the basal level of EGR 1 expression is likely to be regulated mainly at the 
level of transcription (Beckmann and Wilce, 1997). Several response elements have 
been found in the EGR1 promoter, these include serum response elements, Spl sites, 
AP-1 (activator protein 1) sites, CRE (calcium/cAMP response elements), NFkB sites 
and ERE (EGR response elements) (Aicher et al., 1999; Sakamoto et al., 1991; 
Schwachtgen et al., 2000). O f these elements, the serum response elements (SRE) 
appear to play the main role in the coordinated induction of EGR 1 as they are required 
for the induction of EGR1 by serum, platelet-derived growth factor, phorbol 12-
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Table 1.2 Summary of EGR induction after pharmalogical stimulations in the brain and/or cultured neurons
Stimulus EGR mRNA/protein induced Brain region/cell type
Glutamate EGR1 mRNA Cortico-striatal monolayers
NMDA EGR1 mRNA & protein Cerebral cortex, CA1-3, dentate gyrus, inferior colliculus, cerebellum, hypothalamus, olfactory bulb
Quinolinic acid EGR1 mRNA Cortex, CA1-3, dentate gyrus
Kainic acid EGR1 mRNA & protein Neocortex, CA1-3, dentate gyrus, striatum, pyriform, cingulated & primary olfactory cortices, amygdale, lateral fornix
EGR2 protein Somatosensory & pyriform cortices, olfactory tubercle, CA1-3, dentate gyrus, amygdale, striatum, retrosplenal cortex
Kainic acid (cold) EGR1 mRNA & protein Sensory, pyriform & entorhinal cortices, CA1-3, dentate gyrus
AMPA/Quis agonists EGR1 mRNA Cortico-striatal monolayers
Dizocilpine EGR1 protein Retrospenal & cingulated cortices, paraventricular & dorsomedial thalamic nuclei
EGR2 protein Retrospenal & cingulated cortices, paraventricular & dorsomedial thalamic nuclei
Pentylenetetrazole EGR1 mRNA & protein Neocortex, pyriform & cingulated cortices, CA1-3, dentate gyrus
EGR4mRNA Dentate gyrus
Picotoxin EGR1 mRNA Neocortex, pyriform & cingulated cortices, CA1-3, dentate gyrus
Bicuculline EGR1 mRNA
Neocortex, pyriform & cingulated cortices, CA1-3, dentate gyrus, entorhinal & retrospenal cortices, amygdaloid &
habenular nuclei
EGR2 protein Somatosensory pyriform, cingulated & retrospenal cortices, fornix, amygdale
Dopamine (Di) agonist EGR1 mRNA Striatal neurons, cerebral cortical monolayers, caudate putamen, olfactory tubercle, cortex
EGR2mRNA caudate putamen, olfactory tubercle, cortex
Dopamine (D2) agonist EGR1 mRNA & protein Caudate putamen, nucleus accumbens
EGR3mRNA Striatum
Amphetamine (Di) EGR1 mRNA Caudate putamen, nucleus accumbens, olfactory tubercle
Cocaine (Dj) EGR1 mRNA Caudate putamen, nucleus accumbens
EGR3 mRNA Striatum
Cocaine seizure EGR1 mRNA Medial amygdale, striatum, ventral medial thalamus, pyriform & entorhinal cortices, CA1-3, dentate gyrus
a  i adrenoceptor EGR1 mRNA Cerebral cortex
antagonist
Muscarine antagonist EGR1 mRNA & protein Striatum
Caffeine (adenosine A] EGR1 mRNA Striatum& A2 antagonist)
Morphine withdrawal EGR1 mRNA Caudate putamen, nucleus accumbens, anterior cingulated cortex
EGR1 protein Cerebral cortex, CA1-3, dentate gyrus, cerebellum, brain stem
EGR2 mRNA Caudate putamen, nucleus accumbens, anterior cingulated cortex
Vasointestinal peptide EGR1 mRNA Cortical neurons
Ethanol withdrawal EGR1 mRNA & protein Cerebral cortex, olfactory bulb, CA1-3, dentate gyrus, inferior colliculus, cerebellum, brain stem
(Adapted from Beckmann and Wilce, 1997)
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myristate 13-acetate (PMA), nerve growth factor and following antigen receptor cross- 
linking in B lymphocytes (Christy and Nathans, 1989b; DeFranco et al., 1993; 
McMahon and Monroe, 1995). Binding to the other elements on EGR1 promoter seems 
to only modulate the induction conferred by binding to SRE (Knapska and Kaczmarek, 
2004). Bm3a (which will be described later) has also been shown to regulate EGR1 
expression (Smith et al., 1999a). However, whether this interaction involves direct DNA 
binding of Bm3a was not confirmed.
The transcriptional activating function of EGR1 depends on its modifications and 
binding partners. EGR1 has been found to be phosphorylated on serine residues and 
glycosylated (Cao et al., 1990; Lemaire et al., 1990). The activation potential of EGR 1, 
which may be through phosphorylation, is distributed over the extensive 
serine/threonine rich regions as shown previously in Fig. 1.7 (Gashler et al., 1993). In 
addition to protein modifications, interaction with other transcription factors plays a 
major role in modulating EGR1 transcription regulation activity.
Several binding partners have been found for EGR1, these include NR4A1 from the 
nuclear receptor family, NF-kB, c/EBPp, JunD, c-Fos, cAMP responsive element 
binding protein binding protein (CBP/p300), NGFI-A binding protein (NAB1) and 
NAB2 (Knapska and Kaczmarek, 2004). NAB1 and NAB2 were of special notice as 
they were the only proteins that showed repression of EGR1 activity during interaction 
(Russo et al., 1995; Svaren et al., 1996). While NAB1 is an active repressor which 
works by a direct mechanism and its repression is not specific to any particular 
activators (Swimoff et al., 1998), NAB2, which shares two large regions of homology 
with NAB1, is regulated by stimuli that also induce EGR1 expression (Svaren et al.,
54
Chapter I: Introduction
1996). This suggested that NAB2 could act as a negative-feedback mechanism for 
EGR1 (Knapska and Kaczmarek, 2004). The diversity of potential interactions 
emphasizes the versatility and sensitivity of EGR1 mediated regulation.
1.3.2.d EGR2
EGR2 was first isolated from serum treated human 303 cells using a low stringency 
hybridization with EGR1 cDNA probe (Joseph et al., 1988). This newly identified 
protein was found to be co-regulated with EGR1 by fibroblast and lymphocyte mitogens 
(Joseph et al., 1988). However, differences in induction of EGR1 and EGR2 by 
different stimuli were also shown (Joseph et al., 1988). In addition different 
pharmalogical stimuli also induced different responses from EGR1 and EGR2 in 
different regions of the brain (Table 1.2).
The EGR2 promoter contains two SRE-like elements, with a CArG-box as an inner core 
element (Beckmann and Wilce, 1997). CArG-1 was found to be responsible for the 
serum and PMA responsiveness of EGR2 via protein kinase C-dependent and 
independent pathways respectively (Rangnekar et al., 1990). EGR2 transcription could 
be repressed by other inducible transcription factors like c-Fos and Fra-1 and this 
suppression was also found to occur through the CArG-box. Although AP-l-like 
elements are present in the EGR2 promoter, EGR2 is not inducible by NGF (Joseph et 
al., 1988).
The two acidic regions at the EGR2 N-terminal are responsible for the trans-activation 
properties of EGR2 (Chavrier et al., 1990). Modifications in the C-terminal of EGR2 
did not appear to affect its trans-activation abilities (Herdegen and Leah, 1998). Similar
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to EGR1, interactions with NAB1 or NAB2 were also found to block EGR2 trans- 
activation (Russo et al., 1995; Svaren et al., 1996).
1.3.2.e EGR3
EGR3 was later isolated from human 303 cells using a similar strategy as that used to 
identify EGR2 (Patwardhan et al., 1991). The promoter region of EGR3 has not been 
fully characterized.
EGR3 has been found to be induced by a variety of stimuli including mitogens that also 
induced EGR1 and 2 (Patwardhan et al., 1991). Brain derived neurotrophic factor 
(BDNF) has also been found to be the endogenous signal that induces EGR3 
expression, via a PKC/MAPK-dependent pathway, in dentate granule cells of the 
hippocampus (Roberts et al., 2006). EGR3, in turn, was found to regulate type A GABA 
receptor alpha 4 subunits in these neurons (Roberts et al., 2006). The regulation of these 
receptors is associated with temporal lobe epilepsy (Roberts et al., 2006). EGR3 has 
also been linked to learning, memory, stress and novelty in mice (Gallitano-Mendel et 
al., 2007; Li et al., 2007).
EGR3 is believed to have several translation start sites and exists in several isoforms in 
the brain (O'Donovan and Baraban, 1999; O'Donovan et al., 2000). These different 
isoforms were observed to vary in their trans-activation abilities, as the smaller isoforms 
lack the first of two activation domains present at the N-terminal of EGR3 (O'Donovan 
and Baraban, 1999). NF-kB  was shown to interact with EGR3 in T-cells to transactivate 
genes encoding inflammatory cytokines (Wieland et al., 2005). Similar to both EGR1 
not known whether EGR3 could also be similarly repressed by NAB2.
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1.3.2.f EGR4
In contrast to the other EGR proteins, EGR4 has not been studied in such considerable 
detail. EGR4 was isolated from mitogen stimulated human T lymphocytes and 
identified as the human homologue of the rat Egr-4 clone, which itself was isolated via 
homology to the zinc finger region of Egr-1 in NGF-stimulated rats (Crosby et al., 
1991; Muller et al., 1991). Most of the studies on EGR4 were concentrated in T- 
lymphocytes and spermatogenesis (Skerka et al., 1997; Tourtellotte et al., 2000).
The EGR4 promoter was shown to contain two calcium response elements, four sites 
for Nur77 binding, a Spl site and an EGR DNA-binding motif (Crosby et al., 1992). 
EGR4 has been shown to auto-regulate its own expression through binding to the GC- 
rich EGR binding motif on the EGR4 promoter (Zipfel et al., 1997). This auto­
regulation appeared to occur in a dose-dependent manner and could suggest a negative 
feedback mechanism (Zipfel et al., 1997). SREs were not found in the promoter despite 
EGR4 being shown to be strongly induced by serum stimulation (Crosby et al., 1992). 
As mentioned earlier, similarly to EGR1, EGR4 was also found to be induced by NGF 
in rat PC 12 cells (Crosby et al., 1991).
The activation or repression domains of EGR4 have not been clearly characterized. 
Nonetheless, as with EGR3, NF-kB was also shown to interact with EGR4 in T-cells to 
transactivate genes encoding inflammatory cytokines (Wieland et al., 2005). In addition, 
EGR4 was also shown to interact with NFAT (nuclear factors of activated T cells) to 
form heterodimers and regulate pro-inflammatory cytokines gene expression following 
antigenic stimulation (Decker et al., 2003). EGR4 activity has not been shown to be 
repressed by either NAB 1 or NAB2.
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Although none of the EGR members have been associated with Parkinson’s disease, 
their inducible nature via various stimuli, including dopamine, and their strong 
expression in the striatum makes them good candidates for studies into the regulation of 
Parkinson’s disease associated genes in oxidative stress.
1.3.3 Orphan nuclear receptor family of 
Transcription factors
Nur77 (NR4A1/NGFI-B), Nurrl (NR4A2) and Norl (NR4A3) are highly homologous 
receptors that form a sub-group in the nuclear receptor superfamily of ligand-activated 
transcription factors (Law et al., 1992; Mangelsdorf et al., 1995). The nuclear receptor 
family includes receptors for steroid hormones, retinoic acid, thyroid hormone, vitamin 
D, and several other small, lipophilic signaling molecules (Mangelsdorf et al., 1995). 
Nurrl, Norl, Nur77 and a large number of members in the family lack identified 
ligands. Therefore, they are referred to as orphan receptors. Nuclear receptors have a 
common structural organization with a variable N-terminal, a conserved zinc finger 
DNA binding domain of the multicysteine C4 class, and a less conserved ligand binding 
domain.
Nurrl, Norl and Nur77 transcription factors are products of immediate-early genes and 
their expression and activity are regulated in a cell-specific manner by a variety of 
extracellular mitogenic, apoptotic and differentiation stimuli (Jankovic et al., 2005). As 
mentioned earlier (section 1.2.3.b), Nurrl is one of the genes associated with 
Parkinson’s disease and mutations in the Nurrl gene have led to the development of 
Parkinson’s disease.
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Other than the importance of Nurrl in the development and survival of mesencephalic 
dopaminergic neurons, Nurrl also appears to regulate the expression of tyrosine 
hydroxylase (TH), dopamine transporter (DAT), vesicular monoamine transporter 2 
(VMAT2), and 1-aromatic amino acid decarboxylase (AADC), all of which are 
important in the synthesis and storage of dopamine (Jankovic et al., 2005). Nurrl is 
essential to the development and maintenance of dopaminergic neurons through its 
interaction with factors such as Pitx-3, Lmxlb, GDNF receptor, Wnt family of 
glycoproteins and p57kip2. These factors are vital to the various stages in the 
development and maintenance of dopaminergic neurons (Jankovic et al., 2005).
In view of the involvement of Nurrl in Parkinson’s disease, dopaminergic neuron 
survival and functions, it is included in our studies into transcription factors that 
regulate a-synuclein.
1.3.4 Brn3 sub-family of Transcription factors
The POU family of transcription factors was originally defined on the basis of a 
conserved region identified in the Pit-1, Oct-1, Oct-2 and Unc-86 regulatory proteins, 
which play a critical role in regulating gene expression in specific cell types (Latchman, 
1996; Verrijzer and Van der Vliet, 1993; Wegner et al., 1993). The original Bm3 factor 
was first isolated as a novel POU protein by He et al. (He et al., 1989) using a 
degenerate PCR approach to isolate novel POU domain transcription factors specific to 
neuronal cells. The Bm3 factor was later discovered to be, in fact, three distinct factors 
encoded by different genes which are expressed in specific subsets of neuronal cells 
(Gerrero et al., 1993; Theil et al., 1993; Theil et al., 1994; Turner et al., 1994). These
59
Chapter I: Introduction
factors are Bm3a (Gerrero et al., 1993; Lillycrop et al., 1992), Bm3b (Lillycrop et al., 
1992; Turner et al., 1994) and Bm3c (Gerrero et al., 1993; Ninkina et al., 1993). 
Although encoded by different genes, these three factors are closely related to one 
another and exhibit very strong homology to the nematode regulatory factor, unc-86 
(Latchman, 1996). Like unc-86, they also play a critical role in regulating neuronal 
specific gene regulation (Latchman, 1996).
Bm3a is important for the differentiation and survival of sensory as well as motor 
neurons. Knock-out Bm3a mice suffer from severe neuronal developmental defects and 
are usually non-viable (McEvilly et al., 1996). Bm3b and Bm3c are involved in the 
differentiation and maintenance of retinal and vestibular neurons of the inner ear 
respectively. Unlike Bm3a knock-out mice, both Bm3b and Bm3c mice are viable but 
suffer from blindness and deafness respectively (Erkman et al., 1996). Due to the 
importance of Bm3a in the development and maintenance of motor neurons, it was the 
main focus in our experiments and will be described in further detail below. As Bm3b 
has been shown to interact with Bm3a and display possible antagonistic effects on 
Bm3a activity, it will also be described below (Latchman, 1999). Bm3c will not be 
discussed further.
1.3.4.a Bm3a
Bm3a is the most widely expressed Bm3 protein in the nervous system. It is expressed 
both in the peripheral nervous system as well as in the central nervous system. In the 
central nervous system, Bm3a expression is only observed in post-mitotic neurons 
(Fedtsova and Turner, 1995; Gerrero et al., 1993; Turner et al., 1994; Xiang et al.,
1995). High levels of Bm3a are observed in the developing midbrain, hindbrain and in
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the spinal cord (Fedtsova and Turner, 1995; Ninkina et al., 1993). Expression in adult 
brain is restricted to specific regions. These regions include specific areas in the 
hindbrain such as the medial habenula, the nucleus ambiguous and the inferior olivary 
complex; regions in the midbrain such as the red nucleus, the mesencephalic nucleus 
and the superior colliculus (Turner et al., 1994).
The Bm3a protein is encoded by a single gene, but two transcriptional promoters are 
present. Transcription from the upstream promoter followed by splicing to remove an 
intron between the first and second exons results in the long form of Bm3a (Fig. 1.8) 
(Latchman, 1998). On the other hand, transcription from the second promoter, located 
within the intron downstream of the first exon, results in the production of an unspliced 
RNA which encodes the short form of Bm3a lacking the first 84 amino acids, which 
contains a POU IV box (Theil et al., 1993). Both isoforms of Bm3a contain the POU 
domain, as such, they are able to activate genes mainly involved in neuronal 
differentiation. In addition, Bm3a-long is also able to activate genes such as a- 
intemexin and anti-apoptotic genes such as Bcl-2 via its additional POU IV box 
activation domain in the longer N-terminal (Smith et al., 1997a; Smith et al., 1997b).
The two forms of Bm3a are produced in different proportions by different neuronal 
cells (Liu et al., 19%) and have different functional properties. The presence of 
alternative promoters to produce the two different isoforms allows this differential 
regulation (Frass et al., 2002). In addition, two clusters of 1 and 4 copies of Bm3
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POU specific
POU IV box
Variable region domain Homeodomain
— i
inker
N-terminal
activation
domain
POU domain
Bm3a short
Brn3a long
Fig 1.8 Schematic representation of Brn3a isoforms
The long isoform contain and extra N-terminal domain that contains a highly conserved region, the POU 
IV box. The POU domain is found on both the long and short isoforms of Brn3a.
(Adapted from PhD thesis ‘Transcriptional regulation by Brn-3a POU domain containing transcription 
factors' Dr. J. Dennis, 1999)
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consensus binding sequences were found within the Bm3a promoter approximately 10 
and 5kb upstream of the transcription start site respectively (Trieu et al., 1999). These 
sites offer a possible autoregulation mechanism to regulate Bm3a expression in the 
different neurons (Trieu et al., 1999).
Bm3a has been shown to regulate expression of both anti-apoptotic and pro-apoptotic 
factors in neurons. This may represent the main mechanism through which Bm3a 
promotes neuronal survival. As mentioned previously, Bm3a was found to strongly 
activate anti-apoptotic Bcl-2 expression both in vivo and in vitro (Smith et al., 1998a; 
Smith et al., 1998b). Another anti-apoptotic gene, B c1-x l, which shares a high level of 
homology to Bcl-2, was also found to be transactivated by Bm3a (Smith et al., 2001). 
Interestingly, the phenotype o f B c 1 -x l null mice is similar to Bm3a knock-out mice in 
terms of neuronal survival (McEvilly et al., 1996; Motoyama et al., 1995; Xiang et al.,
1996). Hence, this strongly indicates that both proteins may exist in the same neuro- 
protective pathway. The transactivation by Bm3a of Bcl-2 and Bcl-xL was found to be 
via a direct interaction with their promoters (refer to Table 1.3) (Smith et al., 1998b; 
Smith et al., 2001). In addition to the transactivation of anti-apoptotic genes, Bm3a was 
also found to repress a pro-apoptotic Bcl-2 family member, Bax. The mechanism of this 
repression is not yet clear, but may proceed either through a direct repression on Bax 
promoter or indirectly through antagonism of p53, which was found to activate Bax 
expression (Budram-Mahadeo et al., 2002).
Although Bm3a has never been implicated in any disease states, it is important in 
survival and maintenance of neurons (McEvilly et al., 19%), possesses neural- 
protective properties (Latchman, 1998) and is expressed in mid-brain neurons (Gerrero
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et al., 1993). These factors suggest that it would be interesting to study whether Bm3a 
could be involved in the development of Parkinson’s disease.
1.3.4.b Bm3b
Bm3b expression in the developing and adult brain show considerable overlap with 
Bm3a. It is found in particularly high levels in the optical, intermediate and deep gray 
areas of the superior colliculus, the dorsal column of the mesencephalic, pontine central 
gray, and the lateral interpeduncular nucleus in the midbrain of adult rat brains. Bm3b 
was also found in retina, trigeminal ganglia and dorsal root ganglia neurons.
In spite of its presence in many regions of the central nervous system, Bm3b knock-out 
mice only show defects in their retinal ganglion organization, resulting in their 
blindness. In fact, a loss of approximately 70% of retinal ganglion cells was reported by 
Gan et al. and the knock-out mice show disorganized neurites which subsequently fail 
to fasciculate efficiently, thus leading to apoptosis (Erkman et al., 2000; Gan et al., 
1999; Gan et al., 1996). No other apparent defects were observed in regions expressing 
Bm3b in knock-out mice thus suggesting that functional redundancy may occur through 
the presence of other related proteins.
Similarly to Bm3a, Bm3b also exists in two isoforms, a longer spliced form of Bm3b 
consisting of both a POU IV box in the N-terminal and the POU domain, and a shorter 
unspliced form lacking the POU IV box (Fig. 1.9). The functional significance of the 
POU IV box in Bm3b is yet to be determined.
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Fig 1.9 Schematic representation of Brn3b isoforms
The long isoform contain and extra N-terminal domain that contains a highly conserved region, the POU 
IV box. The POU domain is found on both the long and short isoforms of Brn3b.
(Adapted from PhD thesis Transcriptional regulation by Brn-3a POU domain containing transcription 
factors’ Dr. J. Dennis, 1999)
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Bm3b have been found to be antagonistic to Bm3a, and has been shown to repress the 
basal activity of many promoters activated by Bm3a (Latchman, 1999). Table 1.3 gives 
a summary of the various gene targets regulated by Bm3a and Bm3b as well as the 
antagonistic effects of Bm3b on Bm3a. Although Bm3b appears to be less likely to be 
involved in the survival of neurons compared to Bm3a, its interactions and antagonistic 
effects on Bm3a make it worth examining alongside Bm3a.
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Promoter Bm3a Bm3b Domain
Snap-25 + N-term
a-intemexin + POU
Synaptotagmin 1 + - POU
Synapsin 1 + + POU
NFH + POU
NFM + POU
NFL + POU
Bd-2 + 0 N-term
Bd-xt + 0 Upstream promoter requires N-term, the downstream 
promoter requires sequences located between the POU 
and N-term domain
Bax - N.T POU and sequences located between the POU and N- 
term domain
p21w*i/opi + N.T POU
CDK4 N.T + N.T
Plakoglobin N.T - N.T
BRCA1 + - N.T
HSP-27 + + N.T
Vitellogenein 0 + POU
Table 1.3 Promoter regulation by Bm3a and Bm3b transcription factors
Activation of the promoter is indicated by +, repression by no effect by 0, 
effect not tested by N.T and * indicates that Bm3b not only represses the 
promoter, but also negates activation by Bm3a. The domain involved in the 
Bm3 mediated transcription on each promoter is also listed.
(Adapted from PhD thesis Transcriptional regulation by Bm-3a POU domain 
containing transcription factors’ Dr. J. Dennis, 1999)
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1.4 Thesis Aims
Environmental stresses and toxins have long been associated with Parkinson’s disease. 
This view was bolstered following the discovery of MPTP, a toxin found to cause an 
acute Parkinsonian syndrome. Subsequently, various other chemicals such as pesticides 
and herbicides were also associated with the onset of idiopathic Parkinson’s disease. 
These toxins and stresses were mainly oxidative and caused neuronal cell death by the 
production of free reactive oxygen species or caused mitochondrial dysfunction by 
interfering with electron transport chain. Many of these toxins and stresses were used to 
create animal and cell models for Parkinson’s disease research. The linkage between 
environmental stresses and genetics of Parkinson’s disease was then conceived when 
protein abnormalities such as increased levels or aggregation were detected in these 
models.
Since oxidative stresses and genetic factors are important in the development of 
Parkinson’s disease, the principal aim of this thesis was to profile the regulatory 
mechanisms and upstream pathways mediating Parkinson’s disease associated genes in 
normal conditions and in the event of oxidative stress. The main focus was to 
investigate expression changes of these genes in various conditions and to examine the 
transcription factors involved in the regulation.
In addition, mutational and/or protein analysis were also performed on Nurrl and 
PINK1. These genes are more recent discoveries compared to a-synuclein and parkin, 
thus, such studies will give important insights into their Parkinson’s disease properties.
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2.1 General Reagents & Equipment
2.1.1 General Suppliers
General laboratory chemicals were of analytical or molecular biology grade and were 
purchased from the following companies: Sigma Chemical Company Ltd., Poole 
Dorset, UK; BDH Merck Ltd., Lutterworth, Leicestershire, UK; Boehringer Mannheim, 
Lewes, East Sussex, UK. Phosphate buffered saline (PBS) was made using PBS tablets 
(1 tablet in 500ml ddLfeO) from Invitrogen Ltd, Paisley, UK. Millipore water was used 
for solutions and was autoclaved where necessary. General laboratory plasticware was 
purchased from BDH Merck Ltd. and Ependorff, Cambridge, UK.
2.1.2 Plasmid vectors, DNA constructs & siRNA
The a-synuclein promoter plasmids used were ‘1.46’, ‘1.9’, ‘3.4’, ‘3.8’, ‘4.1’ and PGL3 
basic, a promoterless luciferase construct (gifts from Dr Robert L Nussbaum: NHGRI, 
Bethesda, USA).
EGR4 cloned into pSG5 vector was a gift from Dr. C. Skerka (Hans Knoll Institute, 
Netherlands). EGR4 21nt siRNA was obtained from MWG together with a non-specific 
21nt siRNA as control.
Wild type Nurrl and mutant construct -245T>G Nurrl cloned into the pCMX vector 
were kind gifts from Dr Weidong Le (Houston, USA), with permission from Dr Hiroshi 
Ichinose (Tokyo, Japan) who isolated the genomic Nurrl clone. The -309C>T Nurrl 
mutation was introduced by site-directed mutagenesis using the QuikChange site-
70
Chapter II: Methods
directed mutagenesis kit (Stratagene) according to manufacturer’s instructions 
(performed by Dr. M.Muqit, Institute of Child health, London, UK). The empty pCMX 
plasmid and the NuRE-POMC-Luc plasmid were kind gifts from Dr John Achermann 
(London, UK) and Dr Jacques Drouin (Montreal, Canada) respectively.
The Bm3 and pLTR poly constructs were gifts from Dr. T. Moroy (Phillips University, 
Marburg, Germany). The Bm3a-short, a-long, b-short, b-long constructs were obtained 
by amplification from cDNA and cloning into the pLTR poly construct downstream of 
the eukaryotic expression MoMuLV promoter.
The parkin plasmids used were ‘4500’, ‘363’, ‘282’, ‘140’, Control (all gifts from Dr 
Andrew West: UCLA, Los Angeles, USA) and PGL3 basic.
Full-length PINK1 cDNAs were amplified using the primers hPINKl (5'- 
ggcggatccatggcggtgcgacaggcg-3') and hPINK2 (5'-ctcgaattcgggacatcacagggctgc-3') and 
cloned into the Bam \\\ and EcoRl sites of the vector pRK5myc so that a 9E10 (myc) tag 
is attached to the N-terminus. Mutations E476K, R501P, L102Q, R98A, S73A, R71A, 
F70Y, F70Q, R68P and R68G were introduced into pRK5mycPINKl using the 
Quikchange site directed mutagenesis kit (Stratagene) (Dr. Robert Harvey, London 
School of Pharmacology, UK).
21nt siRNA used to knock-down specific genes were from MWG BIOTECH, Germany: 
siRNA Sequence
Nurrl 5 ’-ACGUGUGUUUAGC AAAUAA(dT dT)-3 ’
EGR4 5 ’ -AGAUUGAGGACUUGCUGUC(dT dT)-3 ’
Non-specific control 5’-AGGUAGUGUAAUCGCCUUG(dTdT)-3’
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2.1.3 Laboratory Equipment
Trans-BlotTM cell transfer tanks, Bio-Rad Laboratories Ltd. (Hertfordshire, UK) 
Bio-Rad GS-800 densitometer, Bio-Rad Laboratories Ltd. (Hertfordshire, UK) 
Labsystems Multiskan RC Plate reader (Finland)
Zeiss microscope, Carl Zeiss Micolmaging Inc. (New York, USA)
Beckman Coulter EPICS XL FACS machine, Beckman Coulter Inc. (California, USA)
2.2 Bacterial cell culture
2.2.1 Reagents
Bacto®-Tryptone, Bacto®-Yeast extract, and Bacto® micro-agar bacterial growth 
medium were obtained from Duchefa (Harlem, Netherlands). DH5a strain of E. coli was 
obtained from Invitrogen Ltd. (Paisley, UK). QIAprep Mini and Maxi DNA prep kits 
were from Qiagen Ltd. (Crawley, UK).
2.2.2 Bacterial Competent cells
Reagents required: MR buffer -  lOmM RbCl, lOmM MOPS, pH7
[lOOpl RbCl (2.4g/10ml)
200pl MOPS 1M, pH7 
Make up to 20ml with H2O]
MRC buffer -  lOmM RbCl, 50mM CaCb, lOOmM MOPS, 
pH6.5
[lOOpl RbCl
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400pl CaCl2 (3.7g/10ml)
2ml MOPS 1M, pH6.5 
Make up to 20ml with H20]
A colony of DH5a E.coli untransfected cells was picked from a plate or 5 pi of glycerol 
cell stock was obtained and grown in 10ml of LB (without antibiotics) in a 50ml falcon 
tube overnight (~16hrs) in 37°C shaker.
lml of cultured cells was added to 99ml of LB and grown til an absorbance of 0.3-0.4 
OD at 600nm was reached (~3hrs). The culture was then aliquoted into 50ml falcon 
tubes and centrifuged at 1500g for 5mins at 4°C to pellet the cells. The LB was then 
discarded. lOmls of MR buffer was then used to resuspend each of the pellets gently by 
swirling. The cells were then centrifuged again at 1500g for 5mins at 4°C, and the 
supernatant discarded. 8mls of MRC buffer was used to resuspend each of the pellets. 
This mixture was then incubated on ice for 30mins before centrifuging at 1500g, 5mins, 
4°C. The supernatant is again discarded. The pellets of cells were again resuspended in 
2ml of MRC buffer.
For storage of the competent cells, lml of 80% (v/v) glycerol was added to the 4ml of 
mixture and the final mixture was aliquoted into lOOpl aliquots and snap-freezed using 
methanol and dry ice. These were then stored at -80°C.
2.2.3 Transformation of bacterial cells & retrieval 
of amplified DNA
Materials required:
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LB media (1L) - 1 Og tryptone
5g yeast extract 
lOgNaCl
LB Agar (1L) - LB media
15g microagar
pour onto plates and left to set o/n then store at 4°C
Ampicillin aliquots (50mg/ml) - lg ampicillin
20ml Millipore H20(autoclaved) 
filter through 0.22pm Millex filter 
lml aliquots (store in -20°C)
Xpl of 5mg/ml ampicillin was added to Xml of LB media/agar (The agar was then 
poured onto plates and allowed to set overnight (~16hrs))
The required number of aliquots of competent cells (2 transformations per aliquot) were
retrieved from -80°C freezer and thawed in ice. 50pl of the thawed cells were put into
each labeled eppendorf tube, lpl of 10-50ng/pl DNA sample was added to each 
respective tube and shook gently to mix. This was then incubated on ice for 20mins 
before being subjected to a heat shock of 42°C for 45secs. They were then incubated 
again on ice for 2-3mins before adding 500-800pl of LB (without antibiotics) was added 
to each tube and incubated for lhr on 37°C shaker. 50pl of each culture was plated onto 
agar plates with selection (e.g. ampicillin) and incubated overnight (~16hrs) in 37°C. 
Leftover culture can be stored up to a week in 4°C.
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1 colony from each plate was picked and inoculated in 200-300ml LB (ampicillin 
positive) and incubated overnight (~16hrs)/until confluent in 37°C shaker. For smaller 
cultures, each picked colony could also be inoculated in 5ml LB (ampicillin positive) in 
50ml falcon tubes. The plates were sealed using nesco film and stored in 4°C.
The transformed cells were then stored by aliquoting into 500pl aliquots. 500pl of 
glycerol was added to each aliquot and mixed quickly and thoroughly by vortexing and 
then stored in -80°C
To retrieve amplified DNA, the cultures were then poured into centrifuge barrels and 
balanced with LB media. They are then centrifuged at lOOOOg for 15mins in Sorvall 
RC26 plus centrifuge in SLA-3000 rotor at 4°C. DNA was subsequently retrieved and 
purified by using the Qiagen Maxi/mini prep according to the manufacturer’s protocol.
2.3 Mammalian cell culture
2.3.1 SH-SY5Y neuroblastoma cells
SH-SY5Y cells are human dopaminergic neuroblastoma cell lines. The cell line was 
obtained from the European Collection for Animal Cell Culture (ECACC) in the 13th 
passage.
Cells were grown and maintained in 85cm2 flasks in the following medium:
F12 Hams/1 X MEM with Earles Salts (1:1) (Gibco® Invitrogen, Paisley, UK); 15% 
(v/v) Foetal calf serum (PAA Laboratories); 1% (v/v) Non-essential amino acids; 1% 
(v/v) Penicillin/streptomycin antibiotic; and 1% (v/v) 2mM L-Glutamine (all from
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Gibco® Invitrogen). Cells were incubated in a humidified 5% (v/v) C02 atmosphere at 
37°C.
For storage, cells were frozen long-term in liquid nitrogen in the following medium: 
90% (v/v) Foetal Calf Serum + 10% (v/v) dimethylsulphoxide (DMSO) (Sigma).
Tissue culture media and media supplements were obtained from Invitrogen Ltd. 
(Paisley, UK). All tissue culture plastic-ware was obtained from Nunc (Roskilde, 
Denmark). Sterile 0.2pm filters were obtained from Millipore (Watford, UK). 
Lipofectamine 2000R reagent was obtained from Invitrogen Ltd. (Paisley, UK). 
Disposable sterile 0.22 pM filters were obtained from Millipore, Watford, UK.
2.3.2 Thawing of cells
5ml of warm media (suitable for the cell type being thawed) was put into each 50ml 
falcon tubes required (1 for each aliquot of cells). Aliquots of the required cells were 
retrieved from liquid nitrogen and lml of media from each falcon tube was pipetted into 
each tube and mixed using the pipette to quickly thaw the cells. This mixture was then 
pipetted back into each falcon tube (with remaining 4ml of media), and centrifuged at 
120g for lmin at 20°C. The supernatant including the DMSO initially present with the 
cell aliquots was discarded. Each pellet was resuspended with fresh warm media and 
added into an 85cm2 flask. The total volume in the flask was made up to 5ml using 
media. The flasks were incubated in a humidified 5% (v/v) C02 atmosphere at 37°C. 
The media was changed after 2-3 days if there was significant level of cell death.
76
Chapter II: Methods
2.3.3 Maintanence of cell cultures
When the cells have reached 80-90% confluency in the flask, they would be split. Media 
was retrieved from the confluent flasks and HBSS (Gibco® Invitrogen, Paisley, UK) 
was used to wash the cells.
lml of trypsin-EDTA (Gibco® Invitrogen, Paisley, UK) was put into each flask and the 
flask was shaken to ensure that all the cells have come into contact with the trypsin. The 
trypsin was then retrieved and the flask of cells was incubated in the hood for lOmins 
for the cells to dislodge from the flask wall. Fresh media was then added to suspend the 
cells and split 1 in 8, 85cm2 flasks, to a total volume of 5ml per flask. (SH-SY5Y cells 
are always grown in 85cm2 flasks)
2.3.4 Freezing down of cells
Media was retrieved from the confluent flasks and HBSS was used to wash the cells. 
The cells were dislodged from the flask walls as described above (maintenance of cell 
cultures) and the suspensions were centrifuged at 120g for lmin at 20°C. The 
supernatant was discarded and freeze media was used to resuspend each pellet (1 aliquot 
- 1.5ml; 1 aliquot/ 85cm2 flask) and transferred to cryotubes for freezing in -80°C 
overnight (~16hrs). They were then transferred to liquid nitrogen to be stored.
2.3.5 Transfection of mammalian cells
Cells were plated lday before transfections. SH-SY5Y cells were plated at 2 x 105 cells 
per well in 6 well plates, 3.5 x 104 cells per well in 24 well plates and 1, 95% confluent, 
85cm2 flask per 10cm plate.
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SH-SY5Y cells (passage 21-27) were plated onto 24 well plates at 3.5x104cells per well 
and incubated overnight (~16hrs) to 90% confluency. For 1 plated well of the 24 well 
plate, DNA used for transfection was added at 3pg in 200ml OPTIMEM (Gibco® 
Invitrogen, Paisley, UK), this mixture was then added to 2\x\ Lipofectamine 2000 in 
200ml OPTIMEM and incubated for 15mins. During this time, the plated wells were 
washed with HBSS to get rid of serum in the wells, which would otherwise affect the 
transfection efficiency. The DNA-Lipofectamine-OPTIMEM mixture was then added 
drop wise onto the cells in the wells at 400ml/well. Full culture media was replaced 4hrs 
later.
2.3.6 Cellular stress studies
2.3.6.a Dopamine stress
Cells were incubated for 24 hours in full growth media containing 0.0625mM, 
0.125mM, 0.2mM, 0.25mM dopamine (3-hyroxytyramine hydrochloride; Sigma) or 
vehicle (media) prior to harvesting.
2.3.6.b MPP+ stress
Cells were incubated for 6 or 12 hours in full growth media containing ImM, 5mM or 
lOmM MPP+ iodide (Sigma) or vehicle (media) prior to harvesting.
2.3.6.C MG-132 stress
Cells were incubated for 24 hours in full growth media containing 5mM, lOmM or 
15mM MG-132 (Z-Leu-Leu-Leu-H; Sigma) or vehicle (DMSO) prior to harvesting.
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2.4 In vivo  mice model
2.4.1 Genomic DNA isolation from mouse tissue
Approximately 5-10mm of tail tips from breeding or postnatal dayl mice were removed 
for genotyping analysis. The mouse tissue was placed in 1.5ml centrifuge tube 
containing 700pl of tail tip buffer (50mM Tris pH 8.0, lOOmM EDTA pH 8.0, lOOmM 
NaCl and 1% (w/v) SDS). 35pl of lOmg/ml proteinase K (Roche) was added and the 
tubes were incubated at 55°C overnight (~16hrs) with occasional agitation. Protein was 
extracted by mixing with an equal volume of phenol, centrifuging to separate phases 
and removal of the aqueous phase to a fresh tube. A second phenol extraction was 
performed followed by a chloroform:iso-amyl alcohol extraction. The DNA was 
precipitated by adding an equal volume of isopropanol to the final aqueous phase. The 
DNA was then pelleted by centrifugation, washed in 70% (v/v) ethanol, dried and 
resuspended in water and stored at 4°C until the samples were analysed by PCR.
2.4.2 Genotyping
The Bm3a-KO F (forward)/R (reverse), Bm3b-KO F/R and Neo F/R primers (Table 
2.1) were used to check the genotypes of Bm3a and Bm3b mice to ensure mating of 
heterozygous males and females. The Bm3a KO, Bm3a heterozygous, wildtype, Bm3b 
KO, Bm3b heterozygous and wildtype postnatal dayl mice obtained from these matings 
were dissected to retrieve brain samples and were also genotyped. As the size of the 
products differed, but the conditions for the reaction were the same, both amplifications, 
Bm3 and Neo, were performed in the same tube. Together with the template (50ng of 
genomic DNA isolated from mouse tails) each PCR contained 1 unit of Taq DNA
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polymerase (Promega) in a final volume of 25pi (IX Mg-free buffer, 2.5mM MgCh, 
ImM dNTPmix, lOOng of each primer). The cycling parameter is shown below:
Step Temperature Time Process
1 95 °C 5 mins Denaturation
2 95 °C 45 secs Denaturation
3 64 °C 45 secs Annealing
4 72 °C
Repeat steps 1-4 29 times
45 secs Extension
5 72 °C 5 mins Final extension
6 4 °C qo
The products were visualized on a 1.5% (w/v) agarose gel.
Table 2.1 
Primer 
j Bm3a KO F 
j  Bm3a KO R 
Bm3b KO F 
Bm3b KO R 
Neo F 
Neo R
Primer sequence
5'-GGCGCGC AGCGT GAG A A A AT G A A-3 ’ 
5 -GTCTC AC ACCCTCCT C AGT AACT-3 ’ 
5'- CACATGGGCTGCATGAGCGACGT-3' 
5'- CGGCTTAGTGAGCTTCTCGCGGT-3' 
5'- TGATGCCGCCGTGTTCCGGCTGT-3' 
5’- TCGCCGCCAAGCTCTTCAGCAAT-3'
2.5 DNA analysis
2.5.1 Determination of DNA concentration
DNA concentration was determined by measuring the UV absorbance of samples at 
260nm using NanoDrop ND1000 spectrophotometer (Thermo Scientific). 
Concentrations were calculated on the basis that 1 absorbance unit at 260nm 
corresponds to approximately 50pg/ml DNA. Absorbance at 280nm was also measured 
and the ratio between the absorbances at 260nm and 280nm were used to provide an 
estimate of the purity of the DNA sample.
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2.5.2 Restriction enzyme digestion
Restriction enzymes and DNA modifying enzymes with their respective buffers were 
obtained from Promega (Southampton, UK) or New England Biolabs (Hitchin, UK). 
DNA sequencing of constructs was performed by MWG-Biotech AG (Ebserberg, 
Germany).
DNA analysis was carried out by restriction digests. These digests were carried out in 
20pl reactions with lpg of DNA. Restriction enzymes(s) (5units) were added and the 
buffer recommended by the manufacturer was used at a IX concentration. Digests were 
incubated at the appropriate temperature for 2 hours. The digested DNA was 
electrophoresed on an agarose gel of 1% (w/v). An undigested sample was run in 
parallel, as a reference for the enzyme cut samples.
2.5.3 Agarose gel electrophoresis
Depending on the expected sizes of the DNA fragments, appropriate percentage gels in 
IX TAE were cast, e.g. 1% (w/v) gel was cast for fragments larger than lkb, 1.5% (w/v) 
for general purposes and 2% (w/v) to resolve DNA fragments less than lkb. Ethidium 
bromide was added to a final concentration of 0.5pl/ml. Approximately 0.1 volume of 
10X loading buffer (IX TAE, 50% (v/v) glycerol, 0.025% (v/v) bromophenolblue) was 
added to the DNA samples prior to loading. For size reference, the lkb ladder, lOObp 
ladder or ADNA/HindlH marker, all from Promega, was used. Electrophoresis of the 
DNA was carried out at 70-120V for 0.5-1.5hours allowing for good resolution of 
bands. The bands were visualized on a long wave UV transilluminator and 
photographed using the Syngene doc system.
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2.6 RNA analysis
2.6.1 RNA extraction
Cells were harvested post transfection and/or treatment using TRIZOL® Reagent 
(Invitrogen) and retrieval of RNA was carried out according to the manufacturer’s 
protocol. Each experiment was repeated 3 times. Each mouse brain tissue was immersed 
in 500pl cold TRIZOL® Reagent and homogenised. Retrieval of RNA was then also 
carried out according to the manufacturer’s protocol.
All RNA extracted was subjected to a DNAse step to remove all traces of DNA present. 
This was carried out using DNase I (Amersham-Pharmacia).
Sample reaction mixture: 20pg RNA
lOpl lOx buffer 
1.5pl DNAse I 
Made up to lOOpl with H2O 
The RNA was then purified using phenol/chloroform extraction, precipitated using 
ethanol and dissolved with H2O to a concentration of approximately 0.5pg/pl. RNA 
concentration was determined by measuring the UV absorbance of samples at 260nm 
using NanoDrop ND1000 spectrophotometer (Thermo Scientific). Concentrations were 
calculated on the basis that 1 absorbance unit at 260nm corresponds to approximately 
40pg/ml RNA. Absorbance at 280nm was also measured and the ratio between the 
absorbances at 260nm and 280nm were used to provide an estimate of the purity of the 
RNA sample.
82
2.6.2 cDNA production
Chapter II: Methods
cDNA was produced, with purified RNA as template, using Superscript II reverse 
transcriptase (Invitrogen), according to the manufacturer’s protocol, primed by random 
hexamer primer mix.
Samples of 5pg RNA mixed with 250ng random hexamer primers and the sample 
volumes made up to 11 pi are incubated at 70°C for lOmins and cooled rapidly in ice. 
4pl of superscript II 5x buffer, 2pl of 5% (w/v) DTT, 1 pi of 120ng dNTP and lpl of 
RNase OUT (Invitrogen) is subsequently added to each sample mixture and incubated 
at 25°C for 2mins prior to the final addition of 1 pi of Superscript II reverse transcriptase 
enzyme. The samples were incubated for lOmins at 25°C, then lhr at 42°C. Enzyme 
activity is attenuated by incubated for lOmins at 70°C.
2.6.3 Real Time PCR
Real-time PCR was performed on the DNA Engine Opticon system (MJ Research) 
using SYBR I Green technology (Platinum® SYBR® Green qPCR Supermix-UDG 
(Invitrogen)), according to the manufacturer’s instructions, with an initial denaturation 
step at 95°C for 15 minutes (activating the Platinium® Taq DNA polymerase) and 
subsequently three-step cycling of 95°C for 30 seconds, 58-67°C (depending on the 
primer pair) for 30 seconds and 72°C for 30 seconds. Fluorescence plate measurements 
were then taken after each cycle at 72°C. A final melt curve was then carried out after 
the program, from 65-95°C (in 0.3°C steps). Each cDNA sample was amplified in 
triplicate reactions simultaneously and a standard calibration curve for each target
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primer set was also produced using six appropriate serial dilutions of a cDNA template 
sample. To control for cross- contamination from other sources, in each PCR run, blank 
reactions in which no cDNA were added, were included. The Opticon software on the 
DNA Engine Opticon system was used to determine the threshold amplification cycle 
(CNt), which represents the first discemable PCR cycle at which product fluorescence 
increases to just above background noise, for each reaction.
Control primers - Pactin, (3-microglobulin or CB5B reductase were subsequently used 
for the normalization of the target’s expression relative to its expression, to control for 
variations such as RNA quality, reverse transcription efficiency, and sample-to-sample 
RNA input differences. The sequences of the normalizing gene primer pairs, as well as 
other primers used, are shown in Table 2.2. All the primers span introns, such to prevent 
amplification from genomic DNA. (apart from a-synuclein primers, whereby for each 
sample run, a corresponding negative sample will also be tested to show if 
contaminating genomic DNA levels were at least 5 CNt lower than the other sample. 
This would show that the contamination was low enough not to affect the results. The 
negative samples refer to a portion of each corresponding sample to be tested which 
would not have Superscript II reverse transcriptase (Invitrogen) added when going 
through cDNA production step, and thus will not have any cDNA made from RNA. 
Any DNA present would be contaminating genomic DNA.
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Table 2.2
j  Primer [ DNA primer sequence
a-synuclein F 5’- C AGT GGCT G AG AAG ACC A AA -3'
a-synuclein R 5'- TGTCTTCTGAGCGACTGCTG -3’
EGR1 F 5’- CAGCACCTTCAACCCTCAG-3'
EGR1 R 5'- AGCGGCC AGT AT AGGT GAT G -3’
EGR2F 5'- TTGACCAGATGAACGGAGTG -3’
EGR2R 5'- ACCAGGGTACTGAGGGTCAA -3’
EGR3F 5’- CAATCTGTACCCCGAGGAGA -3’
EGR3R 5'- GG AAGG AGCCGGAGT A AGAG -3’
EGR4F 5?-AACCCAGCGCTGAATTGC-3’
EGR4R 5-GAGTCGGCTAAGTCCCCACT-3’
WT1 F 5’-CAAATGACATCCCAGCTTGA-3’
WT1 R 5'-GATGCCGACCGTACAAGACT-3’
Nurrl F 5 ,  G X X T A A A A G G C C G G A G A G G T  _ 3 ’
| Nurrl R
i 5'- TGCTGGGTGTCATCTCCACT -3’ |
Bm3a F 5'-GGCGCGCAGCGTGAGAAAATGAA-3’
Bm3a R 5’-GTCTCACACCCTCCTCAGTAAGT-3’
Parkin F 5’- CCAGTGACCATGATAGTGTT -3 ’
Parkin R 5’- TGATGTTCCGACTATTTGTTG -3 ’
PINK1 F 5’-TTGAAAGCCGCAGCTACCAA-3’
PINK1 R 5’ -ACCCC AGAGGCTT AG ATGAA-3 ’
Housekeeping control genes
pActin F 5’- AGCCTCGCCTTTGCCGA -3 ’
pActin R 5’- CTGGTGCCTGGGGCG -3 ’
P2microglobulin F 5’- TGCTGTCTCCATGTTTGATGTATCT -3 ’
p2microglobulin R 5’- TCTCTGCTCCCCACCTCTAAGT -3 ’
GAPDH F 5'-AGCCACATCGCTCAGACAC-3'
GAPDH R 5'-GAGGCATTGCTGATGATCTTG-3' j
Cytochrome b5 reductase F 5’ -  T AT AC ACCCATCTCCAGCGA - 3'
Cytochrome b5 reductase R 5' -  CATCTCCTCATTCACGAAGC - 3’
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2.6.4 Data Analysis
The data obtained from real-time PCR were manipulated by the 2-AACt method (Livak 
et al. 2001). To ensure that the PCR efficiency of the primers were comparable such that 
the calculations for AACt were valid, a dilution curve comprising of data from a five 
serial dilutions of a sample had to be plotted, which should have a slope close to 0 and 
thus proving the assumption.
The variation in activation and expression levels in the experiments for each construct, 
determined by luciferase assays and real-time PCR, were assessed by one-way analysis 
of variance (ANOVA) with a Bonferroni post-hoc test.
2.7 Promoter analysis
2.7.1 Dual luciferase assay
Cells were washed with PBS and harvested following transfection and treatment using 
lx passive lysis buffer (Promega) and subsequently assayed for firefly and renilla 
luciferase levels using the Dual-Luciferase® Reporter Assay System according to the 
manufacturer’s protocol. Firefly luciferase is first measured from each sample in the 
luminometer by adding an equal volume of substrate dissolved in buffer I. The firefly 
luciferase is then quenched and renilla luciferase activated and measured by adding 
another equal volume of buffer II with 10% stop and glo substrate. Each experiment 
was repeated 3 times.
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2.8 DNA/protein interaction analysis
2.8.1 Nuclear protein extraction
Reagents required: Hypotonic Buffer - 20mM Hepes, pH7.9
0.5mM DTT
Complete mini protease inhibitors (add 
according to manufacturer’s protocol)
EB-1 Buffer - 20mM Tris-HCl, pH7.5
1% (v/v) Triton X-100 
150mMNaCl 
5mM EDTA 
50mM NaF
Complete mini protease inhibitors (add 
according to manufacturer’s protocol)
SH-SY5Y cells were plated, at 1 90% confluent 85cm2 flask per 10cm plate, for 
extraction 1 day before stress treatment. Dopamine hydrochloride and MPP+ iodide 
were added to each plate at a concentration of OpM, 200 DpM, and OmM, 8mM 
respectively. The plates were then incubated for 24hrs and 12hrs respectively.
The media was removed from each plate and the plates were washed with cold PBS. 
3ml of cold PBS was added to each plate and the cells were scrapped with a scrapper 
and collected in 1.5ml aliquots and placed in ice. The aliquots were then centrifuged at 
1500g for 5min at 4°C. Supernatant was removed and 500pl Hypotonic Buffer was used
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to resuspend the cells. This suspension was incubated for 15min on ice before adding 
20pl of 10% (v/v) Igepal and vortexed for 10 secs. The mixture was centrifuged at 900g 
for lmin to pellet the nucleus. Supernatant may be collected and stored at -20°C 
(cytosolic extract). The remaining pellet was washed using 500pl of Hypotonic Buffer 
and 140pl of 10% (v/v) Igepal and spun down at 900g for lmin. The pelleted nucleus 
was then washed by only 500pl of Hypotonic Buffer. A sample of this mixture may be 
used for viewing under the microscope to check for intact nucleus. The nucleus were 
pelleted at 900g for lmin. 50pl of ice-cold EB-1 Buffer is used to resuspend the pelleted 
nucleus and placed on ice for 30mins. The nuclear debris was then pelleted and 
discarded by spinning at 900g for lmin. The supernatant was then used for EMSA 
experiments or stored at -80°C.
2.8.2 Electrophoretic Mobility Gel Shift Assay
1 EMSA gel: 5ml lOx TBE (108g Tris base, 55g Boric acid, 40ml 0.5M EDTA,
pH 8.0)
23ml Acrylamide 
lOOfil Temed 
240pl 10% (w/v) APS 
72ml H20
DIG Gel Shift Kit, 2nd Generation ROCHE
Cat no. 03 353 591 910
According to Roche manufacturer’s protocol
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Sample reaction mixes
Control (pi) Stressed (pi) Specific Non specific
competitor (pi) competitor (pi)
5x buffer 4 4 4 4
Poly [d(I-C)] (lpg/pl) 1 1 1 1
Poly L-lysine (O.lpg/pl) 1 1 1 1
Labeled oligonucleotide 2 2 2 2
(0.4ng/pl)
H20 10 10 8 8
Nuclear extract 2 2 2 2
(from section 2.8.1)
Unlabelled oligonucleotide - - 2 -
(O.lpg/pl)
Non-specific competitor _ _ - 2
oligonucleotide (O.lpg/pl)
The mixture was incubated for 30mins in room temperature (-21 °C) before adding 
loading buffer and loading onto a 10% (v/v) non-denaturing acrylamide gel. The gel 
was run at 40mA in 4°C and transferred onto nylon membranes via semi-dry passive 
transfer. The DNA was then cross-linked onto the membrane using UV 1.2J and then 
blocked using blocking buffer provided for 2hrs and probed using anti-DIG AP 
antibodies also provided in the kit and developed using CSPD.
2.8.3 Affinity isolation & silver staining
Biotinylated oligonucleotides of specified sequences were obtained from MWG 
Biotech. These oligonucleotides were then affinity bound onto magnetic Dynabeads® 
M-280 streptavidin beads (Dynal Invitrtogen) according to manufacturer’s protocol. The 
bead-oligonucleotide complex were then mixed into a reaction mixture as shown below 
and incubated for 30mins at room temperature (-21 °C) to allow protein/oligonucleotide 
interaction. A sample reaction mixture is shown below:
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Control (pi) Stressed (pi) Specific Non specific
Sx buffer
Poly [d(I-C)] (lpg/pl)
Poly L-lysine (O.lpg/pl)
Bead/oligo
H20
Nuclear extract 
(from section 2.8.1) 
Unlabelled oligonucleotide 
(O.lpg/pl)
Non-specific competitor 
oligonucleotide (O.lpg/pl)
4
1
1
4
6
4
competitor (pi) competitor (pi)
The beads were then washed 3 times with lx buffer used in the reaction mix. The 
mixtures were then subjected to 5mins at 100°C to denature the proteins and release 
interaction bonds. The denatured mixtures were loaded and run in a 10% (v/v) SDS- 
PAGE. The electrophoresed gel was then silver stained in the following procedure to 
visualize the proteins in the gel.
The proteins in the gel are first fixed onto the gel by incubating for 30mins in 400ml 
methanol, 100ml acetic acid glacial and 500ml water. The gel is then sensitized to 
silver-staining by incubation for 30mins in 300ml ethanol, 40ml of 5% (w/v) sodium 
thiosulphate, 68g of sodium acetate and made up to 1L with water. The gel is 
subsequently washed three times for 5mins each with water. A solution made up of 
0.625g of silver nitrate, 0.1ml formaldehyde and made up to 250ml with water is added 
to the gel and incubated for 20mins. The gel is washed twice, lmin each, with water and 
developing solution of 25g sodium carbonate, 0.2ml formaldehyde and made up to 1L 
with water is added and incubated for 10-15mins (until bands show up). The reaction is
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then stopped by adding acetic acid for lOmins and the resulting gel is washed for three 
times with water for 5mins each time.
The target bands were cut out and sent for sequencing.
2.9 Protein analysis
2.9.1 Reagents
Polyacrylamide gels were made using Acrylamide/bisacrylamide (30% w/v) solution 
obtained from Amresco Ltd. (Ohio, USA). Ammonium persulphate, N,N’- 
methylenebis- acrylamide, N,N,N’N’-tetramethylethylene-diamine (TEMED) were 
obtained from Sigma (St Louis, MI, USA). Protein molecular weight RainbowTM 
marker, HybondTM-C nitrocellulose membranes, Enhanced Chemiluminescence 
system (ECL) and Kodak XOMAT imaging photographic film were purchased from 
Amersham Pharmacia Biotech. (Little Chalfont, Bucks., UK). Pre-stained protein 
markers were obtained from NEBS Biolabs. 3MM chromatography paper was obtained 
from Whatman International Ltd. (Maidstone, Kent, UK). Photographic developing and 
fixing chemicals were obtained from X-OGRAPH Ltd. (Tetbury, UK).
2.9.2 Antibodies
Rabbit polyclonal anti-parkin (C-terminal) antibody was purchased from Cell Signalling 
Technologies; mouse anti-p-actin antibody was purchased from Santa Cruz 
Biotechnology. PINK 1-49 antibodies were gifts from Dr. Sonia Gandhi (Institute of 
Neurology, UCL, London, UK) and were produced by immunizing rabbits with a mix
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of the following synthetic peptide, CKSKPGPDPLDTRRLQ corresponding to amino 
acid residues 135- 149 of human PINK1. The peptides were coupled to keyhole limpet 
haemocyanin prior to immunization. Anti-serum was affinity purified on columns 
against each of the synthetic peptides (Eurogentec, Liege, Belgium).
Secondary anti-rabbit and -mouse horseradish peroxidase (hrp) -linked antibodies used 
for western blotting were all from DAKO Ltd., Glostrup, Denmark.
2.9.3 SDS-PAGE
Standard SDS-polyacrylamide gels were prepared with the composition for the stacking 
and resolving gels as described by Sambrook and colleagues (Sambrook et al, 1989). 
Acrylamide gels are defined by their overall acrylamide concentration and percentage 
cross-linker. Protein samples were heated to 95°C for 5 minutes. 50-100 jig of protein 
from each sample and 10 pi of protein marker were prepared and run in a vertical gel 
electrophoresis system (Sambrook et al, 1989). The gels were run at a constant voltage 
of 100 V in 1 X running buffer (25 mM Tris, 250 mM glycine and 0.15 (w/v) SDS, pH 
8.3). Gels were run until the protein of interest was sufficiently resolved as determined 
by the migration of the molecular weight marker.
2.9.4 Western Blot
RIPA buffer (for soluble protein extract): 50mM Tris-HCl, pH 8.0
150mMNaCl 
1.0% (v/v) Igepal CA-630 
0.5% (w/v) sodium deoxycholate 
0.1% (w/v) SDS
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5x Laemmli buffer (for total protein extract):250mM Tris-HCl, pH 6.8
50% (v/v) Glycerol 
500mM DTT 
10% (w/v) SDS
lOx TBS: 876.6 g NaCl (FW 58.44),
121.1 g Tris,
40 ml HC1 
pH 8.0
The cells were lysed and harvested post transfection and/or treatment using RIPA buffer 
or Laemmli buffer to extract soluble or total protein respectively. Each experiment was 
performed 3 times. Lysates were run on 10% (w/v) SDS-PAGE gels, and transferred 
onto nitrocellulose membranes. The membranes were then blocked with 5% (w/v) milk 
powder in 0.1% (v/v) TBS-Tween and probed overnight (~16hrs) at 4°C using primary 
antibody in 5% (v/v) BSA in 0.1% (v/v) TBS-Tween. Membranes were washed and 
probed using appropriate HRP-conjugated secondary antibodies and developed using 
enhanced chemiluminescence (ECL, Amersham Biosciences).
2.10 Molecular Biology analysis
2.10.1 Annexin V apoptosis assay
To determine the level of apoptosis, a FACS based assay was used. Cells were 
transfected and stressed with vehicle or MG-132 as described above. Cells were then 
harvested and washed in PBS and pelleted. Pellets were resuspended in IX Annexin V 
binding buffer (BD Biosciences, Oxford, UK) and then incubated with Annexin V 
conjugated with phycoerythrin (Annexin V-PE) for 15mins at room temperature
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(~21°C) before being analyzed immediately on an Epics XL flow cytometer. For each 
sample, 20,000 cells were analyzed and Annexin V-PE fluorescence was determined in 
the FL2 channel gated for GFP positive events. Experiments were performed in 
triplicate
2.10.2 Mitochondrial membrane potential assay
Tetramethylrhodamine, methyl ester, perchlorate (T-668) (TMRM) was obtained from 
Molecular Probes (Eugene, USA). TMRM was solubilised in methanol (200 mM stock 
concentration, kept in -20°C) and used at final concentration of 100 nM.
To measure mitochondrial membrane potential (A\}/m), a fluorescence-activated cell 
sorting (FACS)-based assay was used. Cells were treated with vehicle or 15pM MG- 
132 for 24 hours, then incubated with lOpM verapamil (Sigma, Paisley, UK) and 
lOOnM of the A\|/m-sensitive dye tetramethylrhodamine methyl ester (Molecular Probes, 
Leiden, Netherlands) in a humidified 5% (v/v) C02 atmosphere at 37°C for 45 min. 
Cells were then harvested with trypsin, pelleted and resuspended in phosphate buffered 
saline (PBS) on ice. For each sample, 20,000 cells (events) were analyzed on an Epics 
XL flow cytometer with a 488-nm argon laser. The TMRM signal was analyzed in the 
FL2 channel gated for GFP positive events. The channel was equipped with a band-pass 
filter at 580t30 nm; the photomultiplier value of the detector was 631V. Data were 
acquired on a logarithmic scale. Arithmetic mean values of the median fluorescence 
intensities (MFI) were generated for graphic representation. Experiments were 
performed in triplicate.
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2.10.3 Immunofluorescence & microscopy
Goat serum was obtained from Invitrogen Ltd. (Paisley, UK). Coverslips and slides 
were obtained from BDH. Fluorescent mounting medium was obtained from Dako Ltd. 
(High Wycombe, Bucks., UK). Mouse monoclonal anti-c-myc (clone 9E10) (Sigma); 
Alexa Fluor 488 goat anti-mouse IgG conjugates (Molecular Probes).
Cells were fixed and prepared for immunofluorescence microscopy. Cells were washed 
three times in PBS and fixed in 4% (w/v) paraformaldehyde for 10 min. Cells were 
washed three times with PBS and permeabilised for 5 min in 0.1% (v/v) Triton X-100 in 
TBS (TBST). Coverslips were then incubated in block buffer (20% (v/v) goat serum, 
0.1% (v/v) TBST) for 20 min. Cells were incubated overnight (~16hrs) at 4°C with the 
appropriate primary antibody in antibody diluting buffer (1% (v/v) goat serum, 0.1% 
(v/v) TBST). Coverslips were washed three times in 0.1% (v/v) TBST and incubated for 
30 min at room temperature (~21°C) with the appropriate secondary antibody in 
antibody diluting buffer. For nuclear staining Hoechst 33258 (2pg/ml) was added to the 
secondary antibodies in buffer. For double labelling studies coverslips were incubated 
with primary antibodies sequentially at 4°C for 12 hours each and after washes were 
incubated with a mixture of both secondaries. Coverslips were washed three times with 
TBS and mounted on glass slides (Fisher) with antifade mounting medium (Dako). 
Standard immunofluorescence was performed using a Zeiss Axioskop 2 plus 
microscope and digital images were captured using a Zeiss Axiocam camera. Negative 
controls omitting each primary antibody separately or in combination were performed in 
each case and no significant staining was seen.
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Chapter 3: Regulation of a- 
synuclein in oxidative
stress
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3.1 Introduction
3.1.1 Regulation of a-synuclein in Parkinson’s 
disease
As established in chapter 1, the dysregulation of a-synuclein has a strong causative role in 
Parkinson’s disease. Not only do mutations in the protein cause disease, but also the over­
expression of a-synuclein was found to be sufficient to cause toxicity to neuronal cells. For 
instance, the amplification of the a-synuclein locus caused an increase in the expression of 
a-synuclein, leading to Parkinson’s disease (Chartier-Harlin et al., 2004; Farrer et al., 2004; 
Ibanez et al., 2004a; Singleton et al., 2003). However, the presence of such amplifications 
are rare and do not account for the majority of Parkinson’s disease cases, which are mostly 
sporadic rather them familial. As such, it is important to examine putative mechanisms that 
may lead to a-synuclein dysregulation associated with sporadic Parkinson’s disease.
3.1.1 Oxidative stress, a-synuclein & Parkinson’s 
disease
As mentioned earlier, genetic predisposition, is only one of several factors that lead to 
Parkinson’s disease. Others include aging, head trauma and environmental factors (Elbaz et 
al., 2007) and they usually lead to sporadic Parkinson’s disease. As aging and head trauma 
mainly lead to non-specific neuronal death, the attention of this study focuses on 
environmental factors, in particular, oxidative stress. Oxidative stresses have been
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previously linked to a-synuclein up-regulation and increased aggregation (Betarbet et al., 
2006; Manning-Bog et al., 2002; Przedborski et al., 2001; Sherer et al., 2002; Sherer et al., 
2003; Vila et al., 2000). However, there have not been any studies as yet, on whether 
oxidative stress may directly regulate a-synuclein at the transcriptional level. To further 
examine the importance and possible role of oxidative stress in the development of 
Parkinson’s disease, we sought to investigate the influence of oxidative stress on the 
regulation of the expression of a key gene, a-synuclein.
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3.1.2 Hypothesis & Aims
As mentioned earlier, several factors contribute to the development of Parkinson’s disease. 
Of these factors, strong evidence associate genetic predisposition and environmental factors 
to the disease. In view of the importance of investigating the causes of idiopathic 
Parkinson’s disease, which account for the majority of cases, this work aimed to extend 
current findings which show the linkage of oxidative stresses with Parkinson’s disease and 
a-synuclein. We propose that one of the ways oxidative stresses may act to increase 
susceptibility to Parkinson’s disease is via altering the regulation of a-synuclein 
expression.
Aims of project:
1. To determine if selected oxidative stresses alter the expression of a-synuclein.
2. If the expression of a-synuclein mRNA is altered, to confirm if this event is 
transcriptional.
3. To investigate the mechanism of a-synuclein regulation by oxidative stress
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3.2 Results
3.2.1 Oxidative stresses can regulate a-synuclein 
expression
Previous studies have shown that certain stresses and toxins can alter the levels of 
intracellular a-synuclein as well as increase its aggregation (Betarbet et al., 2006; 
Manning-Bog et al., 2002; Przedborski et al., 2001; Sherer et al., 2002; Sherer et al., 2003; 
Vila et al., 2000). To confirm such regulation, oxidative stresses such as dopamine were 
used to investigate its effect on the expression of a-synuclein.
Cellular activities are regulated at several levels, namely: transcriptional, post- 
transcriptional, translational, post-translational modifications and protein interaction. In this 
section, a-synuclein gene expression was monitored at the pre-translational level since the 
copy number of a specific mRNA can be used to quantify, not only, changes in the 
regulation of the gene, but also RNA stability.
Traditionally, the amount of a particular mRNA produced, and thus the expression level of 
a gene has been estimated by a technique known as northern blotting, whereby RNA is 
separated by agarose gel electrophoresis, transferred to a filter and then probed with a 
specific DNA probe that is complementary to the gene of interest (Alwine et al., 1977). 
Although this technique is still used to assess gene expression, it requires relatively large 
amounts of RNA and thus cannot be performed when RNA amounts are limited.
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In order to detect gene expression at minute levels from single or small numbers of cells, 
amplification of the gene transcript is necessary. Reverse transcription followed by 
polymerase chain reaction (PCR) is a common method for amplifying the RNA signal 
(Bartlett and Stirling, 2003).
Development of PCR technology using fluorophores permits measurement and 
quantification of DNA amplification in real time (Nolan et al., 2006). In quantitative real­
time PCR, the amplified product is measured at the end of each PCR cycle. The data 
obtained can be analysed by computer software to calculate relative gene expression 
between several samples, or mRNA copy number based on a standard curve. This method 
was used to quantify a-synuclein mRNA during exposure to oxidative stress.
a-synuclein mRNA levels in SHSY5Y cells incubated with OuM, 62.5 pM, 125pM and 
250pM dopamine for 24hrs were quantified using real-time Polymerase Chain Reaction 
(RT PCR). The quality of RNA isolated from the cells was verified prior to production of 
cDNA for RT PCR (Fig. 3.1). Results were normalised to control house-keeping genes, 
p2microglobulin, p-actin and NADH cytochrome b6-reductase mRNA in the cells. The 
normalisation to control for housekeeping genes eliminates variation caused by differences 
in total RNA used in each sample. Two or more control genes are used for the 
normalisations, and results compared, to ensure that expressions of these control genes are 
not also altered by variables used. The identity and specificity of the product of each RT 
PCR was confirmed after the experiment (Fig 3.2).
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RT PCR results demonstrated that dopamine caused a dose-dependent increase in 
endogenous a-synuclein mRNA (Fig. 3.3). The expression increase reached an average of
1.5 fold from normal levels when 250pM dopamine was used. These results indicated that 
dopamine affects a-synuclein expression.
To find out if general oxidative stress, rather than an isolated dopamine-mediated effect, 
may cause this regulation of a-synuclein, another oxidative stress, MPP+, was used to carry 
out a similar quantitative analysis. This time, the cells were incubated with OmM, ImM, 
5mM and lOmM MPP+ for 6 and 12hrs. An increase in a-synuclein mRNA was also 
observed (Fig, 3.4; results for one normalisation are shown; similar results for the different 
normalisations were obtained). There was a two fold higher increase in a-synuclein mRNA 
when cells were incubated with MPP+ for 12hrs compared to 6hrs. The increase in 
expression for both incubation periods of 6hrs and 12hrs was maximal at 5mM MPP+ with 
2 and 4 fold increases from normal respectively, a-synuclein mRNA decreased at lOmM 
MPP+ due to cell death caused by toxicity. The higher expression achieved when cells were 
stressed by MPP+ should not be compared to when dopamine was used as the extent of 
toxicity caused by both stresses were not examined.
The RT PCR results show that oxidative stress increases a-synuclein expression, however, 
this did not indicate if the increase in a-synuclein mRNA was due to transcriptional or 
post-transcriptional regulation.
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28S rRNA _► 
18S rRNA _►
Figure 3.1 RNA quality agarose gel check
1.5% (w/v) agarose gel check on RNA quality of RNA extractions from SH-SY5Y cells which were then 
used for reverse-transcriptions into cDNA and subsequently for real-time PCR analysis. This gel photo 
shows a random set of extracted RNA samples. Lanes 3 and 8 shows degradation of RNA extracted 
while the other lanes show undegraded RNA.
103
Chapter III: a-synuclein
alpha-synuciein f 2-microglobulin f-actin cytochrome f 5-reductase
Figure 3.2 RT PCR a-synuclein, p2-microglobulin, p-actin and cytochrome p5-reductase product agarose gel 
check
Agarose gel check on RT PCR products to confirm product identity and PCR specificity. Specific product of the correct 
size was obtained for each primer set used for each gene in RT PCR. DNA products in bands were cut out, purified and 
sequenced to ensure correct DNA amplification by primers were obtained.
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Figure 3.3 Effects of dopamine on a- 
synuclein mRNA expression
Real-time PCR on cDNA reverse- 
transcribed from mRNA extracted from 
cells incubated for 24hrs in OpM, 62.5pM, 
125pM and 250pM dopamine in full culture 
media, a-synuclein RT PCR results were 
normalised onto RT PCR results of 
different housekeeping genes to correct 
for differences in total mRNA levels in 
each sample. Error bars indicate the 
standard error of 3 experiments each 
performed in triplicates. Differences were 
analysed by paired T-test.
A) Normalisation using housekeeping
gene p2-microglobulin showed that there 
was a dosage-dependent increase of a- 
synuclein with dopamine, a-synuclein in 
250pM dopamine stressed cells was
significantly higher than those in untreated 
cells (*** p<0.001).
B) Normalisation using housekeeping
gene (3-actin also showed increases in a- 
synuclein with dopamine treatment.
C) Normalisation using housekeeping
gene NADH cytochrome b6-reductase 
similarly showed a dosage-dependent 
increase of a-synuclein with dopamine, a- 
synuclein in 125 and 250pM dopamine 
stressed cells were significantly higher 
than those in untreated cells (** p<0.01).
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Figure 3.4 Effects of MPP+ on a-synuclein mRNA expression
Cells were incubated for 6hrs and 12hrs in OmM, 1mM, 5mM and 10mM MPP+ in full media culture 
media before mRNA retrieval. The error bars indicate the standard error of the mean of 3 experiments. 
Differences were analysed by paired T-test. There were significant dose-dependent increases in a- 
synuclein mRNA for cells stressed for both timings (*p<0.05; ***p<0.001).
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3.2.2 Oxidative stress regulation of a-synuclein 
promoter activity
To further investigate if the increase in a-synuclein mRNA obtained previously was due to 
transcriptional or post-transcriptional regulation, dual luciferase reporter assays were used.
Certain genes are chosen as reporters because expression of their corresponding protein is 
easily detected and quantified. Reporter genes can be linked to the promoters of specific 
genes to examine aspects of regulation.
Dual luciferase reporter assay using the luminescence of the firefly (Photinus pyralis) and 
sea pansy (Renilla reniformis) luciferase proteins is used in this section. The assay exploits 
the differing biochemical requirements for each luminescence, thus allowing for the 
sequential quantitative measurement of both luciferase activities in a single protein extract 
(Sherf et al., 1996).
A 5’deletion series of the a-synuclein promoter cloned upstream of the luciferase gene 
(Fig. 3.5) were used to measure a-synuclein promoter transactivation. These included 1.46, 
which contains approximately 1.46kb of the 5’UTR region between the translational and 
transcriptional start sites. 1.9 construct contains ~1.9kb of sequence which includes both 
the 5’UTR and ~0.44kb of promoter. 3.4, 3.8 and 4.1 constructs contain sequences from 1.9 
construct and a further 0.5kb, 0.9kb and 1.2kb upstream respectively. These constructs
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were transfected into SH-SY5Y cells and luciferase activity assayed for their basal levels 
and in response to varying concentrations of dopamine and MPP+.
Under basal conditions (Fig. 3.6), all the constructs displayed different activity levels 
except 3.8 and 4.1 whose activities were similar to each other. 1.9 showed the highest 
promoter activity compared to the other constructs which indicated the presence of essential 
promoter sequences (core promoter) and possible enhancer domains of the a-synuclein 
promoter. Although 1.46 did not contain any sequence upstream of the transcriptional start 
site, some activity above the empty PGL3 basic vector was still observed. 3.4 activity was 
the lowest, indicating possible repressor sites upstream of the core promoter whilst the 
increase in activity in 3.8 and 4.1 indicated presence of enhancer sites further upstream.
Administration of dopamine resulted in significant increases in luciferase activity in all the 
a-synuclein promoter constructs for both 125jiM and 250pM dopamine concentrations 
used (Fig. 3.7). A higher increase in luciferase activity was generally seen in cells treated 
with 250pM dopamine. The biggest increase in activity was observed for construct 1.9 with
1.5 and 2 fold increase for 125pM and 250pM dopamine used respectively. This suggested 
that the increase in a-synuclein mRNA observed in earlier experiments was due to 
transcriptional activation.
Similar dual luciferase assays were also carried out for MPP+ stress to find out if the 
similar results shown in the real-time for both dopamine and MPP+ would also be shown 
here, and thus show that the regulation of a-synuclein was not just an isolated dopamine 
mediated effect but occured during exposure to other oxidative stresses as well (Fig. 3.8).
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MPP+ treatment also resulted in an activation of a-synuclein promoter activity similar to 
that mediated by dopamine. 1.9 construct showed increase in activity of 5.5 fold in 5mM 
MPP+ compared to control conditions. The other constructs showed an increase of an 
average of 3 fold in MPP+. Surprisingly, the minimal promoter activity detected with the 
1.46 construct, which did not contain any of the a-synuclein core promoter, could also be 
up-regulated when subjected to both stresses. This was shown not to be an artificial effect 
as the empty vector did not show any increase in activity in response to the stresses.
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Figure 3.5 a-synuclein promoter luciferase constructs
Constructs used for dual luciferase assays. Each of the inserts was cloned in pGL-basic plasmid 
upstream of the firefly luciferase reporter gene. In all the transfections, they were co-transfected with 
pRL-SV40, which produces Renilla luciferase and thus corrects for transfection efficiency when 
measuring for the overall luciferase activity. 4.1 encodes for approximately 4kb upstream of a-synuclein 
translational start site and thus contains the core a-synuclein promoter and possible additional 
enhancer/repressor sites; 3.8 encodes for about 3.8kb upstream of a-synuclein translational start site; 
3.4 contains about 3.4kb of the a-synuclein promoter; 1.9 encodes for approximately 1.9kb upstream of 
translational start site and contains the core promoter; 1.46 contains about 1,46kb and encodes for the 
3’ untranslated region.
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Figure 3.6 Basal a-synuclein promoter activity
SH-SY5Y cells were co-transfected with different a-synuclein promoter luciferase constructs and SV40 
promoter renilla luciferase construct. Cells were subsequently incubated in full culture media for 24hrs. 
Dual luciferase assay analysis comparing the different luciferase activities was performed. Data was 
analysed by paired T-test. All the contructs expressed luciferase activity that were significantly different 
from each other (***p<0.001) except for between constructs 3.8 and 4.1.
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Figure 3.7 Effects of dopamine on a-synuclein promoter activity
Cells were transfected with the different a-synuclein constructs and incubated for 24hrs in OmM, 125mM 
and 250mM dopamine in full culture media. Constructs 1.46 and 1.9 in treated cells were significantly 
different from untreated cells (***p<0.001). Those stressed with 125mM dopamine was also different 
(*p<0.05) from those stressed with 250mM. For construct 3.4, both stresses resulted in significant 
increases in luciferase activity (**p<0.01). In 4.1, only 250mM dopamine stressed cells were different. 
The error bars indicate the standard error of the mean of 3 experiments, each performed in triplicates.
112
Chapter III: a-synuclein
0.16
0.14
£
£ 0.12
©
3
0.1
£
j j 0.08
C
®o>E 0.06n
o
20u_
0.04
0.02
* *
--
T T *  * *“T ^
_  i
■ OmM 
□ 5mM
1.46 1.9 3.4 3.8
alpha-synuclein luciferase contructs
4.1
Figure 3.8 Effects of MPP+ on a-synuclein promoter activity
Transfected cells were incubated for 6hrs in OmM & 5mM MPP+ in full culture media. There were 
significant increases in luciferase activity for all the constructs tested in 5mM MPP+ compared to OmM 
(**p<0.01, *p<0.05) except for 1.46. The error bars indicate the standard error of the mean of 3 
experiments, each performed in triplicates.
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3.2.3 Promoter Mapping
3.2.3.a Electrophoretic Mobility Shift Assay
From the results above, largest increase in promoter activity between control and oxidative 
stress conditions was detected using 1.9 promoter construct. This indicated that activating 
transcription factors bind to this promoter region during the stress conditions, inducing 
transcription. In view of this, the a-synuclein promoter region contained in this construct 
was subsequently examined for transcription factor interaction during stress.
Electrophoretic Mobility Shift Assay (EMSA) was used to detect protein:DNA interactions 
on the designated promoter region. The EMSA technique is a sensitive method, used to 
determine if a protein or mixture of proteins is capable of binding to a given DNA or RNA 
sequence, and is based on the observation that protein:DNA complexes migrate more 
slowly than free DNA molecules when subjected to non-denaturing polyacrylamide or 
agarose gel electrophoresis (Gamer and Revzin, 1981).
The EMSAs were performed using llObase pairs (bp) long, 20bp overlapping region on 
either side, oligonucleotides that span the 1.9kb sequence upstream of the translational start 
site (Fig. 3.9). The oligonucleotides were incubated with control, dopamine or MPP+ 
stressed nuclear extracts, and the mixture was separated by electrophoresis on a non­
denaturing gel. This was done to identify possible transcription factors that bind to the 
promoter region during stressed conditions. Oligonucleotides with bound protein would be
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retarded when running down the gel. The retarded oligonucleotide-protein complexes 
would then be detected as exposed bands above the signal for free labelled 
oligonucleotides. By adding specific non-labelled oligonucleotides in excess (150x) to the 
labelled ones in the reaction would effectively compete away the specific binding proteins, 
hence no/lowered signal would be detected.
In Fig. 3.10a, a retarded band was obtained for the oligonucleotide representing 112bp 
immediately downstream of the transcriptional start site, when using nuclear extract from 
dopamine treated cells, which was not present when incubated with control nuclear extract 
and was, competed away using specific competitors and not with non-specific competitors. 
This indicated that transcription factors bind to this particular region during dopamine 
stress.
The efficiency of the EMSA was checked using a labelled oligonucleotide with known 
Oct2A binding sites present (Fig. 3.10b). Oct2A is a transcription factor that binds strongly 
to a known consensus sequence. As Oct2A levels are not known to be altered during 
oxidative stresses, the Oct2A binding oligonucleotide was used with nuclear extracts from 
control and dopamine treated cells. A stronger exposed band was obtained with the extract 
from control cells compared to the extracts from treated cells (Fig. 3.10c), thus indicating 
that the band obtained with extract from treated cells but not extract from control cells in 
Fig. 3.10a was not due to a lower protein concentration in control compared to dopamine 
extracts.
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Figure 3.9 Schematic diagram of EMSA oligonucleotides location on a-synuclein promoter
110bp oligonucleotides used in EMSAs both as probe or competitors, to detect the location of possible 
binding by the protein or protein complex
EMSA oligo Sequence
1.9(1) gtcgaccctc aggccctcgg ctctcccagg gcgactctga cgaggggtag ggggtggtcc ccgggaggac ccagaggaaa ggcggggaca 
agaagggagg
1.9(2) ggaaggggaa agaggaagag gcatcatccc tagcccaacc gctcccgatc tccacaagag tgctcgtgac cctaaactta acgtgaggcg
1.9(3) caaaagcgcc cccactttcc cgccttgcgc ggccaggcag gcggctggag ttgatggctc accccgcgcc ccctgcccca tccccatccg
1.9(3.5) agatagggac gaggagcacg ctgcagggaa agcagcgagc gccgggagag gggcgggcag aagcgctgac aaatcagcgg
1.9(4) gagccgagga gaaggagaag gaggaggact aggaggagga ggacggcgac gaccagaaggggcccaagag agggggcgag
1.9(5) ccgcgacgcg gaagtgaggt gcgtgcgggc tgcagcgcag accccggccc ggcccctccgagagcgtcct gggcgctccc tcacgccttg 
ccttcaagcc ttctgcct
1.46(1) tt ccaccctcgt gagcggagaa ctgggagtgg ccattcgacg acaggttagcgggtttgcct cccactcccc cagcctcgcg tcgccggctc 
acagcggcct cctctggg
1.46(2) ga cagtcccccc cgggtgccgc ctccgccctt cctgtgcgct ccttttccttcttctttcct attaaatatt atttgggaat tgtttaaatt tttttttt
1.46(3) aaaaagagag aggcggggag gagtcggagt tgtggagaag cagagggact caggtaagta cctgtggatc taaacgggcg tctttggaaa 
tcctggagaa caccgggt
Table 3.1
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Figure 3.10 Electrophoretic mobility 
shift assay (EMSA) performed using 
DIG labelling.
A) 1.46(1), 112bp DIG-labelled dsoligo 
from the 1st 112bp of the 1.46 construct 
was incubated with control (untreated) 
nuclear extract, 200pM dopamine nuclear 
extract and specific unlabelled competitor 
oligos as well as non-specific unlabelled 
oligos. A retarded band was obtained 
which showed possible transcription 
factor binding.
B) DIG-labelled dsoligo containing 
binding sites for Oct2A was run alone or 
after incubation with Oct2A, and with 
specific competitor unlabelled oligo. A 
single retarded band showed specific 
binding of Oct2A to the oligo.
C) Oct2A binding labelled oligo incubated 
with control nuclear extract or 200pM 
dopamine or 8mM MPP+ nuclear extracts 
with or without specific unlabelled 
competitor oligos. A stronger band is 
obtained for lane with control extract as 
compared to that with dopamine or MPP+ 
extracts. Band is competed away in 
presence of specific competitors.
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In response to the observed band present in Fig. 3.10a, further EMSAs were performed 
using smaller oligonucleotides from the region, 1.46(1), where the proteins were found to 
bind (Fig. 3.11). This would narrow down the binding region to better identify the binding 
sequence. No protein:DNA interaction was detected using these oligonucleotides (result not 
shown).
1.46(1) sequence was submitted to Matlnspector for prediction of potential transcription 
factor sites (Table 3.1). 13 potential binding proteins and their respective binding sites were 
obtained (Table 3.2). Short 15bp oligonucleotides containing the 13 different binding sites 
were used for EMSAs. Oligonucleotides with binding sites for Wilms tumour suppressor 1 
(WT1) and Early growth response 4 (EGR4) showed specific protein binding (Fig. 3.12).
PCRs were performed on SH-SY5Y cells using primers for WT1 and EGR4 (Fig. 3.13). 
There was no DNA amplification obtained for PCRs using WT1 primers. HEK cells, 
known to express WT1, were used as a positive control and DNA amplification was 
obtained. Therefore, the lack of DNA amplification in SH-SY5Y cells was due to WT1 not 
being expressed in the cell and not due to technical difficulties. As the sequence identified 
to bind WT1 and EGR4 was similar and overlapping, it is probable that the same protein(s) 
bound to both sequences in the EMSA shown in Fig. 3.12. As such, it is highly probable 
that EGR4 was responsible for the interactions observed on both the oligonucleotides used.
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1.46(1)
1.9 1.4
Figure 3.11 Schematic diagram of shorter EMSA oligonucleotides location on a-synuclein 
promoter
Shorter oligos subsequently used in EMSAs both as probe or competitors, to narrow down the location 
of binding by the protein/ protein complex as observed in previous EMSAs using 1.46(1) oligo.
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T able 3.2
Matlnspector Release professional 7.4.5, Dec 2006 Wed Mar 21 17:38:55 2007
Sequence file: l_l.seq (110 bp)
Family matches: Yes
Matlnspector library: Matrix Family Library Version 6.2 (October 2006)
Selected groups (core/matrix sim) ALL vertebrates.lib (0.75/Optimized)
Family/matrix Further Information Opt.
Position 
from - to
Str. Core sim. Matrix sim.
Sequence
(red: ci-value > 60 
capitals: core sequence)
1v«n  a  7F /nn a  7 n i ^at C2H2 Zn finger protein involved in vyuA^r/KUAZ.ui olfactory neuronal differentiation 0.73 2 -18 (-) 0.750 0.778 ccGCTC acgagggtgga
I
■
VSEBOX/NMYC.01 N-Mvc 0.92 4 -1 6 (+> 1.000 0.922 caccctCGTGagc
VSNFKB/NFKAPPAB.02 NF-kappaB 0.82 23-35 (+) 1.000 0.822 ctGGGAgtggcca
VSGRHL/GRHU.01 G r a t a ^ - l t e 0.82 40-52 (+) 1.000 0.855 acgacaGGTTagc
■ VSEGRFAVT1.01 Wilms Tumor Suppressor 0.92 55-71 (-) 1.000 0.922 gggagTGGGaggcaaac
1 VSEGRF/NGFIC.01 Nerve growth factor-induced protein C 0.80 57-73 (•) 0.770 0.824 ggggC i AGT gggaggcaa
I
1
VSZBPF/ZBP89.01 Zinc finger transcription factor ZBP-89 0.93 59-81 (+) 1.000 0.944 gcctcccactC CCCcagcctcgc
CccDiF/Trer ni TGFbeta-inducible early gene (TIEG) / Early
growth response gene alpha (EGRalpha) 0.83 61-75 (-) 1.000 0.858 ctgGGGGagtgggag
VSZBPF/ZNF219.01 Kruppel-like zinc finger protein 219 0.91 62-84 (+) 1.000 0.929 tcccactCCCCcagcctcgcgtc
■
I
Transcriptional repressor, binds to elements 
VSZBPF/ZNF202.01 found predominantly in genes that participate
in lipid metabolism
0.73 65-87 (+) 1.000 0.739 cactccCCCAgcctcgcgtcgcc
VSEGRF/EGR3.01 Earlv growth response gene 3 product 0.77 76-92 (+) 1.000 0.788 cctcGCGTcgccggctc
Winged helix protein, involved in hair 
VSWHNF/WHN.01 keratinization and thvmus epithelium
differentiation
0.95 76-86 (-) 1.000 0.964 gcgACGCgagg
VSPAX5/PAX5.03 PAX5 paired domain protein 0.80 78 -106 (+) 0.789 0.827 tcgcgTCGCcggctcacagcggcctcctc
Reference for Matlnspector:
Cartharius K, Freeh K, Grote K, Klocke B, Haltmeier M, Klingenhoff A, Frisch M, Bayerlein M, Werner T (2005) 
Matlnspector and beyond: promoter analysis based on transcription factor binding sites 
Bioinformatics 21, 2933-42
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1 . 4 6 ( 1 )  oligo + control extract 
1 . 4 6 ( 1 )  oligo + 2 0 0 | i M  dopam ine 
1 . 4 6 ( 1 )  oligo + 2 0 0 p M  dopam ine + specific com petitor 
1 . 4 6 ( 1 )  oligo + 2 0 0 p M  dopam ine + C 1  com petitor 
1 . 4 6 ( 1 )  oligo + 2 0 0 n M  dopam ine + C 2  com petitor 
1 . 4 6 ( 1 )  oligo + 200(.iM dopam ine + C 3  com petitor 
1 . 4 6 ( 1 )  oligo + 2 0 0 j a M  dopam ine + C 4  com petitor 
1 . 4 6 ( 1 )  oligo + 2 0 0 p M  dopam ine + C 5  com petitor 
1 . 4 6 ( 1 )  oligo + 2 0 0 | i M  dopam ine + C 6  com petitor 
1 . 4 6 ( 1 )  oligo + 2 0 0 u M  dopam ine + C 7  com petitor 
1 . 4 6 ( 1 )  oligo + 2 0 0 j a M  dopam ine + C 8  com petitor 
1 . 4 6 ( 1 )  oligo + 2 0 0 ( i M  dopam ine + C 9  com petitor 
1 . 4 6 ( 1 )  oligo + 2 0 0 p M  dopam ine + C 1 0  com petitor 
1 . 4 6 ( 1 )  oligo + 2 0 C V M  dopam ine + C 1 1  com petitor 
1 . 4 6 ( 1 )  oligo + 2 0 0 p M  dopam ine + C 1 2  com petitor 
1 . 4 6 ( 1 )  oligo + 2 0 0 p M  dopam ine + C 1 3  competitor
Figure 3.12 EMSA on oligonucleotides derived from Matlnspector analysis
1.46(1), 112bp DIG-labelled dsoligo from the 1st 112bp of the 1.46 construct, was incubated with control 
(untreated) nuclear extract, 200pM dopamine nuclear extract and specific unlabelled competitor oligos 
as well as each of the 13 unlabelled oligos containing transcription factor binding sites as predicted by 
matlnspector. C5 and C6 showed competition for the protein(s), similar to that obtained for the specific 
competitor.
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Figure 3.13 PCR detection of WT1 and 
EGR4
PCR using primers for WT1 and EGR4 
were performed on cDNA made from 
SH-SY5Y RNA extracts. HEK cells, 
known to express WT1, were used as a 
positive control for WT1 PCRs. EGR4 
but not WT1 was detected in SH-SY5Y 
cells. WT1 was detected in the positive 
control.
Blank
E"3R4 in  SHSYSY c e l l s
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3.2.3.b Affinity isolation & silver staining
To identify the protein(s) observed binding to 1.46(1) sequence in Fig. 10a, affinity 
isolation of the binding factor(s) by magnetic beads with streptavadin-biotin bound 1.46(1) 
oligomers was used together with silver-staining. A silver-stained band present in 
dopamine stressed cells lane but not in the control lane was observed (Fig. 3.14). This band 
was cut out, processed and sent for protein sequencing by mass spectrometry. Mass 
spectrometry did not reveal the identity of the proteins as the concentration was too low 
even when protein purified from 4 different bands cut from 4 separate gels were pooled.
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Figure 3.14 Affinity isolation and silver staining of DNA interacting factors
A silver-stained non-denaturing acrylamide gel electrophoresed with bead-DNA-protein mix is shown. 
Magnetic Streptavidin beads were used to pull down biotinylated DNA of the sequence corresponding 
to 1.46(1), which were incubated with nuclear extract of SH-SY5Y cells treated with 200pM dopamine. 
The hollow arrows indicate bands which indicate proteins binding to the DNA during stressed 
conditions. 3’ and 5’ indicate the use of 3’ and 5’ biotinylated-streptavidin bead bound 1.46(1) 
oligonucleotide.
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3.3 Discussion
There exists a substantial amount of evidence in current literature that highlights the 
importance of a-synuclein in Parkinson’s disease (Thomas and Beal, 2007). Other than 
the presence of mutations, there are also numerous reports that show that an altered 
level of expression of a-synuclein, in particular over-expression, was sufficient in 
causing the disease. This has been shown in both in vivo and in vitro systems 
(Hashimoto et al., 1998; Masliah et al., 2000), and has been supported by the discovery 
of duplications and triplications of the a-synuclein locus in affected familial 
Parkinson’s disease patients (Chartier-Harlin et al., 2004; Ibanez et al., 2004a; Singleton 
et al., 2003). The importance of this discovery was boosted by studies which showed 
that the triplication of the region resulted in four functional copies of a-synuclein, 
causing a two-fold increase in a-synuclein mRNA and protein (Farrer et al., 2004; 
Miller et al., 2004). These studies confirmed that an increased level of a-synuclein 
protein was capable of causing the disease and thus emphasising the importance of a- 
synuclein levels in the development of Parkinson’s disease.
However, in the absence of a-synuclein genetic abnormalities in sporadic cases, a- 
synuclein may, instead, play a role in the molecular pathogenesis of sporadic 
Parkinson’s disease following the dysregulation of its expression. Environmental 
stresses as well as factors involved in aging are believed to be the main causations in the 
development of sporadic Parkinson’s disease (Elbaz et al., 2007). The consensus among 
many researchers is that Parkinson’s disease is a result of an interplay between 
susceptibility genes and environmental stress (Elbaz et al., 2007; Thomas and Beal,
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2007). This hypothesis together with the evidence showing that oxidative stress 
increases the intracellular level of a-synuclein and promotes its aggregation 
(Przedborski et al., 2001; Vila et al., 2000), have directed us to look into the regulation 
of normal a-synuclein in the presence of oxidative stress.
From our studies using RT PCR and dual luciferase assays, we have confirmed that 
oxidative stresses such as dopamine and MPP+, caused an up-regulation of a-synuclein, 
and have further shown that this up-regulation was due to transcriptional activation of 
the promoter.
Electrophoretic Mobility Shift Assays (EMSAs) subsequently performed revealed a 
potential transcription factor(s) interaction with a-synuclein promoter during dopamine 
stressed conditions. Utilising an online transcription factor binding site search 
programme, Matlnspector, (Cartharius et al., 2005; Cross et al., 1994) several potential 
transcription factor sites were found of which one particular site, a GC rich consensus 
site, was then confirmed by additional EMSAs to be the site of interaction during 
dopamine stress. As this site was shown by Matlnspector to be shared by either WT1 or 
EGR4 (NGFIC), PCRs were performed on SH-SY5Y cell extracts to ascertain the 
presence of both the proteins in our cell model. This demonstrated that only EGR4 was 
present and not WT1, thus eliminating the possibility of WT1 interacting with a- 
synuclein promoter in our experiments.
Even though the Matlnspector programme indicated EGR4 as a good candidate for the 
interaction with the tested oligomer, the identity of the transcription factor that is 
responsible for this interaction, however, could not yet be confirmed as further literature
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search showed that all the EGR transcription family members were able to bind to the 
same consensus sequence (Beckmann and Wilce, 1997). In addition, affinity isolation of 
the binding protein followed by mass spectrometry could not identify the protein in 
question. Moreover, a GC rich sequence was also known to be able to be bound by a 
variety of transcription factors.
Consequently, to narrow down the list of transcription factors that would have to be 
examined for the interaction, a further search using two online transcription factor 
binding site search programmes, Matlnspector (Table. 3.3) and TFSEARCH (Akiyama, 
; Heinemeyer et al., 1998) (Table. 3.4), was performed and the results compared. Three 
matching transcription factors were identified by both the search programmes, when the 
search stringency was lowered in both from the default 8.0 to 7.5 so as to reveal more 
matches. These three transcription factors include the EGR family of transcription 
factors, in particular EGR4, myeloid zinc finger 1 factors and Ikaros zinc finger family.
EGR4 and its family members, specifically, were identified in Matlnspector as a good 
match with an above optimised similarity score (highlighted in green under matrix 
similarity; Table. 3.3). Both myeloid zinc finger 1 and Ikaros zinc finger family of 
transcription factors are known to be involved in haematopoiesis and lymphocyte 
differentiation. Thus, they are unlikely to be the transcription factors responsible for 
interacting with a-synuclein promoter in neurons during stress. The EGR family of 
transcription factors, on the other hand, are immediate early genes that have been found 
to be able to be induced by diverse extracellular stimuli within the nervous system 
(Beckmann and Wilce, 1997), and therefore most likely to be our candidate
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M atlnspector Release professional 7 .7 .3 , February 2008 Tue Apr 22 17:26:22 2008
Sequence file: l_ 2 .s e q  (17 bp)
Family m atches: Yes
M atlnspector library: Matrix Family Library Version 7 .0  (O ctober 2007)
Selected groups (co re /m atrix  A a  v e r te b ra te s . |ib (0 .7 5 /0 .75)
Check transcrip tion  factor <-> matrix.fPm.ilY 
assignment Opt.
Position
Str. Cere sim. Matrix sim.
Sequence
(red : ci-value > 60 
cap ita ls: core seq u en ce)Family Further Family Inform ation Matrix
from - 
to
|  VSEBOX E-box binding fac to rs V$ATF6.01 0 .93 1 - 13 (-) 1.000 0 .880 ctcCCACtccccc
|  VSEGRF
EG R/nerve grow th fac to r 
induced pro tein  C & re la ted  
fac to rs
V$NGFIC.01 0.80 1 - 17 (+) 0 .770 0 .824 ggggG A GTgggaggcaa
|  V$EKLF Basic and  ery thro id  krueppel like fac to rs V$BKLF.01 0 .95 1 - 17 (+) 0.750 0.810 ggG G G A gtgggaggcaa
j  VSMAZF Myc asso c ia ted  zinc fingers V$MAZR.01 0 .88 1  -  1 3 (+) 0 .7 5 4 0 . 7 7 2 gggggaGTGGgag
|  VSTFII GTF2I re p e a t dom ain- contain ing fac to rs V$GTF3R4.01 0 .97 2  -  1 2 (+) 0.750 0 . 7 6 7 gggGAGTggga
|  V$MAZF Myc asso c ia ted  zinc fingers V$MAZ.01 0 .90 3 - 15 (+) 0 .800 0 . 7 5 9 gggaGTGGgaggc
|  V$IKRS Ikaros zinc finger family V$IK2.01 0 .98 5 - 17 (+) 1 .000 0 .936 gagtGGGAggcaa
|  V$MZF1 Myeloid zinc finger 1 fac to rs V$MZF1.02 0 .99 6 - 16 (+) 0.761 0 . 8 0 5 agTGGGaggca
l  V$BTBF
BTB/POZ (broad  com plex, 
Tram Track, Brie a b rac /pox  
v iru ses  and  zinc fingers) 
transc rip tion  fac to r
V$KAISO.01 0 .92 7 - 17 (-) 0 .750 0 . 7 5 1 ttgcCTCCcac
Table 3.3
Reference for M atlnspector:
C arthariu s K, Freeh K, G rote K, Klocke B, H altm eier M, Klingenhoff A, Frisch M, Bayerlein M, W erner T (2005) 
M atln spec to r and  beyond : p ro m o te r analysis b ased  on transcrip tion  fac to r binding s ite s  
Bioinform atics 21, 2933 -42
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Table 3.4
TFSEARCH Search Result
** TFSEARCH ver.1.3 ** (c)1995 Yutaka Akiyama (Kyoto Univ.)
This simple routine searches highly correlated sequence fragments 
versus TFMATRIX transcription factor binding site profile database 
by E.Wingender, R.Knueppel, P.Dietze, H.Karas (GBF-Braunschweig).
<Warning> Scoring scheme is so straightforward in this version.
score = 100.0 * ('weighted sum1 - min) / (max - min)
The score does not properly reflect statistical significance!
Database: TRANSFAC MATRIX TABLE, Rel.3.3 06-01-1998 
Query: 1.46(l)c6 (17 bases)
Taxonomy: Vertebrate
Threshold: 75.0 point
TFMATRIX entries with High-scoring:
1 GGGGGAGTGG GAGGCAA
 >
 >
 >
 >
 >
entry
M 0 0 Q 8 7  
M0 02  4 4
score
1 MZF1 80.6
. Lyf-1 79.2
? Ik-2 78.5
1 NGFI-C 75.7
S Spl 75.3
Total 5 high-scoring sites found. 
Max score: 80.6 point, Min score: 75.3 point
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factor. Hence, we focused our efforts on deciphering if any of the EGR transcription 
factors were responsible for the observed interaction (Chapter 4).
In conclusion, this is a novel study showing that wild-type a-synuclein expression could 
be influenced by selective oxidative stresses and that this regulation is a transcriptional 
event. The binding of transcription factors to the a-synuclein promoter indicates the 
possible mechanism responsible for this regulation and possible identities of these 
transcription factors have been deduced. More work to conclusively identify the 
transcription factors involved is discussed in the next chapter.
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Chapter 4: Regulation of a- 
synuclein expression in 
oxidative stress by Early 
Growth Response family of 
transcription factors
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4.1 Introduction
4.1.1 Early Growth Response family of transcription 
factors
Early Growth Response (EGR) family of transcription factors belong to a subclass of 
immediate early genes (Beckmann and Wilce, 1997). These genes are inducible by a 
diverse variety of stimuli and usually lead to rapid and often transient transcriptional 
induction. The four members of the family, EGR 1-4, share a homologous zinc finger DNA 
binding domain that recognise the same consensus DNA sequence, GCG(G/T)GGGCG 
(Beckmann and Wilce, 1997). Variation in affinities of each member to slightly different 
sequences has also been found (Skerka et al., 1997). EGR proteins themselves may be 
regulated by transcriptional, translational, or post-translational events as well as protein­
protein interactions (Beckmann and Wilce, 1997). These regulations and/or modifications 
of EGR would therefore subsequently affect their transcription regulation activity.
Expression of the EGR proteins occurs throughout the nervous system at varying levels, but 
substantial levels of all four members are present in the striatum, where dopaminergic 
neurons are found (Beckmann and Wilce, 1997). To date, studies on the effects of 
dopamine on expression have only covered EGR1 (Beckmann and Wilce, 1997; Snyder- 
Keller et al., 2002). These studies revealed the relationship between dopamine and EGR1, 
in that the activation of dopamine receptors increases the basal expression of EGR1 
(Snyder-Keller et al., 2002).
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4.1.2 Regulation of a-synuclein by EGR 
transcription factors
Following the identification of putative transcription factors that may bind the GC rich 
region, 5’(GGGGGAGTGGGAGGCAA)3’, of the a-synuclein promoter following 
dopamine stress, as discussed in the previous chapter, the EGR family of transcription 
factors were selected for further investigation. This group of trans-acting factors were 
selected for the following reasons; their high scores in consensus prediction by two 
different transcription factor binding site search programmes, being inducible by 
extracellular stimuli and their known associations with the nervous system.
4.1.3 Hypothesis & Aims
Experimental observations from Chapter 3 and the results from transcription site prediction 
software indicate that one member of the EGR family of transcription factors may bind to 
the a-synuclein promoter in the presence of dopamine stress and thus regulate the 
expression of a-synuclein.
Aims of project:
4. To determine if any of the EGR transcription factors are regulated by dopamine 
stress
5. To investigate which of the EGR transcription factors are capable of modulating the 
a-synuclein promoter function.
133
Chapter IV: EGR family
4.2 Results
4.2.1 Quantitation of Early Growth Response genes 
in dopamine stress
Changes in EGR mRNA have been shown as an accurate representation of EGR-mediated 
transcriptional activity (O'Donovan et al., 1999; Skerka et al., 1997). On this basis, the 
expression of each of the EGR family members was examined during dopamine stress to 
test whether any of them respond to the stress. Real-time Polymerase Chain Reaction (RT 
PCR) was used to quantify each EGR transcript levels in the presence and absence of 
dopamine stress. Results were normalised onto p2microglobulin and |3actin housekeeping 
control genes. The identity and specificity of the product of each RT PCR was confirmed 
after the experiments (Fig 4.1)
All the EGR genes 1-4 showed up-regulation with dopamine stress (Fig. 4.2; similar results 
for both normalisations were obtained, one representative graph is shown). EGR2 mRNA 
expression increased to the least extent of 2.5 fold and EGR3 mRNA increased the most, 9 
fold, in the presence of dopamine stress (Fig. 4.2b, c). EGR1 and EGR4 both increased 6 
fold with dopamine treatment (Fig. 4.2a, d).
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Figure 4.1 RT PCR EGR1-4 product agarose gel check
Agarose gel check on RT PCR products to confirm product identity and PCR specificity. Specific product 
of the correct size was obtained for each EGR primer set used. Amplified product identity was confirmed 
by sequencing.
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Figure 4.2 Effect of dopamine on EGR1-4 mRNA expression
Cells were incubated for 24hrs in OpM and 200pM dopamine in full media culture media before mRNA 
retrieval. The error bars indicate the standard error of the mean of 3 experiments. Differences were 
analysed by paired T-test. (***p<0.001)
A) EGR1 mRNA levels increased with dopamine stress.
EGR2 mRNA levels also increased with dopamine stress, but to much smaller extent compared 
to EGR1, 3 and 4.
EGR3 mRNA levels showed the greatest increase with dopamine stress 
EGR4 mRNA levels increased to a similar extent as EGR1 with dopamine stress
B)
C)
D)
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4.2.2 Regulation of a-synuclein expression by Early 
Growth Response gene 4 (EGR4)
Of all the EGR members, EGR4 (NGFI-C) was selected by Matlnspector as the potential 
interacting transcription factor to our target sequence. As such, studies into the regulation 
of a-synuclein expression by the EGR transcription factors were prioritized for EGR4.
4.2.2.a Effect of EGR4 on a-synuclein mRNA expression
To investigate if EGR4 might regulate a-synuclein expression during dopamine stress, RT 
PCR was used to examine the effect of knocked-down EGR4 on endogenous a-synuclein 
mRNA expression in cells. This was done by transiently transfecting SH-SY5Y cells with 
small-interfering EGR4 RNA. Levels of EGR4 mRNA in the cells were then quantified by 
RT PCR to ensure knock-down before a-synuclein mRNA expression was quantified. 
Normalisations to 2 house-keeping genes, |32-microglobulin and (3actin were performed to 
ensure results were consistent.
EGR4 increased 6 fold from basal expression levels when SH-SY5Y cells were subjected 
to 200pM dopamine stress (Fig. 4.3a). Knock-down of EGR4 using short-interference RNA 
caused a 50% decrease of EGR4 expression in normal conditions but a 70% decrease when 
dopamine stressed. The knock-down of EGR4 in each condition resulted in a significant 
increase of a-synuclein expression by 30% and 79% in the presence and absence of 
dopamine respectively (Fig. 4.3b).
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The effect of over-expression of EGR4 on endogenous a-synuclein mRNA expression was 
also examined. SH-SY5Y cells were transiently transfected with EGR4 over- expressing 
construct and levels of EGR4 and a-synuclein mRNA in the cells were quantified by RT 
PCR. Normalisations to 2 house-keeping genes, p2-microglobulin and NADH cytochrome 
b5-reductase were performed. Over-expression of EGR4 in the cells did not cause any 
significant difference in a-synuclein expression (Fig. 4.4).
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Figure 4.3 Effect of EGR4 
knock-down on a-synuclein
mRNA expression
EGR4 siRNA and non-specific 
siRNA transfected cells were 
incubated for 24hrs in OpM and 
200pM dopamine in full media 
culture media before mRNA 
retrieval. The error bars indicate 
the standard error of the mean of 
3 experiments. Differences were 
analysed by paired T-test.
A) EGR4 mRNA levels were
measured. All the differently 
transfected and treated cells had 
significantly different levels of 
EGR4 mRNA expressed
(**p<0.01, ***p<0.001 when
compared to all other samples).
B) a-synuclein mRNA levels were 
measured, a-synuclein levels 
were significantly lower in 
untreated cells transfected with 
non-specific siRNA compared to 
all other samples (***p<0.001). 
The other samples were also 
significantly different, but to a 
lesser extent (*p<0.05).
* * *
45000
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Figure 4.4 Effect of EGR4 over­
expression on a-synuclein mRNA 
expression
EGR4 overexpressing and empty 
pSG5 constructs were transfected 
into SH-SY5Y cells were incubated 
for 24hrs in full media culture media 
before mRNA retrieval. The results 
of the RT PCR was normalised onto 
results obtained using housekeeping 
gene primers -  p2-microglobulin and 
NADH cytochrome b5-reductase. 
Results were similar for both 
normalisations. The error bars 
indicate the standard error of the 
mean of 3 experiments. Differences 
were analysed by paired T-test.
A) EGR4 mRNA levels were
measured. EGR4 overexpressing 
construct transfected cells had 
significantly higher EGR4 levels
compared to those transfected with
pSG5 r*p<0.001).
B) a-synuclein mRNA levels were 
measured, a-synuclein levels were 
not different between those 
transfected with EGR4 over­
expressing construct and pSG5.
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4.2.2.b Effect of EGR4 on a-synuclein promoter activity
Dual luciferase assays was performed on extracts from cells co-transfected with a- 
synuclein promoter luciferase constructs, SV40 renilla construct and EGR4 siRNA to 
investigate the effect of EGR4 knock-down on a-synuclein promoter activity. The 1.9 a- 
synuclein promoter luciferase construct was used as it contained both the predicted EGR4 
binding site as well as the a-synuclein core promoter region to confer efficient 
transcription.
In contrast to results obtained from RT PCR experiments described previously, luciferase 
constructs containing ~1.9kb of a-synuclein promoter responded negatively to EGR4 
knock-down (Fig. 4.5). The 1.9kb promoter activity decreased by 50% when EGR4 was 
knocked down in both dopamine treated and control conditions. There was no significant 
change in the activity of the 1.46kb promoter in all the samples.
The effect of EGR4 over-expression on a-synuclein promoter activity was also examined. 
Extracts from cells co-transfected with a-synuclein promoter luciferase constructs, SV40 
renilla construct and EGR4 over-expressing construct were used. The 1.9 a-synuclein 
promoter luciferase activity increased 2.5 fold with EGR4 over-expression (Fig. 4.6). There 
was also no change detected on the 1.46 promoter activity.
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Figure 4.5 Effects of EGR4 knock-down and dopamine on a-synuclein promoter activity
SH-SY5Y cells were transfected with 1.46, 1.9 a-synuclein promoter construct or PGL3 empty construct 
and EGR4 siRNA or non-specific RNA and incubated for 24hrs with OpM or 200pM dopamine in full 
culture media. Cells transfected with non-specific RNA and treated with dopamine had significantly 
higher luciferase activity compared to all the other samples (**p<0.01). Data was analysed by paired T- 
test. EGR4siDop indicate cells co-transfected with EGR4siRNA and treated with dopamine; ciDop: cells 
co-transfected with control siRNA and treated with dopamine; EGR4siC: non-treated cells co-transfected 
with EGR4siRNA; ciC: non-treated cells co-transfected with control siRNA. PGL3 indicates level of 
normalised luciferase activity when cells are co-transfected with empty plasmid PGL3.
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Figure 4.6 Effects of EGR4 over-expression on a-synuclein promoter activity
Cells were transfected with 1.46, 1.9 a-synuclein promoter construct or PGL3 empty construct and 
EGR4 overexpressing construct or empty pSG5 construct. Cells co-transfected with 1.9 a-synuclein 
promoter construct and EGR4 overexpressing constructs had significantly higher luciferase activity 
compared to their counterpart with empty pSG5 constructs (***p<0.001). Data was analysed by paired 
T-test.
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4.3 Discussion
To pinpoint which of the EGR family might bind to the a-synuclein promoter during 
dopamine stress, levels of EGR mRNAs were examined during stressed conditions. RT 
PCR analysis of endogenous EGR1-4 mRNA expressions under dopamine stress 
revealed that all four genes were up-regulated in the presence of stress. This result did 
not identify a specific EGR family member but did reinforce the possibility that one of 
them may be responsible for the interaction with a-synuclein promoter during dopamine 
stress.
EGR4 was subsequently examined to see if it was capable of regulating a-synuclein 
expression during dopamine stress. EGR4-driven transcription regulation was 
investigated first because both Matlnspector and TFSEARCH transcription factor 
binding site search software identified EGR4 as the main match to the sequence 
submitted, despite other EGRs theoretically being able to bind to the same consensus 
sequence (Beckmann and Wilce, 1997). This consensus sequence, on the a-synuclein 
promoter, was where protein was found to interact during dopamine stress, as discussed 
in the previous chapter. Both a-synuclein promoter activity and mRNA expression were 
studied during EGR4 over-expression and knock-down. Despite a-synuclein promoter 
being responsive to both EGR4 over-expression and knock-down, such effects were not 
observed on the mRNA level. In fact, the opposite effect on a-synuclein mRNA was 
observed with EGR4 knock-down.
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The two experimental approaches, RTPCR and promoter reporter analysis, produced 
conflicting results. Due to the limitation of transfection efficiency, only a portion of 
cells in the total sample examined by RTPCR would have been transfected with EGR4 
siRNA or EGR4 over-expressing constructs. Since the transfected cells could not be 
specifically selected, the extent of the modulation on a-synuclein expression may be 
understated. In this regards, luciferase reporter assays allow for the selection of 
transfected cells, since the cells producing a-synuclein promoter-regulated luciferase 
were also co-transfected with EGR4 siRNA or EGR4 over-expressing construct. Thus 
the results presented in this chapter indicate towards EGR4 being involved in the 
regulation of a-synuclein both with and without dopamine. In addition, the promoter 
reporter analysis results relates to the EMSA results obtained earlier in Chapter 3 
section 3.2.3.a, in that, a protein-DNA interaction band was observed with dopamine 
treatment but not in control.
Similar studies on the effects of EGR1-3 on a-synuclein expression and promoter 
activity using short-interference RNA knockdown and also over-expression of each of 
the EGR1-3 genes would be the next step in this study. Subsequently, supershift assays 
could also be carried out using antibodies specific for the EGR gene. This would 
confirm the identity of the interacting EGR protein and also if the regulational effects 
produced on a-synuclein by the transcription factor is direct.
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Chapter 5: Regulation of a- 
synuclein expression by 
Nurrl (NR4A2)
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5.1 Introduction
5.1.1 Early Growth Response Nurrl (NR4A2)
Nurrl (NR4A2) is a transcription factor which belongs to the orphan nuclear receptor 
superfamily and is also categorized under immediate-early genes, whose expression and 
activity are regulated in a cell-specific manner by a variety of extracellular mitogenic, 
apoptotic and differentiation stimuli (Jankovic et al., 2005).
Le et al. (Le et al., 2003) were the first to report two mutations (-291Tdel and -245T/G) in 
the 5’-untranslated region (UTR) of the Nurrl gene in families with autosomal dominant 
Parkinson’s disease. Since then, only four additional mutations (-253C/T, -223C/T, 
Serl25Cys and -309C/T) have been discovered, indicating that Nurrl mutations are rare 
(Abou-Sleiman et al., 2008; Grimes et al., 2006; Hering et al., 2004; Tan et al., 2004b; 
Wellenbrock et al., 2003). To date, functional data have only been obtained for 3 of the 6 
mutations (-291Tdel and -245T/G and -309C/T) (Abou-Sleiman et al., 2008; Le et al., 
2003). The 3 mutations studied showed decreased Nurrl expression levels in vitro and in 
patient lymphocytes or brain. In addition, a-synuclein-rich lewy bodies were also found in 
the brain of a patient with the -309C/T mutation (Abou-Sleiman et al., 2008). So far 
however, no functional link between Nurrl and a-synuclein has been reported.
Only a few Nurrl regulated genes have been identified so far (Hermanson et al., 2006; Luo 
et al., 2007; Sacchetti et al., 2001; Sakurada et al., 1999; Volpicelli et al., 2007), mostly due
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to the difficulty in the study of the regulatory functions of Nurrl as knock-out mice fail to 
develop midbrain dopaminergic neurons altogether. In addition to being a transcription 
factor, Nurrl is also classified as an immediate early gene due to its rapid induction in 
response to stimuli such as growth factors, ischemia, seizures and inflammation (Crispino 
et al., 1998). These factors have led us to consider the possibility of Nurrl involvement in 
the regulation of a-synuclein. a-synuclein is another gene strongly associated with 
Parkinson’s disease, and can be regulated in response to stress, especially oxidative 
stresses, and subtle changes in cellular levels could lead to genesis of Parkinson’s disease 
(Abou-Sleiman et al., 2006b). This hypothesis was further supported by a study by Baptista 
et.al., which showed that the expression of Nurrl in cells decreased in response to 
transfection with either WT or mutant a-synuclein, in vitro (Baptista et al., 2003).
In the previous two chapters, the effect of oxidative stress on a-synuclein expression has 
been characterised and one of the EGR family of proteins was identified as a possible trans­
acting factor. However, in a further study of additional transcription factors with known 
association with either Parkinson’s disease (Nurrl) or neuronal tissue (Bm3) was prepared. 
This selection was used to examine their possible role in the regulation of a-synuclein 
expression, in relationship to the healthy and diseased states. In this chapter the regulation 
of a-synuclein by Nurrl was examined.
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5.1.2 Hypothesis & Aims
Le et al. 2003 demonstrated that the pathogenicity of the two Nurrl 5’ untranslated region 
(UTR) mutations they found mainly lay in expression changes (Le et al., 2003). As such, 
this study was initiated to examine if the newly found 5’ UTR -309C/T Nurrl mutation, 
together with other Parkinson’s disease pathogenic signatures, also lead to similar 
alterations in expression level. In addition, since Nurrl functions as a transcription factor, 
and changes in its expression as well as sequence mutations can lead to Parkinson’s 
disease, this study was extended to include investigations into whether Nurrl might 
regulate a-synuclein.
Aims of project:
6. To investigate if Nurrl expression was altered by the -309C/T mutation
7. To then examine if the difference in expression of Nurrl would in turn affect the 
expression of its target genes
8. To investigate if Nurrl could transcriptionally regulate a-synuclein
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5.2 Results
5.2.1 In vitro analysis of -309C/T Nurrl mutation
5.2.1.a Quantitation of -309C/T Nurrl mRNA
SH-SY5Y cells were transfected with wild type (WT) and mutant Nurrl cDNA and real­
time PCR methods were used to compare the mRNA expression in vitro of -309C/T Nurrl 
cDNA with mRNA levels from pCMX vector, WT Nurrl and the -245T/G Nurrl mutant 
(previously reported by Le et al. 2003 (Le et al., 2003)). Co-transfection of a GFP reporter 
with Nurrl constructs, in parallel wells, revealed no difference in transfection efficiency 
between constructs (Fig. 5.1). The identity and specificity of the product of each RT PCR 
was confirmed after the experiments (Fig 5.2)
The mRNA expression level of the -245T/G Nurrl mutant was significantly reduced by 
approximately 80-90% compared to WT, in agreement with a previous study (Le et al., 
2003). We observed an approximate 50% reduction in mRNA expression of the -309C/T 
Nurrl mutant that was significantly different from both the WT and the -245T/G Nurrl 
mutant respectively (Fig. 5.3).
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Figure 5.1 Transfection efficiency of Nurrl constructs
Mean GFP positive cells shown corrected to pCMX. The cells were co-transfected with Nurrl (WT/mut) 
construct, POMC promoter luciferase fusion construct, sv40 renilla construct and GFP construct. 309 
and 245 are -309C/T and -245T/G mutants of Nurrl, and pCMX indicates the empty vector. There were 
no significant differences in transfection efficiencies.
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Figure 5.2 RT PCR Nurrl product agarose gel check
Agarose gel check on RT PCR Nurrl product to confirm product identity and PCR specificity. Specific 
product of the correct size was obtained. Amplified product was confirmed by sequencing to be Nurrl.
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* * *
* * *
Figure 5.3 mRNA expression of WT, -309C/T and -245T/G Nurrl constructs
Mean mRNA expression shown as a percentage of wild type (WT) Nurrl construct (100%) co­
transfected in SH-SY5Y cells, with POMC promoter luciferase fusion construct and sv40 renilla 
construct. The error bars indicate the standard error of the mean of 3 experiments in triplicates each. 
The significance of differences was analysed by ANOVA and Bonferroni post hoc test. WT versus - 
309C/T or -245T/G (**p<0.01, ***p<0.001) and -3090^  vs -245T/G (**p<0.01)
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The -50% decrease in -309C/T Nurrl mRNA expression was then investigated to 
determine if it was sufficient to alter its trans-activating properties on downstream target 
genes. We co-transfected Nurrl constructs with a construct containing the 
proopiomelanocortin gene (POMC) promoter that contains tandem NuRE (Nur77 response 
element) sites fused to luciferase. A SV40 renilla plasmid was also co-transfected to control 
for variation in transfection efficiency. The luciferase activities induced by the -309C/T and 
-245T/G Nurrl mutants were both significantly lower than WT Nurrl by -60%, but not 
significantly different from each other (ANOVA, overall p< 0.0001, Fig. 5.4). These in 
vitro data confirmed that the -309C/T mutant was sufficient to affect the trans-activating 
role of Nurrl by reducing its expression.
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Figure 5.4 Transactivation abilities of WT, -309C/T and -245T/G Nurrl constructs
Mean luciferase activities shown as a percentage of wild type (WT) Nurrl construct (100%) transfected 
in SH-SY5Y cells, with POMC promoter luciferase fusion construct and SV40 renilla construct. The error 
bars indicate the standard error of the mean of 3 experiments in triplicates each. The significance of 
differences was analysed by ANOVA and Bonferroni post hoc test. -309C/T vs WT and -245T/G vs WT 
were both significantly different (***p<0.001)
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5.2.2 Nurrl transcriptional regulation of a- 
synuciein
5.2.2.a Nurrl regulation on expression of PD associated 
genes
To mimic the loss of expression caused by 5’ UTR Nurrl mutation as found in some 
patients with Parkinson’s disease, endogenous Nurrl was knocked-down in SH-SY5Y cells 
using siRNA targeting Nurrl. Analysis by real-time PCR of mRNA levels present in 
transfected cells, demonstrated siRNA knockdown of endogenous Nurrl mRNA by 
approximately 50% in the cells. This significantly up-regulated endogenous a-synuclein, 
parkin and PINK1 mRNA expressions by 3 fold, 3 fold and 2 fold respectively (Fig. 5.5).
The effect of Nurrl over-expression was also tested by the transient transfection of Nurrl 
expression construct. The over-expression of Nurrl did not result in any significant change 
in the expression of endogenous a-synuclein and parkin transcript levels. A slight decrease 
in the expression of PINK1 transcript was observed (Fig. 5.6).
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Figure 5.5 Effect of Nurrl knock-down on Parkinson’s disease associated genes
mRNA from SHSY-5Y cells transfected with siRNA targeting Nurrl mRNA or non-specific mRNA were 
measured for a-synuclein, parkin, PINK1 mRNA and Nurrl mRNA using RT-PCR. Nurrl mRNA levels 
were knocked-down by -  60% with Nurrl targeting siRNA compared to control, a-synuclein and parkin 
mRNA levels, in turn, increased 3 fold and PINK1 mRNA levels doubled when Nurrl was knocked- 
down.
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Figure 5.6 Effect of Nurrl over-expression on Parkinson’s disease associated genes
mRNA from SHSY-5Y cells transfected with Nurrl expressing construct or empty vector were measured 
for a-synuclein mRNA and Nurrl mRNA using RT-PCR. The Nurrl expression construct overexpressed 
Nurrl by 15000 fold but this resulted only to modest decreases in a-synuclein, parkin and PINK1 
expressions.
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5.2.2.b Nurrl regulation of a-synuclein promoter activity
The effect of Nurrl on the a-synuclein promoter was assessed with the co-transfection of 
Nurrl constructs or siRNA targeting Nurrl and a 5’ deletion series of the a-synuclein 
promoter as described in Chapter 3 (Fig. 3.5).
These experiments using siRNA further reinforced the data from real-time PCRs. It was 
observed that a-synuclein promoter activity increased by -30% with Nurrl knock-down 
(Fig. 5.7), Furthermore, Nurrl over-expression, caused substantial repression to the a- 
synuclein promoter, leading to a 3-4 fold decrease in activity (Fig. 5.8).
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Figure 5.7 Effects of Nurrl knock-down on a-synuclein promoter activity
SH-SY5Y cells were co-transfected with siRNA targeting Nurrl or non-specific mRNA and with different 
a-synuclein promoter constructs and incubated in full culture media for 24hrs. A significant increase in 
promoter activity was obtained for constructs 1.9, 3.4 and 4.1 (*p<0.05, **p<0.01).
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Figure 5.8 Effects of Nurrl over-expression on a-synuclein promoter activity
Cells were co-transfected with Nurrl WT or empty vector and with different a-synuclein promoter 
constructs. Significant decreases in promoter activity were obtained for all the Nurrl transfected cells 
compared to control cells (***p<0.001).
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5.3 Discussion
5.3.1 Analysis of Nurrl 5’ UTR mutation
In vitro studies demonstrated that the -309C/T Nurrl mutation caused a significant 
decrease in Nurrl expression. Although this mutation resulted in less reduction in Nurrl 
mRNA expression compared with the -245T/G mutant discovered by Le et.al. 2003 (Le 
et al., 2003), it caused an equivalent reduction in the transactivation of a downstream 
target gene. This suggested that even a loss of -50% expression by -309C/T was 
sufficient to affect its downstream gene transcriptional role. Important targets for Nurrl 
include tyrosine hydroxylase, the dopamine transporter and vesicular monoamine 
transporter are all critical for dopaminergic neuron survival and further work would be 
required to establish the effect of Nurrl mutants on the expression of these target genes 
in vivo.
In sporadic Parkinson’s disease, Nurrl expression was reportedly reduced in nigral 
neurones containing Lewy bodies, but not inclusion negative neurones (Chu et al., 
2006). The possible mechanisms of how 5’ UTR mutations could downregulate Nurrl 
expression include effects on transcription, RNA stability and/or translation. Our in 
vitro mRNA studies and in vivo studies performed as part of a study with Healy, Muqit 
and Abou-Sleiman et.al. suggested that the mutant -309 C/T allele affects transcriptional 
expression by resulting in a decrease in Nurrl mRNA level, but the possibility that the 
mutation may affect mRNA stability cannot be excluded. Further studies would be 
required to elucidate the functional role of the 5’ UTR region of Nurrl (Abou-Sleiman 
et al., 2008).
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5.3.2 Nurrl regulation of a-synuclein expression
To simulate Nurrl mutations found in Parkinson’s disease patients, which result in 
reduction of Nurrl levels, Nurrl was down-regulated using Nurrl targeted siRNA. This 
resulted in a significant increase in a-synuclein expression. Furthermore, activity of a- 
synuclein promoter constructs increased with decreased Nurrl. These results extend 
substantial research done on both genes so far on the pro- and anti-Parkinson’s disease 
properties of Nurrl and a-synuclein respectively. Heterozygous Nurrl knock-down 
mice showed increased sensitivity to stresses such as MPTP (Le et al., 1999) whilst a- 
synuclein was found to be increased in the presence of such stresses (Abou-Sleiman et 
al., 2006b). Moreover, decreased functional Nurrl results in the genesis of Parkinson’s 
disease (Le et al., 2003) while increased a-synuclein, due to factors such as 
multiplication of the gene locus, also result in Parkinson’s disease (Eriksen et al., 2005).
To investigate if the reverse were true, Nurrl was overexpressed in SH-SY5Y cells and 
the endogenous expression of a-synuclein as well as its promoter activity was 
examined. Endogenous a-synuclein showed a modest decrease in expression with Nurrl 
overexpression, whereas its promoter constructs were strongly repressed by Nurrl 
increase. Several factors could explain this discrepancy, e.g. constitutive levels of Nurrl 
could function to invoke a maximal suppression of a-synuclein gene expression, thus, 
any further increase in Nurrl expression does not cause a further repression whereas its 
removal lifts the blockade and allows a-synuclein expression. It could also be due to the 
efficiency of transient transfection, with only 40% of the cells over-expressing Nurrl 
(result not shown). As the effect of increased Nurrl is small compared to constitutive 
levels of Nurrl already present, this renders the change in a-synuclein expression
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insignificant. Nonetheless, the a-synuclein promoter luciferase assays showed that 
Nurrl was able to repress the promoter.
Concurrently, electrophoretic mobility shift assays were also used to assess any possible 
binding of Nurrl to the a-synuclein promoter from the core promoter region to the 
translation start site which is Nurrl-responsive. No interactions were detected, 
suggesting that as in dopamine transporter gene, Nurrl acts indirectly and not via a 
specific binding site.
Here, we have shown for the first time, linkage between the transcriptional activity of 
Nurrl and the regulation of a-synuclein. Further studies are needed to investigate 
whether an increase in a-synuclein is the cause of Parkinson’s disease in patients with 
mutations causing decreased Nurrl activity or whether other effects of Nurrl are also 
involved.
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Chapter 6: Regulation of a- 
synuclein expression by 
Brn3 transcription factors
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6.1 Introduction
Following on from the a-synuclein promoter regulation study (Chapters 3 and 4), an 
investigation of transcription factor regulation of a-synuclein was performed. A selection 
of candidate transcription factors were studied including Nurrl (Chapter 5) and, in this 
chapter, Bm3. Additionally, the relationship between Nurrl and Bm3 as regards a- 
synuclein was investigated.
6.1.1 Bm3 family of transcription factors
Bm3 subfamily of factors, consisting of Bm3a, Bm3b and Bm3c, belong to the POU (Pit- 
Oct-Unc) family of transcription factors. These three factors are transcribed from separate 
genes and they all contain a conserved POU domain, but otherwise show little homology 
(Latchman, 1999).
Bm3a is important for the differentiation and survival of sensory as well as motor neurons. 
Knock-out Bm3a mice suffer from severe neuronal developmental defects and are usually 
non-viable (McEvilly et al., 1996). Bm3a exists as two forms, the short and long form, 
which are generated by alternative splicing at the 5’ end of Bm3a RNA (Theil et al., 1993). 
The presence of a longer N-terminal in Bm3a long enables it to activate not only genes 
such as neurofrlamnets and SNAP-25, activated by the POU domain, but also others, such 
as a  intemexin and the protective Bcl-2 by its additional N-terminal activation domain. 
Bm3a long has, in consequence, been found to have a protective effect on neurons against
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apoptosis (Smith et al., 1997a; Smith et al., 1997b). Although Bm3a has not been 
previously associated with any disease states, its neural protective properties make it an 
interesting factor to study for potential regulation of anti-Parkinson mechanisms, since the 
development of Parkinson's disease entails the enhanced apoptosis of specific neurons, 
leading to loss of neurological function (Latchman, 1998).
Bm3b and Bm3c are involved mainly in the differentiation and maintenance of retinal and 
vestibular neurons of the inner ear respectively. Although neither Bm3b nor c appear to 
cause any other neurological defects other than in retinal and vestibular neurons 
respectively and seems unlikely to be involved in survival of neurons important in 
Parkinson’s disease, Bm3b being known to be antagonistic (Latchman, 1999) with Bm3a, 
makes it worth examining alongside Bm3a.
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In view of the importance of the Bm3a transcription factor in the survival of motor neurons 
and its role in protecting neurons against apoptosis, we were interested to characterise the 
properties of Bm3a in relation to the progression and development of Parkinson’s disease. 
The first step was to investigate the regulation effects of Bm3a on a-synuclein. This was 
followed by studying the transcriptional effect of Bm3a on Nurrl, another Parkinson’s 
disease associated gene. Bm3b was also included in the experiments to assess any 
antagonistic effects to Bm3a.
Aims of project:
9. To investigate if Bm3a and b could regulate a-synuclein expression
10. To investigate if Bm3a and b could regulate Nurrl expression
11. If regulation was established for the first two aims, to further probe into the link 
between Bm3, Nurrl and a-synuclein
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6.2 Results
6.2.1 Brn3 regulation of a-synuclein expression
6.2.1.a Presence of Brn3 in brain region important in 
Parkinson’s disease
To first establish if Bm3a and Bm3b may indeed be important in Parkinson’s disease, PCR 
detection of Bm3a and Bm3b was carried out in 8 different cDNA samples obtained from 
control human substantia nigra region of brains (Fig. 6.1). Bm3a but not Bm3b was 
detected in this region of the human brain.
6.2. l.b Effect of Brn3 on endogenous a-synuclein expression
Although only Bm3a and not Bm3b was detected in the substatia nigra of human brains, 
Bm3b was still included in subsequent experiments as other regions in the brain are also 
affected in Parkinson’s disease and the antagonistic effects of Bm3b on Bm3a may reveal 
interesting regulation control of a-synuclein.
To investigate if Bm3 might influence endogenous a-synuclein expression, a-synuclein 
mRNA was quantified, using RT PCR, from SH-SY5Y cells transfected with constructs 
expressing different forms of Bm3, Bm3a short, Bm3a long, Bm3b short and Bm3b long 
(Fig. 6.2). Normalisations were performed to housekeeping genes, (32-microglobulin and (3- 
actin, with similar results.
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Fig. 6.1 PCR detection of Brn3a and b in substantia nigra brain region
Gel check on PCR amplification of Brn3a and Brn3b in 8 cDNA samples from human substantia nigra 
regions. Brn3a but not Brn3b was amplified from the samples.
170
Chapter VI: Bm3
MoMuLV promoter |
Variable region
POU specific
domain Homeodomain
Bm3a short
linker
MoMuLV promoter
Bm3a long
activation
POU
domain
POU specific
I— ► Variable region domain Homeodomain
i n    1 n 1MoMuLV promoter
linker
Bm3b short
r* i
MoMuLV promoter | | | | | | | | [ Bm3blong
T4-terminar ^  pou ^
activation domain
Figure 6.2 Schematic diagram of Brn3a and b isoforms in LTR plasmid
Brn3a and b long constructs contain Brn3a and b long cDNA sequences and 
Brn3a and b short contain Brn3a and b short gene sequences inserted into the 
LTR plasmid
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Bm3a-short, a-long and b-long were found to increase a-synuclein expression significantly 
(Fig. 6.3). Bm3a-short and Bm3b-long caused similar increases in a-synuclein expression 
by 1.4-1.5 fold. Bm3a-long was shown to have the greatest effect on a-synuclein 
expression, causing a 2 fold increase. No change in a-synuclein expression was observed 
with Bm3b-short.
6 . 2 . 1 . C  Brn3 regulation of a-synuclein promoter activity
The different forms of Bm3 were examined to see if they could transcriptionally regulate 
a-synuclein promoter activity. Dual luciferase assays were performed using cells co­
transfected with constructs expressing different forms of Bm3 and the various a-synuclein 
promoter constructs (Fig. 3.3). All the different Bm3 forms were found to up-regulate a- 
synuclein promoter activity (Fig. 6.4). The long forms of Bm3 showed higher up-regulation 
compared to the short forms. Bm3a-long did not, however, confer an increased level of 
induction on a-synuclein promoter compared to Bm3b-long.
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Figure 6.3 Effects of Brn3a and b isoforms over-expression on a-synuclein mRNA expression
Cells were transfected with control LTR construct, brn3a-short, a-long, b-short or b-long constructs, a- 
synuclein mRNA expression in cells transfected with brn3a-short, a-long and b-long were significantly 
higher than those transfected with LTR or brn3b-short (** p<0.01). Cells transfected with Brn3a-long had 
a-synuclein mRNA levels significantly higher than all the other samples. Data was analysed by paired T- 
test.
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Figure 6.4 Effects of Brn3a and b isoforms over-expression on a-synuclein promoter activity
Cells were co-transfected with control LTR construct, brn3a-short, a-long, b-short or b-long constructs 
and with different a-synuclein promoter constructs. Significant increases in promoter activities were 
obtained when cells were co-transfected with a brn3 construct compared to LTR construct for almost all 
the a-synuclein constructs (*p<0.05; **p< 0.01; ***p<0.001).
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6.2.2 Bm3 regulation of Nurrl expression
Our previous investigations showed that, other than Bm3, Nurrl could also 
transcriptionally regulate a-synuclein (chapter 5). Therefore, we investigated if there might 
be any interactions or pathway cross over between Nurrl and Bm3 in the regulation of a- 
synuclein.
6.2.2.a Nurrl expression in Brn3 KO mice
Nurrl expression was analysed in Bm3a and b knock-out mice. This in vivo study allows 
for a more physiological analysis of gene regulation compared to in vitro cell culture 
models. The analysis was performed through quantifying Nurrl mRNA in RNA extractions 
obtained from total mice brains. 5 postnatal day 1 brain extractions were done for each 
genotype, wild-type, heterozygous and knock-out, for both Bm3a and b. Postnatal day 1 
mice were selected as Bm3a knock-out mice die shortly after they are conceived. RT PCR 
was used to quantify the RNA and housekeeping genes, p2-microglobulin and p-actin, were 
used for normalisations, similar results were obtained with both means of normalisation. 
Nurrl expression was found to increase with the decrease in Bm3a being expressed, with 
the highest increase in Nurrl expression of 1.6 fold in Bm3a knock-out brains, followed by 
heterozygous Bm3a with 1.2 fold increase and the least expression in wild-type brains (Fig.
6.5). No significant trend was observed for Nurrl expression in Bm3b knock-out mice (Fig.
6 .6).
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Figure 6.5 Nurrl mRNA expression in Brn3a KO mice
Nurrl mRNA was quantified in RNA extractions from 9 Brn3a mice, 3 for each genotype. Nurrl 
expression increased with decrease in Brn3a dosage, and was significantly higher in Brn3a knock-out 
mice compared to the other 2 genotypes (*p<0.05).
176
1.2
</)
</)
0>i—
Q_
X
CD
a>
O)c
ra
-c
o
2
o
0.8
0.6
0.4
0.2
0
Brn3b knock-out Brn3b heterozygous Brn3b wild type
Figure 6.6 Nurrl mRNA expression in Brn3b KO mice
Nurrl mRNA was quantified in RNA extractions from 15 Brn3b mice, 5 for each genotype. No significant 
trend in Nurrl expression was observed.
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6.2.2.b Effects of Bm3 overexpression on Nurrl
To follow on the results obtained from the Bm3 knock-out mice, Nurrl expression was 
also examined when Bm3 was over-expressed in vitro cell culture. In this case, Nurrl 
mRNA was quantified in RNA extractions from SH-SY5Y cells transfected with 
constructs expressing different forms of Bm3, Bm3a short, Bm3a long, Bm3b short and 
Bm3b long. Normalisations were performed to housekeeping genes, p2-microglobulin, 
(3-actin and GAPDH. Similar results were obtained. In each case, over-expression of all 
the Bm3 forms produced an increase in Nurrl expression of 3-4 fold except for Bm3a 
long which did not show any change (Fig. 6.7).
6 . 2 . 2 . C  Effects of increase in Nurrl expression on Brn3
To investigate if changes in Nurrl expression might also have an impact on the 
expression of Bm3. Bm3 mRNA was also quantified from SH-SY5Y cells transfected 
with overexpressing Nurrl construct. As Bm3a is our main focus and consistent 
changes in Nurrl expression were only seen in Bm3a experiments, we looked mainly at 
changes in Bm3a expression. The identity and specificity of the Bm3a product was 
confirmed after each RT PCR (Fig 6.8). There were no significant changes in Bm3a 
expression with the overexpression of Nurrl (Fig. 6.9).
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Figure 6.7 Effects of Brn3a and b isoforms over-expression on Nurrl mRNA expression
Nurrl mRNA levels were quantified in RNA extractions from SH-SY5Y cells transfected with different 
Brn3 forms and empty control plasmid. Increases in Nurrl expression were obtained for cells transfected 
with all the different forms for Brn3 except for Brn3a long.
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Figure 6.8 RT PCR Brn3a product agarose gel check
Agarose gel check on Brn3a RT PCR products to confirm product identity and PCR specificity. Specific 
product of the correct size was obtained. Amplified product was confirmed to be Bm3a by sequencing.
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Figure 6.9 Effect of Nurrl over-expression on Brn3a mRNA expression
Brn3a mRNA expression was quantified in mRNA extractions from SH-SY5Y cells transfected with Nurrl 
overexpressing construct or control construct transfected SH-SY5Y cells. There was no significant 
difference in the Brn3a expression between the samples.
181
Chapter VI: Bm3
6.2.3 Regulation of a-synuclein by Brn3 & Nurrl
Nurrl was found to down-regulate a-synuclein expression (chapter 5), whereas Bm3 
was shown to up-regulate a-synuclein expression and Bm3a reduced the expression of 
Nurrl. It would therefore be of interest to investigate if the simultaneous over- 
expression o f Nurrl with the over-expression of Bm3 would abrogate the effects of 
Bm3 on a-synuclein, i.e. to find out if the transcriptional influence is sequential: 
Bm3—►Nurrl —►a-synuclein.
The over-expression o f Nurrl did not have a consistent effect across the Bm3 forms 
(Fig. 6.10). In the presence of increased Nurrl, a 1.5 fold increase in a-synuclein 
expression was observed in Bm3a short over-expression and a large 3 fold decrease was 
obtained with Bm3b long. Results for Bm3a long and Bm3b short did not differ 
significantly.
To further investigate the possible interaction between Bm3, Nurrl and a-synuclein, 
Nurrl expression was knocked-down using Nurrl specific siRNA to assess whether its 
effect on a-synuclein might be synergistic to overexpression of Bm3a. Knocking-down 
of Nurrl in the presence o f Bm3 over-expression only slightly increased a-synuclein 
expression in comparison to that with constitutive levels of Nurrl (Fig. 6.11). Using 
dual luciferase assays to investigate a-synuclein promoter activity, we confirmed that 
Bm3a long and Nurrl knock-down had additive effects on a-synuclein promoter up- 
regulation (Fig. 6.12). It was observed that a-synuclein 1.9 construct promoter activity 
increased 1.3 fold with Nurrl knock-down, 2 fold with Bm3a-long over-expression and
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Figure 6.10 Effects of Brn3 and Nurrl over-expression on a-synuclein mRNA expression
a-synuclein mRNA was quantified in RNA extractions from SH-SY5Y cells co-transfected with the 
different Brn3 constructs and Nurrl constructs. The presence of Nurrl increased a-synuclein expression 
in Brn3a overexpressing cells, and decreased a-synuclein expression in Brn3b overexpressing cells
(***p<0.001).
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Figure 6.11 Effects of Brn3 over-expression and Nurrl knock-down on a-synuclein mRNA 
expression
a-synuclein mRNA was quantified in RNA extractions from SH-SY5Y cells co-transfected with the 
different Brn3 constructs and Nurrl siRNA or nonspecific siRNA. The knockdown of Nurrl slightly 
increased a-synuclein expression in all Brn3 overexpressinq cells.
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Figure 6.12 Effects of Brn3a over-expression and Nurrl knock-down on a-synuclein promoter 
activity
SH-SY5Y cells were co-transfected with a-synuclein promoter luciferase plasmids and Brn3a long and 
Nurrl specific siRNA or their respective control plasmids or siRNA. 1.9 a-synuclein promoter activity 
showed additive increase with the overexpression of Brn3a and Nurrl. The additive effect diminished 
with longer a-synuclein promoter (**p<0.01; ***p<0.005).
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2.5 fold with both. However, with the increase in a-synuclein promoter length, the up- 
regulatory effects of Bm3a-long and Nurrl knock-down diminished and no additive 
effects were observed. Nonetheless, there was still a significant but similar 30% 
increase in 4.1 promoter activity when Nurrl was knocked-down, Bm3a-long was over­
expressed or the combination of both, compared to control cells.
6.2.4 Protective & apoptotic balance of Brn3 & 
Nurrl
As shown earlier, either the over-expression of Bm3a-long or the knock-down of Nurrl 
both cause an up-regulation of a-synuclein. In addition, the combination of the over- 
expression of Bm3a-long and knock-down of Nurrl resulted in an additive up- 
regulational effect on the core promoter region of a-synuclein promoter. To examine if 
there might be dominance in effects of over-expression of either Bm3a-long or Nurrl, 
apoptosis assays were used. Bm3a-long is known to be protective while Nurrl is 
believed to be pro-apoptotic, as such, cells over-expressing Bm3a-long should have a 
lower proportion of cells undergoing apoptosis compared to control while over- 
expressing Nurrl should have a higher proportion of cells undergoing apoptosis. 
Apoptosis assays were used to exploit this difference and find out if either was 
dominant over the other. This was based on the assumption that the dominance could 
also be translated to dominance over the regulation of a-synuclein.
Although effects are slight, results confirm that Bm3a is protective while Nurrl is pro- 
apoptotic (Fig. 6.13). When SH-SY5Y cells were co-transfected with both Bm3a and 
Nurrl, the apoptosis level was found to be similar to control cells, showing that neither 
Bm3a nor Nurrl were functionally dominant over the other.
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Figure 6.13 Apoptotic effect of Brn3a and Nurrl
SH-SY5Y cells transfected with Brn3a long were less apoptotic compared to control cells while those 
transfected with Nurrl were more apoptotic. Co-transfection of both Brn3a long and Nurrl still reduced 
the number of early apoptotic cells slightly compared to control cells
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6.3 Discussion
6.3.1 Brn3 regulation of a-synuclein expression
Although Bm3a has never been implicated in Parkinson's disease, it is important in 
survival and maintenance of sensory and more importantly, motor neurons (McEvilly et 
al., 1996). In addition, we also confirmed expression of Bm3a in a region most 
important in Parkinson’s disease, the substantia nigra. It is therefore of interest whether 
it could be involved in the genesis of Parkinson’s disease. As Bm3b has been shown to 
be antagonistic to Bm3a in the regulation of several genes, the role of Bm3b was also 
examined, even though it is mainly known to be involved in the differentiation and 
maintenance of retinal ganglions and not motor or dopaminergic neurons (Latchman, 
1999), and its presence was not detected in human substantia nigra region of the brain. 
Analysis of the mRNA expression and promoter activity of a-synuclein revealed that all 
Bm3a and b forms were able to up-regulate a-synuclein expression. Interestingly, this 
up-regulation was most evident with Bm3a-long. This contributes to our hypothesis, 
mentioned earlier, that Bm3a-long could be protective in Parkinson’s disease.
6.3.2 Brn3 regulation of Nurrl expression
As previous results showing that, other than Bm3, Nurrl could also transcriptionally 
regulate a-synuclein (chapter 5), we proceeded to investigate the possible interaction 
between Nurrl and Bm3. In vivo studies on Bm3 knockout mice brains showed an up- 
regulation of Nurrl with the knockdown of Bm3a. In vitro Bm3a over-expression, 
however, did not lead to down-regulation of Nurrl. In fact, Bm3a short over-expression
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led to Nurrl up-regulation. Bm3a short, on the other hand, did not alter the expression 
of Nurrl. It is plausible that Bm3a long is responsible for the regulation of Nurrl in 
Bm3a knockout mice. The over-expression of Bm3a long does not show an opposite 
effect to its knockdown could simply be due to constitutive levels of Bm3a long 
functioning to invoke a maximal suppression of Nurrl gene expression, thus, any further 
increase in Bm3a long expression does not cause a further repression whereas its 
removal lifts the blockade and allows Nurrl expression. It could also be due to the 
efficiency o f transient transfection. With only a portion of the cells over-expressing 
Bm3a long, the effect of increased Bm3a long is nominal compared to constitutive 
levels of Bm3a long already present, this renders the change in Nurrl expression 
insignificant. This case scenario is similar to that observed earlier in the regulation of a- 
synuclein by Nurrl (Chapter 5).
As Nurrl has been shown to regulate Bm3a, the reverse regulation was also tested to 
determine if Nurrl could also regulate the expression of Bm3a, in a feed back loop. 
Although the over-expression o f Nurrl did seem to slightly down-regulate Bm3a, the 
change was not significant. More experiments would have to be performed to 
conclusively identify the relationship between Bm3a and Nurrl.
6.3.3 Regulation of a-synuclein by Brn3 & Nurrl
With over-expression of Bm3a and knock-down of Nurrl both up-regulating the 
expression of a-synuclein, and that the knock-down of Bm3a increasing the expression 
of Nurrl, we sought to find out if Bm3a and Nurrl could act synergistically on the 
expression of a-synuclein. Predictably, the over-expression of Bm3a long together with 
the over-expression of Nurrl did not result in any change in a-synuclein expression.
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The knocking-down o f Nurrl in the presence o f Bm3a long over-expression, 
surprisingly, however, only very slightly increased a-synuclein expression compared to 
when Nurrl was not knocked-down. Studying a-synuclein promoter activity, confirmed 
that Bm3a long and Nurrl knock-down had additive effects on a-synuclein promoter 
up-regulation. However, with the increase in a-synuclein promoter length, the up- 
regulatory effects o f Bm3a long and Nurrl knock-down diminished and additive effects 
were no longer observed. The decrease in activation o f the promoter was undoubtedly 
due to the presence o f  repressor sites further upstream of the gene, thus dampening the 
up-regulation caused. Yet, it is not clear why the up-regulation of a-synuclein could not 
be observed on the endogenous mRNA level when either the over-expression o f Bm3a 
long or the knock-down o f Nurrl alone could. Nonetheless, this is a novel display of 
interplay between Bm3a-long, Nurrl and a-synuclein gene regulations.
The regulation o f a-synuclein by Bm3a and Nurrl might occur through two different
Extracellular
models: u Cytoplasm
Synaptic vesicle
a-synuclein
protein
Stimuli
Brn3a
Nucleus
Brn3a
Nurrl
Nurrl
a-synuclein
Figure 6.14 Possible regulation models of a-synuclein by Bm3 and Nurrl.
Two possible pathways to regulate a-synuclein by Bm3a and Nurrl may occur Pathway of 
model 1 is indicated by orange arrows while pathway of model 2 is indicated by blue 
arrows.
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From our results in the apoptosis assays, dominance of either Bm3a or Nurrl over the 
other was not found. Moreover, additive rather than synergistic effects were obtained 
from a-synuclein promoter assays when Bm3a and Nurrl were used. As such, it is 
deduced that both Bm3a and Nurrl might act seperately on the a-synuclein promoter, 
and the second model could better represent the regulation effects of Bm3a and Nurrl 
on a-synuclein.
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Chapter 7: Regulation of 
Parkin in oxidative stress
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7.1 Introduction
In the previous result chapters, a detailed analysis into the regulation of Parkinson’s disease 
associated gene, a-synuclein, in the presence of oxidative stress or in normal conditions 
was carried out The oxidative stresses used evoked a robust transcriptional up-regulation 
of a-synuclein. As these stresses appear to play an important role in the development of 
Parkinson’s disease, we also examined their effects on another Parkinson’s disease 
associated gene, Parkin.
7.1.1 Oxidative stress, Parkin & Parkinson’s 
disease
The majority of parkin mutations are found to either impair its binding to putative 
substrates or render its ligase activity defective, thus resulting in a decrease in its activity. 
This loss-of-function mechanism leads to neurodegeneration and PD (Imai and Takahashi, 
2004). Recent studies of parkin knock out models have suggested that parkin loss-of- 
function may lead to mitochondrial dysfunction and oxidative stress (Greene et al., 2003; 
Palacino et al., 2004).
Oxidative stress has long been implicated in the pathogenesis of PD. Dopamine may be the 
major contributor since it can be generated endogenously by the substantia nigral neurons 
(Barzilai et al., 2001; Sherer et al., 2002). An increase in dopamine may lead to 
mitochondrial dysfunction and impaired proteolysis via its reactive metabolites,
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dihydroxyphenylacetic acid and dopamine-quinones, or directly due to its oxidative nature 
(Khan et al., 2001; Kruger et al., 1998; Pearson et al., 2001; Stokes et al., 1999). The 
neurotoxin, MPP+, a reactive metabolite of MPTP (1-methy 1-4-phenyl-1.2.3.6- 
tetrahydropyridine), is a mitochondrial complex 1 inhibitor and is selectively taken up into 
dopaminergic neurons via the dopamine transporter leading to severe oxidative damage and 
neuronal degeneration resulting in Parkinsonism in rodents, primates and humans (Javitch 
et al., 1985; Javitch and Snyder, 1984; Mizuno et al., 1987; Ramsay et al., 1986).
Parkin knock-out mice develop mitochondrial deficits (Palacino et al., 2004) and parkin 
knock-down in cell lines renders cells more vulnerable to oxidative stress (MacCormac et 
al., 2004). Parkin’s ubiquitin ligase activity is also modified by nitric oxide mediated 
oxidative stress. It has have recently reported (LaVoie et al., 2005; Tan et al., 2004b; Yao et 
al., 2004) that the reactive metabolite of dopamine, dopamine quinone may decrease the 
solubility of endogenous parkin by covalently binding to cysteine residues of parkin. This 
results in the loss of parkin’s activity. Furthermore, this study found increased insoluble 
parkin in the caudate nucleus of PD patients (LaVoie et al., 2005). It was also previously 
shown that endogenous parkin localizes to aggregates following exposure to dopamine in 
neuroblastoma cells (Muqit et al., 2004).
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7.1.2 Hypothesis & Aims
Oxidative stress has been found to affect the expression of a variety of proteins 
implicated in PD, e.g. a-synuclein (Karamohamed et al., 2005). However, no studies to 
date have examined the effect of oxidative stress on the regulation of parkin at the level 
of transcription. To examine whether there is any up-regulation of parkin in the face of 
oxidative stress that might represent a compensatory mechanism following a reduction 
in parkin solubility, we studied the effects of two well characterized oxidants, dopamine 
and MPP+, on the regulation of parkin expression.
Aims of project:
12. To determine if the presence of extracellular dopamine, MPP+ or MG 132 could 
alter the expression of parkin mRNA.
13. To investigate if the change in parkin mRNA expression is reflected in its 
protein levels, and also to confirm if parkin protein solubility is affected by the 
stresses used.
14. If the expression of parkin mRNA is altered, to confirm if this event is 
transcriptional.
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7.2 Results
7.2.1 Quantitation of parkin mRNA
To determine if dopamine might have an effect on the transcription of parkin, real-time 
PCR was used to measure the amount of parkin mRNA in SHSY5Y cells incubated with 
OpM, 62.5pM, 125pM and 250pM dopamine for 24hrs. Similar results were obtained in 
normalisations to three different control house-keeping genes, (32-microglobulin, (3-actin 
and NADH cytochrome b5-reductase (one representative graph is shown). The identity and 
specificity of parkin product was confirmed after each RT PCR (Fig 7.1).
RT PCR results demonstrated that dopamine caused a dose-dependent increase in 
endogenous parkin mRNA (Fig. 7.2). A maximal increase of 120 fold was achieved with 
250jiM dopamine treatment.
To find out if this was specific to dopamine or a general response to oxidative stress 
another oxidative stressor, MPP+, was used to carry out a similar quantitative analysis. 
Cells were incubated with OmM, ImM, 5mM and lOmM MPP+ for 6hrs. The results from 
real-time PCR were similarly normalised and a dose-dependent increase of 3-4 fold in 
mRNA was also observed (Fig. 7.3).
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Figure 7.1 RT PCR parkin product agarose gel check
Agarose gel check on parkin RT PCR products to confirm product identity and PCR specificity. Specific 
product of the correct size was obtained. Sequencing of amplified product confirmed the identity of 
product as parkin.
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Figure 7.2 Effects of dopamine on parkin mRNA expression
Cells were incubated for 24hrs in OpM, 62.5jliM, 125pM and 250pM dopamine in full culture media, 
before mRNA was retrieved. The error bars indicate the standard error of the mean of 3 experiments 
performed in triplicate. Differences was analysed by ANOVA + Bonferroni post hoc test. The amount of 
parkin mRNA in cells stressed with 250mM dopamine was significantly higher than those in unstressed 
cells and cells stressed with only 62.5mM dopamine (** p<0.01).
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Figure 7.3 Effects of MPP+ on parkin mRNA expression
Cells were incubated for 6hrs in OmM, 1mM, 5mM and 10mM MPP+ in full media culture media before 
mRNA retrieval. The error bars indicate the standard error of the mean of 5 experiments. Differences 
was analysed by ANOVA + Bonferroni post hoc test. There was a significant dose-dependent increase 
in parkin mRNA for stressed cells (*p<0.05).
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Figure 7.4 Effects of MG132 on parkin mRNA expression
Cells were incubated for 24hrs in OmM, 5mM and 10mM MG132 in full media culture media before 
mRNA retrieval. There was a significant increase in parkin mRNA in stressed cells compared to 
untreated cells (***p<0.001). The error bars indicate the standard error of the mean of 3 experiments. 
Differences was analysed by ANOVA + Bonferroni post hoc test.
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To further investigate the regulation of parkin expression by stresses, proteasomal inhibitor, 
MG 132, was also used. This is of relevance as parkin is an E3 ligase involved in the 
ubiquitin proteasomal system. Using a proteasomal inhibitor would allow us to understand 
if the same principle applies to general cellular detrimental stresses, which may lead to 
proteasomal dysfunction, but does not target the proteasome specifically could lead to 
parkin up-regulation in a bid to overcome the dysfunction, and a stress that specifically 
targets and inhibits proteasomes. Cells were incubated with OmM, 5mM and lOmM 
MG 132 for 24hrs. The results from RT PCR were similarly normalized as with dopamine 
and MPP+ experiments and a significant increase of 2 and 2.5 fold in mRNA was observed 
in 5mM and lOmM MG 132 treated cells compared to untreated cells (Fig. 7.4).
The RT PCR results show that both oxidative stresses and proteasomal inhibitors could 
increase parkin expression, however, this did not indicate if the increase in parkin mRNA 
was due to transcriptional or post-transcriptional regulation. It also did not reveal if the 
increase was reflected on the protein level.
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7.2.2 Protein analysis
Western blot analysis was performed to determine if the regulation of parkin by oxidative 
stress observed at the mRNA level could also be seen at the protein level. In addition, in 
light of recent work showing altered parkin solubility by oxidative stress (LaVoie et al., 
2005; Petit et al., 2005), parkin protein concentrations were analysed in both total (soluble 
and insoluble) and soluble cell extracts. 250pM dopamine and lOmM MPP+ was used to 
stress the cells. A significant increase in total parkin protein was obtained following 
dopamine stress (55% increase in signal). This was consistent with our mRNA results 
above. However, there was a significant decrease in soluble parkin protein (35% decreases 
in signal) suggesting that the increased parkin was sequestered into the insoluble fraction 
(Fig. 7.4). In MPP+ stressed cells, an increase in total parkin protein compared to control 
was also observed (100% increase in signal), but in contrast to dopamine, there was no 
change in the proportion of soluble parkin protein (Fig. 7.5).
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Figure 7.5 Effects of dopamine on parkin protein levels
Cells were incubated for 24hrs in OmM and 250mM dopamine in full culture media before lysing in either 
RIPA buffer or Laemmli buffer to extract soluble and total protein respectively. The exposed bands were 
analysed using GS-800 BioRad densitometer and the results were normalised with p-actin protein and 
shown as a percentage change compared to untreated cells. Differences were analysed by paired T- 
test. Dopamine stressed soluble parkin showed a significant decrease while total parkin showed a 
significant increase compared to untreated samples (* p<0.05).
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Figure 7.6 Effects of MPP+ on parkin protein levels
Cells were incubated for 6hrs in OmM and 10mM MPP+ in full media culture media before lysing in 
either RIPA buffer or Laemlli buffer to extract soluble and total protein respectively. The exposed bands 
were analysed using GS-800 BioRad densitometer and the results were normalised onto p-actin protein 
and shown as a percentage change compared to untreated cells. There was a strong trend for an 
increase in total parkin protein expression compared to untreated control.
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7.2.3 Parkin promoter activity
To further investigate if the increase in parkin mRNA obtained previously was due to 
transcriptional or post-transcriptional regulation, dual luciferase assays were used. A 
variety of parkin promoter regions cloned upstream of the luciferase gene (Fig. 7.7) were 
used to measure parkin promoter transactivation. The constructs include 4500 construct, 
which contains approximately 4kb upstream of parkin exon 1 and thus includes the core 
parkin promoter and possible additional enhancer/repressor sites; 363 construct which 
contains about 300bp upstream of parkin transcriptional start site and includes the core 
parkin promoter; 282 contains the antisense strand of the parkin promoter and represents 
the PARCG core promoter; 140 contains only about 40bp upstream of parkin transcription 
start site. These constructs were transfected into SH-SY5Y cells and luciferase activity was 
assayed for their basal levels and in response to varying concentrations of dopamine and 
MPP+.
Under basal conditions, constructs 363 and 282 displayed significantly higher activity 
compared to 4500 (Fig, 7.8). There was no significant difference in activity between 4500 
compared to the control construct 140. This indicated the presence of essential promoter 
sequences (core promoter) and possible enhancer domains of the parkin promoter (363). 
The lower activity observed with 4500 construct indicated possible repressor domains in 
the sequences upstream of the promoter. The activity of 363 was also observed to be 
significantly higher than 282 which consists of the core promoter of the co-regulated anti­
sense gene, PACRG.
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Figure 7.7 Parkin luciferase promoter constructs
Constructs used for dual luciferase assays. Each of the inserts was cloned in pGL-basic plasmid 
upstream of the firefly luciferase reporter gene. In all the transfections, they were co-transfected with 
pRL-SV40, which produces Renilla luciferase and thus corrects for transfection efficiency when 
measuring for the overall luciferase activity. 4500 encodes for approximately 4kb upstream of parkin 
exon 1 and thus contains the core parkin promoter and possible additional enhancer/repressor sites; 
363 encodes for about 300bp upstream of parkin transcriptional start site and contains the core parkin 
promoter; 282 contains the antisense of the parkin promoter and codes for the PARCG core promoter; 
140 contains only about 40bp upstream of parkin and PGL3basic indicates the empty vector.
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3ells were transfected with the different parkin promoter constructs and incubated in full culture media 
or 24hrs. Data was analysed by ANOVA with post hoc Bonferroni correction. Constructs 363 and 282 
Depressed significantly higher luciferase activity compared to the other constructs (***p<0.001) 363, in 
urn, also expressed significantly higher luciferase than 282
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Administration of dopamine resulted in a significant increase in luciferase activity for the 
full length parkin promoter construct 4500 at 125pM and dose-dependent increase for the 
363 promoter (Fig. 7.9). This suggested that the increase in parkin mRNA observed in 
earlier experiments was due to transcriptional activation. A 2 fold increase in promoter 
activity of 282 construct was also obtained with 125pM dopamine treatment, but decreased 
to control levels with 250pM dopamine. Activity was not changed for 140 construct in all 
conditions.
Similar dual luciferase assays were carried out with MPP+ to determine if the MPP+ 
induced regulation observed at the mRNA level was also via transcriptional activation. 
MPP+ treatment also resulted in a similar activation of parkin promoter (Fig. 7.10). A 3-4 
fold increase in activity was observed in all the constructs tested in lOmM MPP+ treatment 
except for 140 construct which only showed a 2 fold increase. When stressed with 5mM 
MPP+, only construct 363 showed a significant activity increase.
Dual luciferase assays performed on 5mM MG 132 stressed cells showed an increase in 
promoter activity for all the parkin promoter constructs used (Fig. 7.11). The greatest 
increase in treated versus untreated cells was observed with 4500 and 363 constructs at 2 
fold each. Significant but small increases were observed with 282 and 140 constructs.
A significant activation was observed with the 282 construct when stressed with both 
dopamine and MPP+. Although there was also a significant increase when treated with 
MG 132, the increase is negligible compared to the other two stresses. 282 construct
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Figure 7.9 Effects of dopamine on parkin promoter activity
Cells were transfected with the different parkin promoter constructs and incubated for 24hrs in OmM, 
125mM and 250mM dopamine in full culture media. Constructs 4500 and 282 in 125mM dopamine were 
significantly (*p<0.05) different from untreated cells. The luciferase activity in cells transfected with 
construct 363, in 250mM dopamine, was also significantly higher than untreated cells (*p<0.05). 
Luciferase activity for 140 was not significantly altered in the different dosages of dopamine. The 
luciferase values were corrected for PGL3basic vector activity. The error bars indicate the standard error 
of the mean of 3 experiments, each performed in triplicates.
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Figure 7.10 Effects of MPP+ on parkin promoter activity
Transfected cells were incubated for 6hrs in OmM, 5mM & 10mM MPP+ in full culture media. There was a 
significant increase in luciferase activity for all the constructs tested in 10mM MPP+ (***p<0.001) and a less 
significant increase in activity of construct 363 in 5mM (*<0.05). The luciferase values were corrected for 
PGL3basic vector activity. The error bars indicate the standard error of the mean of 3 experiments, each 
performed in triplicates.
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Figure 7.11 Effects of MG132 on parkin promoter activity
Transfected cells were incubated for 24hrs in OmM and 5mM MG 132 in full culture media. There were a 
significant increases in luciferase activity for all the constructs tested in stressed cells compared to 
untreated cells (*p<0.05; **p<0.01; ***p<0.001). The luciferase values were corrected for PGL3basic 
vector activity. Differences was analysed by ANOVA + Bonferroni post hoc test.
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consists of the core promoter of the co-regulated anti-sense gene, PACRG, which suggests 
that activation of the PACRG (parkin co-regulated gene) promoter may also be stress 
responsive. There is currently some evidence that PACRG may play a role during cell 
stress (West et al., 2003; Yang et al., 2003). As such, it would be of interest to examine if 
the PACRG promoter up-regulation in the presence of dopamine and MPP+ would be 
reflected in the mRNA level.
7.2.4 Quantitation of PACRG (parkin co-regulated 
gene) mRNA
In view of the luciferase results for construct 282, which consist of the core promoter of 
PACRG, we examined whether PACRG mRNA expression was increased in response to 
dopamine and MPP+ using PACRG primers (Table 2.1). The identity and specificity of 
parkin product was confirmed after each RT PCR (Fig 7.12). There was a dose-dependent 
increase in both dopamine and MPP+ stressed samples consistent with the luciferase data 
(Fig. 7.13 & 7.14). The increase in PACRG expression observed was lower when treated 
with lOmM MPP+ compared to 5mM mainly because of cell death due to toxicity.
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Figure 7.12 RT PCR PACRG product agarose gel check
Agarose gel check on PACRG RT PCR products to confirm product identity and PCR specificity. Specific 
product of the correct size was obtained. Amplified product identity was confirmed by sequencing to be 
PACRG
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Figure 7.13 Effects of dopamine in PACRG mRNA expression
Cells were incubated for 24hrs in OmM, 31.25mM, 62.5mM, 125mM and 250mM dopamine in full culture 
media, before mRNA was retrieved. The results of the RT PCR was normalised onto results obtained 
using housekeeping gene primers -  b2-microglobulin. The error bars indicate the standard error of the 
mean of 3 experiments. Differences was analysed by ANOVA + Bonferroni post hoc test. The results 
indicated a significant dose-dependent increase in PACRG mRNA (*p<0.05 for 31.25mM, ***p<0.001 for 
62.5mM, 125mM and 250mM).
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Figure 7.14 Effects of MPP+ on PACRG mRNA expression
Cells were incubated for 6hrs in OmM, 1mM, 5mM and 10mM MPP+ in full media culture media before 
mRNA retrieval. Similarly, the results of the RT PCR was normalised onto results obtained using 
housekeeping gene primers -  b2-microglobulin. The error bars indicate the standard error of the mean 
of 3 experiments. Differences was analysed by ANOVA + Bonferroni post hoc test. All the MPP+ 
stressed cells showed significant increases in PACRG mRNA with those stressed with 5mM MPP+ 
showing the highest increase (*p<0.05 for 1mM and 10mM, ***p<0.001 for 5mM).
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7.3 Discussion
Parkin is generally thought to be neuro-protective due to its role in the ubiquitin 
proteasome system (UPS), facilitating the transfer of ubiquitin to damaged, or misfolded 
target substrates leading ultimately to their degradation. Mutations of the parkin gene 
have been associated with a large proportion of familial PD especially early-onset PD. 
As the age of onset of PD is usually higher in sporadic cases, the role of ageing and 
environmental stress in these cases becomes more important. There is also accumulating 
evidence for interplay between oxidative stress and parkin and recently parkin has 
shown to become more insoluble and inactivated by dopamine (LaVoie et al., 2005). 
One previous study has also shown that over-expression of parkin in cultured cells may 
confer protection against dopaminergic stress (Jiang et al., 2004) although we did not 
observe this in our system (Muqit et al., 2004). However, we have shown that parkin 
knock-down in cell lines renders them more susceptible to dopaminergic stress 
(MacCormac et al., 2004). However, no studies to date have focused on the regulation 
of endogenous parkin at the transcriptional level in the presence of oxidative stress.
In our studies, we have used dopamine, MPP+ and MG 132 to determine if they might 
result in any alterations in the transcription of parkin. These stressors were used as 
dopamine has been shown to inactivate parkin, and MPP+/MPTP is another potent 
neurotoxin that generates free radical induced oxidative stress in vivo and in vitro 
(Javitch et al., 1985; Javitch and Snyder, 1984; Mizuno et al., 1987; Ramsay et al., 
1986). Both these stresses have been reported previously to increase the transcription 
levels of another PD related gene, a-synuclein (Gomez-Santos et al., 2003). In the case 
of dopamine stressed cells, it is believed that stress-response kinases such as
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SAPK/JNK and p38, as well as factors involved in autophagy, are activated which 
subsequently activate the expression of a-synuclein. For MPP+ stress, however, the 
mechanism of up-regulation is not clear. MG 132 is a proteasomal inhibitor. As parkin is 
an E3 ligase involved in the ubiquitin proteasomal system, it would be interesting to 
observe the effects of MG 132 on parkin regulation.
We show here that dopamine treatment results in up-regulation of parkin at both the 
mRNA and protein level. Moreover, this appears to be due to transcriptional activation 
since luciferase assays confirmed that specific parkin promoter constructs could confer 
transcriptional activation in response to dopamine. It is surprising that we did not see 
induction of luciferase for the 4500 construct (full length promoter) in light of our 
mRNA findings. However, this suggests that there may be additional enhancer 
sequences in the endogenous parkin promoter of SH-SY5Y cells. The possible role of 
alteration in chromatin structure as a regulation control also cannot be over-looked. The 
parkin protein cellular distribution also appeared to be altered during dopamine 
treatment. In spite o f an overall increase in total parkin protein, there was a decrease in 
soluble parkin protein. This indicated a shift in the solubility of parkin and is in line 
with previous reports of increased insolubility of parkin in the presence of dopamine 
(LaVoie et al., 2005; Petit et al., 2005). Whether the solubility shift in this case was due 
to the molecular alterations caused by dopamine or to the increase in parkin is not 
known.
Up-regulation of parkin also appears to be a general response to oxidative stress since 
MPP+ also caused up-regulation in parkin mRNA and activation of parkin promoter 
constructs. In addition, we also showed that possible repressor domains might be
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present in the promoter region upstream of the core parkin promoter, since the 
activation of the promoter present in construct 4500 is less than that of the core 
promoter.
Treatment with proteasomal inhibitor, MG 132, up-regulated both the promoter activity 
and mRNA expression of parkin in SH-SY5Y cells. Therefore, like dopamine and 
MPP+, MG 132 is able to stimulate parkin expression. However at this stage such 
conclusions are tentative and follow-on studies are required for confirmation. This is of 
special significance due to a contemporary publication reporting that MG 132 repressed 
parkin expression (Koch et al., 2008).
The strength of the Koch et. al. result is difficult to judge since the relevant MG 132 
result was not shown in their report. Furthermore, the experimental design differed in 
that rat adrenal medulla PC 12 cells were used for the study. The differences in the 
origin of the cell line used, PC 12 versus SH-SY5Y, may account for the differences in 
results on the experiments. Results on using an alternative proteasomal inhibitor, 
epoxomicin, were shown for both PC 12 and SH-SY5Y cells. However, it is not clear 
whether the displayed results can be used to support the interpretation since the number 
of experimental replicates was not specified, there was no statistical testing and some 
results appear skewed. For example, the figure lc graph showing parkin mRNA 
expression in SH-SY5Y cells treated with epoxomicin, showed increasing parkin 
mRNA in untreated cells over time that was interpreted as a decrease in parkin mRNA 
in treated cells. In addition, although both MG 132 and epoxomicin are proteasomal 
inhibitors, they may act differently thus leading to different regulational responses. In 
fact, even Koch et. al. claimed that they were surprised by own results.
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Publications on the effects of proteasomal inhibition on parkin expression are limited in 
number to support either our present study or the Koch et. al. paper. Indeed, the only 
other mention in literature, Biasini et. al. showed that there was no significant change in 
parkin expression under proteasomal inhibition (Biasini et al., 2004). Despite the 
differences in the results and interpretations regarding proteasomal inhibition and 
parkin, the findings described in the present study follow the rationale that with 
proteasomal inhibition, protein degradation and the elimination of damaged proteins 
would cease. Consequently, parkin and other proteasomal associated genes may be up- 
regulated by positive feed-back due to excessive build of parkin. This will be discussed 
in more detail in chapter 9.
It remains unknown whether our findings in undifferentiated SH-SY5Y cells occur in 
human brain in vivo. Further studies will therefore be required to be performed in 
differentiated SH-SY5Y cells, primary neurons as well as human post-mortem brain in 
vivo to confirm our findings.
Our results also show that PACRG was upregulated in both dopamine and MPP+ 
stressed cells. PACRG (parkin co-regulated gene) is a recently identified gene whose 
function is not yet clearly known. PACRG gene is 0.6Mb long and transcriptionally 
starts at 204bp upstream and in antisense to parkin (West et al., 2003). There is some 
evidence that PACRG may play a role in protection against stress-induced cell death 
(West et al., 2003; Yang et al., 2003). However, the significance of PACRG in PD is 
unclear -  notably, the PACRG/parkin knockout mouse mutant, Quaking, does not 
exhibit nigral degeneration (Farrer et al., 2001b; Lorenzetti et al., 2004).
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It is still unclear how oxidative stress causes transcriptional activation of the parkin 
gene. It is likely that certain transcriptional factors that are stress-related are up- 
regulated and activate specific parkin promoter domains. Therefore, we analyzed the 
parkin core promoter sequence for putative stress-related transcription factor sites. 
Using Matlnspector, version 7.4, (Cartharius et al., 2005; Cross et al., 1994) several 
potential transcription factor sites of oxidative-stress-induced transcription factors were 
found in the parkin core promoter. These transcription factors include stimulating 
protein 1 (SP1) and AP-1/CREB. They are known to be oxidative stress inducible and 
are increased or activated upon such stresses to enhance the transcription of prosurvival 
genes, which subsequently prevent cell death in response to the stress, DNA damage or 
both (Ryu et al., 2003; Shi et al., 2004). N rfl, is also another bZIP family transcription 
factor, whose potential binding site was predicted to be present within the parkin 
promoter. This transcription factor has also been shown to respond to oxidative stresses 
(Kwong et al., 1999). It would be o f interest to determine if these factors play any role 
in the regulation of parkin.
In conclusion, we have shown that when subjected to oxidative stresses such as 
dopamine and MPP+, the transcription of endogenous parkin increases. This may be a 
compensatory up-regulation in response to decreased parkin activity and decreased 
parkin solubility. The next step will be to investigate stress-specific transcription factors 
that may regulate parkin and determine whether these are altered in PD.
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8.1 Introduction
As previously discussed, PINK1 is considered a Parkinson’s disease associated gene. In 
this chapter regulational, functional and structural characteristics of PINK1 will be 
studied. The importance of stress conditions in Parkinson’s disease has already been 
explained in previous chapters; therefore the response of PINK1 expression to these 
conditions was studied. Mutation of the protein is also a critical factor in Parkinson’s 
disease, a variety of mutated forms of PINK1 expressed by patients were studied to 
reveal their effects in cell culture. Protein cleavage is also believed to be very important 
for its function, for this reason, random mutations in predicted region of PINK1 
cleavage site were tested for cleavage properties. These studies combined should give a 
significant insight into PINK function and regulation in relation to Parkinson’s disease.
8.1.1 Regulation of PINK1 in stress
The function of PINK 1 is still currently unknown; however, studies have given a degree 
of insight into possible actions of this protein. It is produced as a precursor protein that 
is targeted to the mitochondria where it is then cleaved (Muqit et al., 2006). The cleaved 
forms of PINK1, in turn, localises mainly in the cytosol and to a smaller extent, in the 
mitochondria (Takatori et al., 2008; Weihofen et al., 2008). Unlike other mitochondrial 
proteins, the active, cleaved forms of PINK1 are subsequently degraded by the 
proteasome (Lin and Kang, 2008).
PINK1 is mainly known to be a cytoprotective protein. Wild type cytosolic PINK1 have 
been shown to protect neuronal cells against mitochondrial and oxidative stress caused 
by MPTP (Haque et al., 2008). Overexpression of PINK1 was also found to prevent
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staurosprine-induced apoptosis (Petit et al., 2005) and its knock-down increased cell 
vulnerability to rotenone as well as MPP+ (Deng et al., 2005). Intact PINK1 kinase 
activity was also found to be crucial in activating its substrate TRAP1, which 
subsequently protects cells against oxidative stresses (Pridgeon et al., 2007). Lastly, 
exposure to the apoptotic inducing proteasome inhibitor, MG 132, was shown to result 
in PINK1 aggregation (Muqit et al., 2006). It is evident that PINK I is functionally 
involved in cellular pathways linked to stress; however, these studies have so far been 
limited to the protein level and no evidence of whether PINK1 regulation may be 
affected by the presence of these stresses has been obtained.
8.1.2 PINK1 heterozygous mutations
The majority of mutations of the PINK1 gene have been reported within the kinase 
domain (Abou-Sleiman et al., 2006b; Bonifati et al., 2005; Hatano et al., 2004; Li et al., 
2005; Rogaeva et al., 2004; Rohe et al., 2004; Valente et al., 2004a; Valente et al., 
2004b). The reason for this higher rate of detection in this region is because kinase 
domain is a functional domain of PINK1; hence mutations in this area are more readily 
detectable. This also indicates that disruption of this kinase activity is deemed the most 
probable disease mechanism.
All the mutations found previously were detected in homozygous situations in rare 
familial Parkinson’s disease patients and until recently, have been believed to only be 
pathogenic when occurring homozygously. Nonetheless, heterozygous mutations have 
recently been discovered by Abou-Sleiman et.al. (Abou-Sleiman et al., 2006a) in 1.2% 
of the tested patients (9 in 768) who all apparently suffered from typical late onset 
idiopathic Parkinson’s disease. Seven of these heterozygous PINK1 mutations found
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were missense mutations in the kinase domain, a further missense in the C-terminal 
hydrophilic region, and a nonsense mutation at codon 456 which resulted in truncation 
of the last 125 amino acids were also discovered (Abou-Sleiman et al., 2006a). Despite 
extensive sequencing and assessment of gene arrangements, a second mutation was not 
found in any of these nine patients. Another three PINK1 heterozygous mutations were 
subsequently found, in this same study, in 1,536 control subjects. However, a much 
greater incidence of mutations was detected in the Parkinson's disease cohort, showing 
that heterozygous PINK1 mutations posed a risk factor in the development of late onset 
Parkinson’s disease (Abou-Sleiman et al., 2006a). Three of the nine patient mutations 
were selected for in vitro functional analysis and were found to adversely affect PINK1 
function and thus impaired mitochondrial membrane potential leading to an increase in 
cellular susceptibility to stress.
8.1.3 Mitochondrial membrane potential A\|/m
To determine the functional consequences of PINK 1 mutations, the effect of the mutant 
protein on mitochondrial function was examined.
To examine mitochondrial function, biochemical studies have been used to examine 
various parameters of bioenergetic function such as electron transport chain activity in 
mitochondrial preparations (Merlo-Pich et al., 2004). Fluorometric assays and 
fluorescence imaging techniques have also been used in the study of mitochondrial 
membrane potential (A\j/m) in single cells or populations of cells (Abou-Sleiman et al., 
2006b). The A\|/m is the main electrical component of the protomotive force and is 
central to mitochondrial function since it provides the force that drives the influx of 
protons (crucial for ATP synthase) or of calcium into the mitochondria as well as
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determining the generation of the free radical superoxide (O2). Depolarisation of A\j/m 
usually reflects opening of the mitochondrial permeability transition pore (mPTP).
Measurement of the A\j/m has become established as a sensitive indicator for the 
energetic state of the mitochondria and the cell (Brand et ah, 1994) and previously 
cationic probes have been used to measure A\|/m isolated mitochondria. More recent 
techniques utilize fluorescent membrane permeable lipophilic cationic dyes that can 
cross the plasma membrane and be taken up by mitochondria in response to the 
electrochemical gradient and Avj/m. These compounds include tetramethylrhodamine 
ethyl and methyl esters (TMRE and TMRM respectively). The ‘redistribution method’ 
to study the dyes is used in our studies (Duchen, 2004). This method is described below.
The principle of the ‘redistribution method’ is that the fluorescence signal of the 
compound is directly proportional to the dye concentration which represents the 
distribution of dye in response to the potential difference across membranes. Thus 
mitochondria with a higher membrane potential (-150mV) will result in a greater 
concentration of the dye from the cytosol (400-800 fold) compared to that conferred by 
the plasma membrane (-60mV) from extracellular space (10 fold). Therefore the 
available fluorescent probes are relatively selective for mitochondrial function. 
Measurements are normally taken after the dye has reached steady-state equilibrium.
In the following studies into PINK1 mutations, the redistribution of TMRM in SH- 
SY5Y cells was examined and populations of cells with altered PINK1 levels exposed 
to different conditions namely vehicle or proteasomal stress were compared. It was 
assumed, in these studies, that after equilibrium has been reached, the mitochondrial
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fluorescence signal would reflect the mitochondrial dye concentration that would be a 
direct function of the Aym. Thus in the presence of proteasomal stress, A\|/m would 
decrease, and less dye would accumulate in the mitochondria. Therefore, the mean 
fluorescent signal of the dye in stressed cells would be less than control. The signal can 
thus be determined using methods such as confocal microscopy. Fluorescence activated 
cell sorting (FACs) was selected for quantitative analysis due to the efficiency and high 
throughput of the method, allowing a large number of cells to be analysed for inter­
group comparison of different samples. It is possible to measure by FACS the relative 
reduction in mean fluorescence intensity (MFI), which can be interpreted as an 
indication of the A\jmi dissipation (Zoratti and Szabo, 1995).
8.1.4 PINK1 cleavage
Mutations in the PINK1 gene leading to familial Parkinson’s disease as well as 
increased susceptibility to the disease in the case of heterozygous occurrence have 
brought PINK1 to the attention o f many Parkinson’s disease researchers. Although the 
majority of the disease causing mutations are located in the kinase domain, which is the 
only functional domain found in PINK1, a subset of mutations were found outside, 
mainly in the N-terminal region between the mitochondrial targeting motif and the 
kinase domain. It is currently still not clear how these mutations may affect PINK1 
function. Findings that PINK1 is cleaved to produce a lOkDa N-terminal fragment, 
approximately 100 amino acids long (Beilina et al., 2005; Muqit et al., 2006), raised the 
possibility that some of these mutations may act to disrupt the processing of precursor 
PINK1 to its active form.
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Cell death via apoptosis and necrosis differ in that cell membranes maintain their 
integrity during the early stages of apoptosis, while they become leaky during necrotic 
cell death. Several methods of identifying apoptotic cells are available. In our studies, 
we utilised the detection of early apoptosis by measurement of AnnexinV-PI.
During cell death by apoptosis or necrosis, phosphatidylserine, a protein that interacts 
with the inner cell membrane is translocated to the outer layer of the membrane. This 
serves as one of several signals by which cells destined for death are recognised by 
phagocytes. To detect early apoptosis, Annexin V may be used. Annexin V is a member 
of a highly conserved family that bind acidic phospholipids in a calcium-dependent 
manner. Annexin V binds to the phosphatidylserine present on the cell surface in the 
initial stages of cell death. To differentiate apoptotic cell death from necrotic cell death, 
a dye exclusion test using propidium iodide (PI), which establishes whether the cell 
membrane intergrity is conserved or leaky, is included. The measurement of Annexin 
V-PI by various means such as flow cytometry, light or electron microscopy may be 
used to identify early apoptotic cells. Fluorescence activated cell sorting (FACs) was 
used in our studies to calculate the percentage of early apoptotic cells in total cells. This 
system was used as it allows large quantities of cells to be analysed in a short space of 
time, and is therefore a robust method for inter-group comparisons.
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8.1.6 Hypothesis & Aims
Much in vitro and in vivo evidence have shown the protective function of PINK1 in 
presence of various stresses. For example, PINK1 prevents mitochondria cytochrome C 
release, and thus cell death, in the presence of oxidative stress by activating TRAP1 via 
phosphorylation through the kinase domain in PINK1. In this study of PINK1, in 
conjuction with previous chapters, we sought to determine if the increased protection 
produced by PINK1 during such conditions might partly, also be due to alterations in 
PINK1 regulation in the presence of such stresses.
To better understand the function of PINK1, mutation and protein analysis of PINK1 
were also carried out. Three heterozygous PINK1 mutations were discovered in control 
subjects by Abou-Sleiman et.al. 2006. Two of these mutations were examined in vitro, 
to find out if they affect PINK1 function, similar to other heterozygous mutations 
reported in the paper. As there is strong evidence that proteasomal inhibition induces 
mitochondrial depolarisation and apoptosis, MG 132 was selected as a stress agent for 
the experiments.
Considering the possible importance of PINK1 cleavage to its function, cleavage site 
was studied to find out how mutations in the vicinity of this site affect the processing 
and function of PINK 1.
Aims of Project:
15. To find out if regulation of PINK1 is altered in the presence of different 
stresses.
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16. To investigate if the two PINK1 mutations found in control patients affect 
PINK1 function using the measure of mitochondria membrane potential in the 
presence of proteasomal stress.
17a. To investigate the location of PINK 1 cleavage site by utilising PINK1
expressing constructs with point mutations in and surrounding the predicted 
cleavage site.
17b. To examine the functional consequences when PINK1 cleavage site is 
disrupted.
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8.2 Results
8.2.1 Regulation of PINK1 in stress
PINK1 expression was examined in SH-SY5Y cells subjected to various stresses, 
oxidative stress: dopamine, mitochondrial complex I inhibitor, MPP+ and proteasomal 
inhibitor, MG132. RT-PCR was used to quantify PINK1 mRNA in these cells and 
expression was compared to at least two other housekeeping genes to ensure 
consistency in results (one representative graph for each stress is shown). The identity 
and specificity of PINK 1 product was confirmed after each RT PCR (Fig. 8.1).
All the stresses caused a strong response on PINK1. Dopamine and MG 132 both 
resulted in a decrease in PINK1 mRNA expression, however, the down-regulation 
induced by MG 132 was much more substantial than that of dopamine with a 60% 
decrease compared to 35% (Fig. 8.2 and 8.3). The profile of the response exerted by 
MPP+ was opposite to that of the other stresses. MPP+ treatment caused a 70% increase 
in PINK1 mRNA expression (Fig. 8.4).
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Figure 8.1 RT PCR PINK1 product agarose gel check
Agarose gel check on RT PCR PINK1 product to confirm product identity and PCR specificity. Specific 
product of the correct size was obtained. Amplified product was confirmed to be PINK1 by sequencing.
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Figure 8.2 Effects of dopamine on PINK1 mRNA expression
SH-SY5Y cells were incubated with OmM, 31.25mM, 62.5mM, 125mM and 250mM dopamine for 24hrs 
before RNA was extracted for analysis. The error bars indicate the standard error of the mean of 3 
experiments performed in triplicate. Differences was analysed by ANOVA + Bonferroni post hoc test. 
There is an overall decrease in PINK1 expression with the increase in dopamine dosage (*p<0.05;
***p<0.001).
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Figure 8.3 Effects of MPP+ on PINK1 mRNA expression
SH-SY5Y cells were incubated with OmM, 1mM, 5mM and 10mM MPP+ for 6hrs before RNA was 
extracted for analysis. The error bars indicate the standard error of the mean of 3 experiments 
performed in triplicate. Differences was analysed by ANOVA + Bonferroni post hoc test. There is an 
overall increase in PINK1 expression with the increase in MPP+ dosage (*p<0.05; ***p<0.001).
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Figure 8.4 Effects of MG132 on PINK1 mRNA expression
SH-SY5Y cells were incubated with OmM, 5mM, 10mM and 15mM MG132 for 24hrs before RNA was 
extracted for analysis. The error bars indicate the standard error of the mean of 3 experiments 
performed in triplicate. Differences was analysed by ANOVA + Bonferroni post hoc test. There is 
significant decrease in PINK1 expression with MG132 stress (***p<0.001).
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8.2.2 Pathogenecity of PINK1 heterozygous 
mutants
It has been shown previously that the G309D PINK1 homozygous mutation impairs Av|/m 
following cellular stress rendering cells more susceptible to the stress (Valente et al., 
2004a; Valente et al., 2004b). Homozygous mutants Y431H, N451S and C575R which 
were identified in PD patients were also recently found to similarly impair Av|/m following 
cellular stress (Abou-Sleiman et al., 2006a), thus making them potentially pathogenic and a 
possible candidate for the onset of PD. E476K and R501P are heterozygous mutants 
identified in normal controls.
To investigate if these heterozygous mutations found in control patients were potentially 
pathogenic especially in the presence of stress, they were subjected to stress induced 
alterations in mitochondrial membrane potential (Aij/m) and examined. The addition of the 
proteosomal inhibitor, MG-132 which induces apoptosis via mitochondrial injury, to native 
SH-SY5Y cells resulted in a 30% decrease in TMRM fluorescence from basal values (data 
shown in (Abou-Sleiman et al., 2006a)). It has been shown that decreases in TMRM 
fluorescence reflected depolarization of the Ai|/m (Martin and Koshland, 1991). This was 
confirmed by Abou-Sleiman et.al. (Abou-Sleiman et al., 2006a), showing that native SH- 
SY5Y cells treated with the protonophore carbonyl cyanide m-chlorophenylhydrazone 
(CCCP), dissipated the Avj/m by abolishing the linkage between the respiratory chain and 
the phosphorylation system. Abou-Sleiman et.al also showed that following the addition of
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CCCP, TMRM values were reduced by 70% compared to basal values (data shown in 
(Abou-Sleiman et al., 2006a)).
SH-SY5Y cells were transiently co-transfected with wild-type or mutant P1NK1 plasmid 
and a green fluorescent protein (GFP) reporter plasmid and then treated with vehicle or 
MG-132 for 24hrs. Analysis of TMRM fluorescence in GFP-positive cells revealed that 
none of the PINK1 mutations had a significant effect on Aij/m under basal conditions (Fig. 
8.5). However, following stress with MG-132 there was a significant decrease in Avjmi from 
basal levels in cells transfected with E476K and R501P PINK1 compared with wild-type 
PINK1 (Fig. 8.6: E476K, -54.7% ± 10.1; R501P, -58.1% ± 10.9 vs. wt PINK1 -16.3% ± 
6.0; *p < 0.01; n= 12). In contrast, transfection of wt PINK1 resulted in approximately 50% 
less reduction in Avj/m compared to vector, following stress suggesting that PINK1 is able 
to protect against some of the damaging effect of the mutants on Ai|/m following stress 
(Fig. 8.6). Transfection per se did not alter Avym in our system, whereby following stress, 
the reduction in Aij/m in vector transfected cells was similar to that of native SH-SY5Y 
(data shown in (Abou-Sleiman et al., 2006a)).
8.2.3 PINK1 cleavage
From previous evidence of PINK1 cleavage to produce a lOkDa cleaved product, the 
cleavage site of precursor PINK1 is estimated to be around 100 amino acids from the N- 
terminal. To locate the precise site of PINK1 cleavage, various PINK1 expressing 
constructs with random point mutations around the predicted cleavage site, including one 
known pathogenic PINK1 mutation, were used in western blots to examine if the
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Figure 8.5 Basal Aym of PINK1 constructs
Median Aym of cells co-transfected with WT PINK1 construct, E476K or R501P PINK1 mutant 
constructs and GFP shown as a percentage to empty vector transfected cells (100%). Results were not 
significantly different
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Figure 8.6 Change in Aym of PINK1 constructs in MG132
Percentage change of median Aym in GFP positive cells in basal conditions transfected with WT, 
E476K, R501P and empty vector and those stressed with 15mM MG 132 for 24hrs. E476K and R501P 
fluorescence decreased significantly compared to WT (**p<0.01)
238
Chapter VIII: PINK1
presence of these mutations might affect the cleavage process. One of the mutants 
studied, L102Q PINK1, showed significantly lowered cleavage from full length (Fig. 
8.7). It could be deduced that the L102Q mutation either changed the PINK1 cleavage 
site or altered the structural configuration of PINK1 such that cleavage was blocked 
(Fig. 8.8). However, the L102Q mutation might also alter the localisation of PINK1, 
changing the environment, thus, cleavage could not occur. L102Q is a random and not a 
pathogenic mutation.
To ensure that the localisation of L102Q PINK1 was not changed, and that the lack of 
cleavage was mainly due to sequence or configuration modifications, fluorescence 
microscopy was used. L102Q PINK1 was found to localise as normal to the 
mitochondria, together with MitoTracker (Fig. 8.9).
Cells transfected with wild-type or L02Q mutant PINK1 expressing constructs were 
exposed to MG 132 stress and analysed, using FACs, for the percentage of early 
apoptotic cells. This allows the investigation of whether cleaved PINK1 is required for 
the protection of cells against MG 132 stress. More L102Q mutant PINK1 transfected 
cells were apoptotic compared to wild-type in the presence of MG 132 stress (Fig. 
8.10b). The percentages of apoptotic cells in stress free basal conditions were similar 
(Fig. 8.10a).
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Figure 8.7 Protein cleavage of PINK1 mutants
Protein extract was obtained from cells transfected with wt PINK1 and various PINK1 homozygous 
mutants. The exposed bands were analysed using GS-800 BioRad densitometer and shown as a ratio 
of cleaved vs full length PINK1. The error bars indicate the standard error of the mean of 3 
experiments. Differences were analysed by paired T-test. The amount of cleaved L102Q PINK1 was 
significantly lower than its full length product (*p<0.05).
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Figure 8.8 Predicted PINK1 cleavage site
A schem atic diagram of PINK1 protein is shown. The dotted line indicates the predicted 
cleavage site of PINK1 and * shows a naturally found mutation site. S/T/G indicates other less 
obtrusive am ino acids that could be used instead of Q in the mutation of L102 to further study 
the cleavage of PINK1
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Myc-L102Q Mitotracker Merge
Figure 8.9 Fluorescence microscopy localization of L102Q PINK1
Fluorescence microscope view of fixed SH-SY5Y cell transfected with Fitz-Myc-L102Q PINK1 and 
treated with MitoTracker-red. L102Q PINK1 localised in the mitochondria, together with MitoTracker.
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vector L102Q
Figure 8.10 Apoptotic effect 
of L102Q PINK1
SH-SY5Y cells were 
transiently transfected with 
wild-type and L102Q mutant 
PINK1 expressing constructs 
as well as the empty control 
vector. These cells were 
subsequently stressed for 
24hrs with 15mM MG 132 and 
counted using FACs, in the 
presence of Annexin V, for the 
percentage of early apoptotic 
cells.
A.) Cells transfected with wild- 
type and L102Q mutant PINK1 
showed similar percentage of 
early apoptotic cells. Cells 
containing the empty vector were 
slightly less apoptotic.
B.) In the presence of MG 132, 
cells transfected with L102Q 
mutant PINK1 and empty vector 
had more early apoptotic cells 
compared to wild-type PINK1 
transfected cells (**p<0.01).
V ector WT L102Q
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8.3 Discussion
8.3.1 Regulation of PINK1 expression in stress
PINK1 was found to display protective effects in the event of cellular stress (Deng et 
al., 2005; Haque et al., 2008; Petit et al., 2005; Pridgeon et al., 2007). However, these 
studies into the functional consequences of PINK 1 in the presence of stresses have, until 
now, been restricted solely to the study of PINK1 protein. In view of this, we show for 
the first time that PINK1 expression was altered in the presence of different stresses. 
Proteasomal inhibitor, MG 132, and oxidative stress, dopamine, were found to decrease 
PINK1 expression while oxidative and mitochondria complex I inhibitor, MPP+, 
increased PINK1 expression. As MG 132 has been shown prevent PINK1 degradation 
and cause PINK1 aggregation (Muqit et al., 2006), it is therefore possible that the 
decrease in PINK1 expression occurred as a response to the increase in cellular PINK1 
resulting from its reduced degradation and aggregation.
MPP+ is a mitochondrial toxin and can also cause oxidative stress by producing free 
oxide radicals. The over-expression of PINK1 hs been shown to produce protection 
during exposure to MPP+ (Haque et al., 2008). This protection from oxidative stress 
was believed to be through the prevention of mitochondria cytochrome C release which 
leads to cell death via apoptosis. The mechanism of this action is through phospho- 
activation of TRAP1 by the kinase domain in PINK1 (Pridgeon et al., 2007). Activated 
TRAP1 is then responsible for maintaining mitochondria integrity and prevention of 
cytochrome C release. As such, the up-regulation of PINK 1 could be due to a positive 
feed-back loop, with the result of increasing cellular PINK1 leading to increased
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activation of TRAP1 and preventing cell death by MPP+. The mechanism of down- 
regulation of PINK1 expression by dopamine is not clear, although the difference in 
PINK1 regulation between the oxidative dopamine and MPP+ could be due to MPP+ 
being a mitochondria complex I inhibitor as well as induce oxidative stress.
It would be interesting to identify the factors responsible for the alteration in PINK 1 
expression during the stresses studied, and subsequently study the pathways involved. 
However, due to the lack of PINK1 promoter constructs, we were not able to better 
study the effects of these stresses on the regulation of PINK 1 promoter. The ability to 
activate such pathways is of clinical interest with the potential to develop novel 
therapeutic approaches to protect and prevent neuronal cell death.
8.3.2 Pathogenecity of PINK1 heterozygous 
mutants
Two mutations found in control subjects were assayed, E476K and R501P. 
Neuroblastoma cells over-expressing the mutants or wild-type PINK1 were stressed 
with the proteasome inhibitor MG-132 and their mitochondrial membrane potential 
(Aii/m) recorded. Both mutants resulted in a statistically significant decrease in Avj/m 
when compared to wild type PINK1. This result was similar to that found in 3 
pathogenic mutations found in patients, N451S, Y431H and C575R, which indicated 
that these mutants adversely affected PINK1 function (Abou-Sleiman et al., 2006a).
While the pathogenecity of heterozygous PINK1 mutations remained to be definitively 
proven, the results of this study add significant weight to the previously published PET 
data which suggested that heterozygous PINK1 mutations result in nigrostriatal
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dysfunction (Binkofski et al., 2007). Abou-Sleiman et.al. showed a three-fold 
enrichment of heterozygous PINK1 mutations in Parkinson’s disease patients compared 
to controls (Abou-Sleiman et al., 2006a). They further demonstrated, using an in vitro 
assay similar to that performed here, that the patient mutations adversely affected 
PINK1 function, implying they were not simply neutral polymorphisms. Although the 
mutations examined here were obtained from control subjects, the decreased tolerance 
to stress contributed by these mutants implied that either these controls were also 
susceptible to developing Parkinson’s disease or that other factors may also be required 
before the onset of the disease. As such, we conclude that haploinsufficency of PINK1 
may render the dopaminergic cells of the substantia nigra more susceptible to cellular 
stress. However, the identification of heterozygous mutations in individuals apparently 
unaffected by Parkinson’s disease leads us to suggest that the susceptibility to cellular 
stress is probably insufficient within their lifespan to manifest as clinical Parkinson’s 
disease; rather a second factor is required. This second factor may take the form of an 
additional mutation in another Parkinson’s disease gene or related pathway or exposure 
to exogenous toxins. Indeed, digenic inheritance, whereby characteristics or traits 
controlled by the integrated action of two genes, of Parkinson’s disease, has recently 
been demonstrated for heterozygous mutations of PINK 1 and DJ-1.
Nevertheless, having identified heterozygous mutations in approximately 1.2% of 
Parkinson’s disease patients indicates that haploinsufficency at PINK1 is a significant 
risk factor for the development of Parkinson’s disease.
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A L102Q mutation of the PINK1 gene was found to block the cleavage of precursor 
PINK1 to its active form. This mutation was not found to affect the targeting and 
translocation of PINK 1 to the mitochondria, showing that the mitochondrial targeting 
motif of precursor PINK1 is not affected. Whether the site at amino acid 102 is the 
precise cleavage location is not yet clear. Other explanations might account for the 
significant decrease in PINK1 cleavage with L102Q mutation. The change of non-polar 
residue, leucine, to a larger and polar glutamine residue could have altered the protein 
configuration of PINK1, enough to hide the true cleavage site and block its cleavage. 
The ability of PINK1 to cleave was found to be important in its protection of cells 
against MG 132 stress.
More experiments, including structural homology comparisons with other mitochondria 
targeted proteins and performing experiments using a more similar residue substitution 
at LI02, would have to be performed to conclusively pinpoint the exact PINK1 
cleavage site. In the meantime, functional experiments could also be done to further 
investigate the extent of functional consequences when the PINK1 cleavage is blocked.
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9.1 Conclusions & Future Prospects
The causes of idiopathic Parkinson’s disease remain unknown. Several factors may 
contribute to its onset, including: susceptibility genes, environmental stress and aging. 
Among these factors, genetic and environmental factors have been given the foremost 
attention in research, as reviewed earlier in chapter 1, sections 1.1 and 1.2.
Studies in this thesis aimed to characterize the influence of environmental factors, in 
particular oxidative stresses, on the regulation of genes associated with Parkinson’s 
disease. The expression of all the genes studied, a-synuclein, parkin and PINK1, were 
responsive to stresses (Table 9.1; Fig. 9.1). Levels of a-synuclein increased following 
exposure of cells to dopamine or l-methyl-4-phenylpyridinium (MPP+). Parkin was 
also up-regulated when cells were treated with either dopamine, MPP+, or the 
proteasomal inhibitor, MG 132. In contrast, PINK1 levels were up-regulated only by 
MPP+, but down-regulated in both dopamine and MG 132 treatments. The different 
responses to different stresses were worthy of note due to the different functions, 
localization and protective nature of these proteins studied.
Gene Stressexposed
Gene
expression Cellular location Cellular function
a-
synuclein
Dopamine
MPP+
*
*
Vesicle membrane 
associated, cytoplasmic
Synaptic vesicle 
transport
parkin
Dopamine
MPP+
MG132
*
*
*
cytoplasmic Ubiquitination,Protective
PINK1
Dopamine
MPP+
MG 132
*
*
*
Mitochondria, 
small portion in 
cytoplasm
Phosphorylation,
Protective
Table 9.1
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a-synuclein
E n v iro n m e n ta l F acto rs
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via ubiquitin 
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pathways
(Cha et al.. 2005;
Clough and Stefanis,
^ 007)
Mitochondrial
dysfunction
Mitochondria
Protect against
mitochondrial
dysfunction
Nucleus
Figure 9.1 Regulation of Parkinson’s disease-associated genes by 
environmental factors
ROS refers to reactive oxygen species. The red arrows indicate pathways 
that may lead to toxicity and/or cell death, while the green arrows indicate 
protective pathways. The question marks indicate areas which require more 
research to fully understand the mechanisms to neuronal cell death induced 
by harmful environmental factors and protective pathways which may be 
utilized in therapy to prevent cell deaths.
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As described in the first chapter, a-synuclein is a cytoplasmic protein of yet unknown 
function. The over-expression of a-synuclein, as a result of the duplications and 
triplications of the a-synuclein locus, was sufficient to lead to neuronal cell death and 
Parkinson’s disease (Chartier-Harlin et al., 2004; Farrer et al., 2004; Ibanez et al., 
2004a; Singleton et al., 2003). Certain polymorphisms of the a-synuclein promoter 
could also lead to subtle up-regulations and have been associated with the disease 
(Chiba-Falek and Nussbaum, 2001). It may be postulated that aberrant up-regulation of 
a-synuclein could lead to excess amounts and accumulation of a-synuclein, leading to 
its aggregation and to the formation of Lewy bodies. Although it is not clear whether 
Lewy bodies are toxic to cells, they are the main pathologic characteristic of 
Parkinson’s disease. Our results showing that oxidative stresses up-regulate a-synuclein 
supports the hypothesis that these stresses lead to Parkinson’s disease by causing 
aberration in gene regulation as mentioned in chapter 1, section 1.2.1.
Both parkin and PINK1 are known to be protective against cell death. PINK1 is 
predominantly localized within the mitochondria and is involved in maintaining 
mitochondrial integrity. Parkin, on the other hand, is a cytoplasmic E3 ligase involved 
in ubiquitin proteasomal function. However, an association between the two genes 
relating to mitochondria has described in a Drosophila model. It showed PINK1 as an 
upstream activator of parkin function in maintaining mitochondrial integrity. The up- 
regulational response of both genes when exposed to MPP+ is of added interest since it 
is not only an oxidative stress but also a toxin targeting mitochondrial complex I. 
Therefore, the increase in PINK1 and parkin levels in response to MPP+ may be 
explained as a mechanism to further prevent mitochondrial dysfunction.
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Although MG 132 has been observed to lead to mitochondrial dysfunction, due to the 
generation of reactive oxygen species (Goldbaum et al., 2006), the primary target of the 
inhibitor is the proteasome. This might thus explain the difference in regulation of 
parkin and of PINK1. Certain transcription factors, for example Rpn4 (Dohmen et al.,
2007), which are usually degraded by the proteasome, accumulate due to its inhibition. 
It may be postulated that such factors could then transverse into the nucleus to activate 
genes associated with the proteasomal system, resulting in the activation of parkin 
expression.
The stress caused by the increase of reactive oxygen species leads to the oxidative 
damage of cellular proteins. This results in the misfolding and aggregation of the 
damaged proteins, which require removal by proteasomal degradation or autophagy 
(Petropoulos and Friguet, 2006). Parkin was up-regulated when exposed to each of the 
oxidative stresses used in our experiments. This increase in parkin expression may be a 
component of mechanisms involved in the removal of oxidatively damaged a-synuclein 
and other denatured proteins. Parkin ubiquitinates damaged proteins, targeting them for 
degradation via the proteasomal or autophagy pathways (Olzmann and Chin, 2008; 
Tanaka et al., 2004). An increase in parkin could therefore lead to more rapid clearance 
of these oxidatively damaged proteins. Moreover, the accumulation of parkin following 
the use of proteasomal inhibitors, as mentioned in the previous paragraph, may also be a 
response to compensate for the proteosomal malfunction.
Other than merely targeting proteins for proteasomal degradation, ubiquitination has 
also been known to stimulate the activity of some transcription factors, for example 
Myc, and also activate certain signaling pathways, such as c-Jun kinase and NFkB
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pathways (Depraetere, 2001; Lipford and Deshaies, 2003). Many of these pathways and 
transcription factors are involved in protective or apoptotic responses to oxidative 
stresses; in particular, parkin has been shown to inhibit the apoptotic JNK (c-Jun N- 
terminal kinase) pathway (Cha et al., 2005) (Fig. 9.1). This may contribute another 
explanation towards the purpose of increased parkin in oxidative conditions, as 
activation of parkin expression could subsequently lead to activation of protective 
signalling or deactivation of deleterious pathways via altered ubiquitination.
The study described above outlines an interesting interaction between stresses and the 
expression levels of the selected genes. However such regulation can involve a number 
of mechanisms at different stages of gene expression. The in depth elucidation of the 
intricate control mechanisms regulating these genes is of great interest and worthy of 
further analysis. Follow-on studies to further clarify the effect of stresses should include 
research into the level of regulation targeted by these stresses, for example promoter 
regulation or post-transcriptional modification, and other factors that mediate the 
response. We established that stress-induced regulation for both a-synuclein and parkin 
operated at the promoter level. A further study into the transcription factors responsible 
for the regulation of a-synuclein showed a novel interaction between the a-synuclein 
promoter and an Early Response Gene transcription factor family member in oxidative 
stress conditions (Fig. 9.1).
The discovery of a-synuclein promoter regulation by an Early Response Gene 
transcription factor is a novel finding. Literature search reveals two other transcription 
factors previously found to be involved in the regulation of a-synuclein, although not in
253
Chapter ix: Conclusion
Extracellular
Cytoplasm
Synaptic vesicle
Nucleus
N urrl
Brn3
a-synucle in
Figure 9.2 Regulation of a-synuclein by Brn3 and Nurrl.
Our research shows that Brn3a and Nurrl may regulate may a-synuclein transcription in an antagonistic 
manner. The mechanism of the regulation is not yet clear. The question marks indicate areas where 
further research is required to elucidate the mechanisms of normal regulation of a-synuclein. This would 
allow us to better understand the cellular functions of a-synuclein and the general workings in a 
neuronal cell.
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oxidative stress conditions. These include poly-ADP-ribose polymerase-1, which 
binds to the polymorphic Repl region of the a-synuclein promoter and the other is 
GATA. The interaction between GATA and the a-synuclein promoter is not known 
(Chiba-Falek et al., 2005; Scherzer et al., 2008).
The regulation of a-synuclein promoter was examined in more detail, to analyze the 
interaction of trans-acting factors with the cis-acting elements of a-synuclein. Two 
known transcription factors, the Parkinson’s disease-associated Nurrl and the 
neuronally expressed Bm3a were used for this study (Fig. 9.2) their relevance to the 
study is outlined in chapter 1 (section 1.3.3 and 1.3.4), chapters 5 and 6. The knock­
down of Nurrl increased a-synuclein transcription. This is a novel observation, and 
of considerable importance, as variations in the levels of either of these genes can 
cause Parkinson’s disease. This work further demonstrated that the POU family 
trancription factor, Bm3a, was involved in this pathway, it was observed that 
overexpression of Bm3a up-regulated a-synuclein expression and the knock-down of 
Bm3a resulted in an increase in Nurrl expression. Thus, the action of Bm3a appeared 
to function antagonistically to Nurrl in a-synuclein regulation.
A novel interaction between Nurrl, Bm3a and a-synuclein has been outlined above. 
Due to the significance of these findings further investigation is necessary. Such 
studies will include the confirmation of the interactions of transcription factors with 
the a-synuclein promoter using CHIP (chromatin immuno-precipitation) assays to 
pull-down any interacting factors in the presence and absence of stresses. Having 
confirmed the trans-acting factors involved, the signal transduction pathways that 
mediate the stress response on a-synuclein can be identified. Similar studies may also
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be extended to the other Parkinson’s disease-associated genes to establish 
mechanisms that lead to the onset o f disease.
The investigation described above details novel studies on Parkinson’s disease- 
associated genes at the level of transcriptional regulation. Having initiated the study, it 
was also possible to study these factors at other levels. For example in the case of 
PINK1, a mutation in the PINK1 gene leading to the loss of a cleavage site in the 
protein resulted in decreased PINK1 protection from cell death. This short study 
highlighted the significance of protein function, to compliment research in regulation. 
Such studies will provide important insights into Parkinson’s disease.
The three genes, a-synuclein, parkin and PINK1, have been succesfully profiled to 
different extents, in that a-synuclein regulation has been characterized to the greatest 
extent, at the level of mRNA expression, promoter regulation and identification of 
trans-acting factors. In contrast, studies on parkin involved analysis of the mRNA 
expression regulation and the identification of cis-acting elements on the promoter. 
The elucidation of PINK 1 regulation focused on the transcriptional level.
Future progress in these projects would benefit from profiling parkin and PINK1 to 
the same extent as that achieved in the investigation of a-synuclein. These would 
involve performing EMSAs on the parkin promoter to identify trans-acting factors 
that may bind to the parkin promoter during stress and both promoter reporter assays 
and EMSAs on PINK1 promoter. These further studies may uncover commonalities 
between the three genes under stress; of particular interest is the similarity between
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mechanisms (---►) are shown. The three major mechanisms of cell death are ubiquitin proteasomal 
dysfunction, mitochondrial dysfunction and autophagy impairment.
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the interactions of transacting factors with the cis-acting elements on the three 
promoters. This data will provide an important insight to the molecular signaling 
mechanisms that may define the healthy regulation of these genes as compared to the 
pathogenic deregulation leading to Parkinson’s disease.
As discussed earlier in chapter 1, several potential pathways have been used to explain 
the mechanisms that lead to neuronal cell death and ultimately Parkinson’s disease. 
These include: ubiquitin proteasomal dysfunction, mitochondrial dysfunction and the 
autophagy impairment (Fig. 9.3). Of these pathways, both ubiquitin proteasomal 
dysfunction and mitochondrial dysfunction pathways are strongly associated with toxins 
and oxidative stresses. The results in this thesis demonstrate that such toxins and 
stresses play an important role in the regulation of genes involved in the above 
pathways; this further reinforces the relevance of our studies and contributes to the 
understanding of Parkinson’s disease.
The investigations described above have successfully identified and profiled important 
regulatory events relating to Parkinson’s disease-related stresses on the regulation of 
key genes. However, understanding key regulatory events does not clearly define the 
particular mechanism of cell death that they induce. There are a number of key 
hypotheses such as toxicity due to aggregation, proteasomal, mitochondrial dysfunction 
and autophagy disruption (refer to chapter 1). However, it is difficult to assess their 
significance in patients and due to the limitations of animal models it is difficult to 
make firm conclusions on the exact course of the selective death of dopaminergic 
neurons. A myriad of cellular systems are known to be affected, however, which of 
these is the predominant factor in the onset of Parkinson’s disease is still unknown.
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The lack of resources to study the development of the disease in patients or the presence 
of a strong model, presents limitations to the further study of Parkinson’s disease, which 
would otherwise allow greater understanding of the pathology. For example, the nature 
of Lewy bodies is still yet unknown. Determination of whether the production and 
aggregation of insoluble proteins to form Lewy bodies is a protective mechanism or a 
source of toxicity to the dopaminergic neurons would be important in therapy. Once 
known, they could be regarded as therapeutically beneficial or as a target for 
intervention.
Regarding the consequences of the presented research in the context of therapeutic 
intervention, to date, the exogenous replacement of dopamine to the striatum by the 
administration of levo-dopa is the mainstay of Parkinson’s disease therapy. However, 
this only improves the symptoms present and does not alter the progression of the 
disease. There has been some research into the identification of either new or re­
purposed drugs that exhibit benefit in slowing the age-dependent neuronal damage that 
occurs in Parkinson’s disease (Casper et al., 2000; Hirohata et al., 2008; Maharaj et al., 
2004). These mainly include anti-inflammatory drugs, however, their mode of action is 
still unclear.
The advantage of our studies into factors responsible for regulation of genes associated 
with Parkinson’s disease allows these factors to be exploited in therapy. As mentioned 
above, these studies described here can be expanded to clarify the difference between 
normal gene regulation and that associated with disease development. Genes may be 
artificially activated or repressed according to needs for the survival of the neuronal
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cells. Molecular interventions such as gene therapy or introducing trophic factors to 
stimulate pathways that activate these transcription factors could be used. Similar 
methods have already been utilized with limited success.
Gene therapy and restorative treatments such as stem cell transplantation and growth 
factor delivery have shown promising results in Parkinson’s disease therapy (Deierborg 
et al., 2008; Mochizuki et al., 2008). For example, GDNF (gial-derived neurotrophic 
factor) and Neurturin are trophic factors produced naturally in the brain and are 
important for the development and maintenance of dopaminergic neurons. They have 
been shown to have both protective and neuro-restorative effects on these neurons in 
vitro and in vivo and therefore have been the subject of clinical trials (Peterson and Nutt,
2008).. Unfortunately, there was limited success in the trials. The problem lay mainly in 
the delivery of the factors across the blood-brain barrier due to their large size and 
chemical structure (Peterson and Nutt, 2008).
Many solutions have been put forward to solve the problem of targeted delivery. They 
include camouflaging their structure using nanoparticles and direct injection into the 
brain (Peterson and Nutt, 2008). One other solution was to use gene therapy. This 
involved mainly viral delivery of genes in the signaling pathway of these trophic 
factors. For example, Akt/PKB, an oncoprotein which is activated by GDNF, when 
delivered into the striatum of mice and not only protected them from 6- 
hydroxydopamine, but also promoted the regeneration of the neurons after exposure 
(Ries et al., 2006).
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Parkinson’s disease involves multiple causations that lead to a very similar outcome -  
death of dopaminergic neurons. Research at a molecular level may identify the link, 
association or commonality between each cause. Such studies, as outlined in this thesis, 
are critical to gain the understanding for effective intervention of the condition. 
Hopefully, with more knowledge gained from on-going research, more focus could be 
put on the development of therapies to curtail the death, regenerate or restore function to 
these neurons and improve the quality of life for approximately 6.3 million sufferers 
worldwide (Baker and Graham, 2004).
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Molecular basis of Parkinson’s disease
Yan Xiang Yang3, Nicholas W. Woodb and David S. Latchman3,0
Parkinson’s disease is the second most common 
neurodegenerative disorder and remains incurable. 
Considerable progress has been made in understanding 
the molecular mechanisms of this disease, in particular, a 
distinct set of genes have emerged, whose dysfunctional 
regulation is strongly associated with the condition. These 
genes indude a-synudein, parkin, PTEN induced Putative 
Kinase 1 (PINKO, DJ-1, Leudne Rich Repeat Kinase 2 
(LRRK2) and ATP13A2. Here we discuss what has been 
leamt in the study of these genes and how these genes 
may contribute to the pathogenesis of Parkinson’s disease 
through different molecular pathways and consider how 
these pathways might converge to lead to the onset of 
Parkinson’s disease. NeuroReport 00:000-000 © 2009 
Wolters Kluwer Health | Lippincott Williams & Wilkins.
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Introduction
Parkinson’s disease is th e  second  m ost com m on neu ro ­
degenerative  d isorder a f te r  .A lzheim er’s disease. I t is 
pathologically charac terized  by th e  presence o f Lew y 
bodies and cell loss in various brain regions, in particu lar 
dopam inerg ic neurons in th e  substan tia  nigra pas 
com pacta  [1]. Lewy bodies are eosinophilic cytoplasm ic 
inclusions th a t have a fibrillar stru c tu re  and a dense core, 
su rro u n d ed  by a halo. T h e y  are often  associated w ith 
I x:\vy n eu ritc s .
T h e  average age o f on se t o f Parkinson’s disease is 
b e tw een  60 and 80 years, and about \% of the  general 
population  above th e  age o f 65 years is affected [2]. 
H owever, rare familial form s o f Parkinson’s disease, which 
account for less than  5% o f th e  Parkinson’s disease cases, 
may also occur, w ith  a m ore variable age o f onset 
d e p e n d in g  on th e  m ode o f inheritance , bu t generally at 
a younger average age o f below  45 years [3].
I linkage and positional cloning studies have led to the 
identification of six genes and four other genetic loci 
associated with familial Parkinson’s disease. A strong genetic 
evidence supporting a causal role for the following genes in 
familial Parkinson’s disease is available: a-synuclein (PARK/; 
PARKA), parkin (PARKA), phosphatase and tensin homologue 
(F IT N )-in d u cc d  putative kinase 1 [PT E N -induced kinase 1 
(P lN K l); PARK6], DJ-1 (PARK7), leucine-rich repeat 
kinase 2 [leucine-rich repeat kinase 2 (LRRK2); PARK#]), 
and more recently, ATP 13.A2 (PARK9) (Table 1).
T h e  discovery o f these  genes has aided th e  characterization 
of key factors and abnorm alities in the  protein pathways 
that lead to the neurological degeneration  in Parkinson’s
0959-4965 (g 2009 Wolters Kluwer Health | Lippincott Williams & Wilkins
disease. T h is review will focus on how the  study  of 
Parkinson’s disease associated proteins has allowed the 
elucidation of these pathways. T h e  genes involved are 
categorized on w h e th e r disease causation is by autosom al 
dom inant or recessive behavior. W ithin th ese  categories, 
th e  dysfunctions leading to Parkinson’s d isease have been  
characterized  by association to m echanistic  pathways; 
im pairm ent in the  u b iq u itin -d ep en d e n t proteasom al 
pathway, m itochondrial dysfunction , and, m ore recen tly  
described  the  degradative pathway, autophagy.
Autosomal dominant Parkinson’s disease
Autosomal dom inant Parkinson’s disease results from gain 
of function m utations that lead to the clinical m anifestation 
of Parkinsonism.
Alpha synudein (PARK1; PARK4)
Alpha synuciein  was the  first gene iden tified  to  be 
associated w ith Parkinson’s disease. Several a-synuclein  
m u ta tions, A53T, A30P, and E46K, w ere found to resu lt in 
familial Parkinson’s disease in several k indreds [4 j. M ore 
recently , genom ic duplications and trip lications w ere also 
discovered at the  a-synuclein  locus in fam ilies w ith 
autosom al-dom inant Parkinson’s disease. T h is  am plifica­
tion of the  a-synuclein  locus, although rarewas found to 
occur at a higher frequency  in p a tien ts  than  a-synuclein  
m uta tions. The severity’ and age of onse t o f Parkinson’s 
disease in these  pa tien ts  correlate w ith a-synucle in  copy 
num ber suggesting  a gene-dosage effect [5], T he exact 
function  o f a-synuclein  is still unknow n, although it is 
su sp ec ted  to be involved in the  regulation of neuro ­
tran sm itte r  vesicle function  at the  p resvnaptic  m em brane 
because o f its ability to bind and stabilize lipid bilavers 
and its apparen t en rich m en t in p resvnaptic term inals [6].
DOI: 10.1097/WNR.0b013e32831 c50df
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Table 1 Parkinson’s disease-associated genes
Locus Gene Inheritance Function Neuropathology Age of onset References
PARK1/4 SNCA (a-synucletn) Autosomal dominant Involved in synaptic 
function
Lewy bodies, Lewy neuntes; variable 
presence of glial inclusion, tau 
inclusion, and amyloid plaque
3 0-60 [41]
PARK2 Parkin Autosomal recessive E3 Ligase Lewy bodies reported in a single case -  30 [42]
PARK6 PINK1 Autosomal recessive Mitochondrial kinase Unknown 3 0 -5 0 [4]
PARK7 DJ 1 Autosomal recessive Involved in oxidative 
stress response
Unknown 20-40 [4]
PARK8 LRRK2 (dardarm) Autosomal dominant Protein kinase Vanable presence of Lewy body, 
Lewy neuntes, tau inclusion, and 
amyloid plague
4 0 -8 0 [4]
PARK9 ATP13A2 Autosomal recessive Possible ion pump Unknown < 2 0 [5]
In addition, a-synuclein also rescues from neurodegeneration 
in cysteine-string protein-ot knockout mice 14,6). As such it 
is believed  to be pro tective by m a in ta in in g  levels of 
co -chaperones, which m aintain th e  in te g rity  o f the  nerve 
term inals, and may have partial ac tion  in place of 
a synaptic co-chaperone, cy s te in e -s trin g  p ro te in -a .
T h e re  is consensus th a t any change in th e  levels o f 
a-synucle in  expression or th e  p rese n ce  o f m u ta tions in 
a-synuclein  has a toxic effec t on dopam inerg ic neurons. 
.Alpha synuciein  m onom ers in te ra c t, un d er certain  
c ircum stances, to form protofibrils or fibrillar (J-pleated 
sh ee ts , w hich has brought abou t m uch d e b a te  as to which 
configuration  is actually toxic. T h e  lead ing  suspect is 
though t to  be a-synuclein  p ro tofibrils because both the 
A 53T  and A30P m u tan ts prom ote protofibril formation, 
b u t only A 53T  prom oted  P -p lea ted  fibril formation 
in vitro [4], Phosphorylation o f a-sy n u c le in , especially at 
S er 129, is im portan t for th e  form ation o f fibrils, shown 
both  in vitro and in vko , using a D rosophila m odel and in 
brains o f p a tien ts  w ith  P ark insons d isease  and o ther 
re la ted  synucle inopath ies [4]. T oxicity  caused by the 
a-synuclein  protofibrils may involve th e  leakage of 
dopam ine from synaptic vesicles because o f perforation 
o f th e  vesicular m em branes by th e se  protofibrils [7J. T h is  
may account for th e  se lec tiv e  toxicity  o f a-synuclein in 
th e  dopam ine-p roducing  n eu rons o f th e  substan tia nigra. 
In con trast to  the  da ta  re la ting  to  protofibril-related 
toxicity, it is uncerta in  w h e th e r  a-synuclein fibrillar 
aggregates are actually toxic or p ro tec tive . T h e  form ation 
o f a-synucle in  aggregates was show n to be protective in 
Drosophila and parkin, a ub iqu itin  K3 ligase involved in the 
ub iqu itin -dependen t proteasom al protein degradation 
pathway, was shown both in vk'o and in vitro to enhance 
a-synuclein aggregation, which th en  resulted in reduction 
of its toxicity (4].
It is not clear w h e th e r  a -synucle in  is degraded th rough 
th e  ub iq u itin  proteasom al pathw ay [8], T h e  presence of 
proteasom al subun its  and u b iq u itin  in Lewy bodies in 
association w ith  a-synuclein , how ever, strongly supports  
its involvem ent in a-synuclein  pa thogen ic ity  (9). N ev e r­
the less, a-synuclein  may also be degraded  by an o th er
pathw ay -  chaperone-m ed iated  autophagy (CM A) 110J. 
It has also been  shown th a t disease-causing m u ta n ts  of 
a-synuclein , although localized by CM A chaperones to 
lvsosomes, rem ain bound  to  recep tors on th e  lvsosom es 
and are not in ternalized , thus blocking lysosomal function  
and preven ting  th e  clearance of o th e r  p ro te ins [101. 
M oreover, in a cell m odel, m acroautophagy was found to 
be up regu la ted  afte r im pairm ent o f CM A and ac ted  as 
a com pensatory ' pathw ay for pro tein  clearance; however, 
th ese  cells w ere nonetheless m ore sensitive to  oxidative 
stresses than  those w ith normal CM A function  [11]. 
M ore ev idence is accum ulating  for th e  pathogenic role 
o f im paired cellular autophagy leading to Park insons 
disease , including the  discovery’ o f m u ta tio n s in 
ATP13A2, which is im plicated  in PARK9.
LRRK2/dardarin {PARKS)
M utations in LRRK2 have been  found in a large num ber 
o f Parkinson’s d isease patien ts . T h e  G 2019S m u ta tion , in 
particular, was d e te c te d  in 5-6%  of autosom al dom inant 
familial Parkinson’s disease and 1-2% o f sporadic cases 
[4], T h is  prevalence was found to be even  higher for 
specific populations such as .Ashkenazi Jew s and N orth  
African Arabs [4].
LRRK2 is a large m ultidom ain  p ro te in  com prising, 
from th e  A -term inal, residues p red ic ted  to adopt the  
configuration  o f arm adillo repeats and ankyrin repeats 
[ 12], a leucine-rich  repeat dom ain, a R oc-G T Pasc dom ain 
and 6 -te rm in a l o f Ras dom ain, a kinase dom ain sim ilar to 
bo th  the  recep to r-in terac ting  p ro tein  kinase and th a t of 
th e  tyrosine kinase-like subfamily, and a 6 -te rm ina l 
W D 40 dom ain 112]. T h e  presence o f m u ltip le  p rotein  
in te raction  and catalytic dom ains in LRRK2 highlights its 
ce llu lar im portance and postu la tes its role as a hub  for 
m u ltip ro te in  signaling.
Pathogenic m uta tions sc a tte r  th roughou t all functional 
dom ains o f LRRK2 |13J. T h e  predom inance o f the 
G 2019S m uta tion  in Parkinson’s d isease p a tien ts  has, 
however, led it becom e th e  main focal po in t o f research 
in to  LRRK2’s role in Parkinson’s disease. T h e  LRRK2 
G 2019S m uta tion  is s itu a ted  in a highly conserved DYG
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m o tif o f th e  kinase dom ain. T h is  m u ta tion  resu lts  in 
a two-fold to th ree-fo ld  increase in th e  k inase activ ity  of 
LRRK2, th u s im plicating  a gain o f function  in its 
pathogenic m echanism  (14]. Several s tu d ies  show ed tha t 
th e  kinase activ ity  o f th e  m u tan t LRRK2 was responsib le 
for neuronal toxicity, and th a t this, in tu rn , was likely 
d e p e n d e n t on th e  activ ity  o f its G T P ase Roc dom ain 
.V-terminal to  th e  k inase dom ain (14). It was shown, 
using  m u ta tions in th e  Roc dom ain, th a t th e  b in d in g  of 
G T P  to th is dom ain  regulates th e  k inase ac tiv ity  of 
LRRK2 as well as its phosphorylation by o th e r  kinases 
(1 5 |. Furtherm ore, the  lack of deletions or truncations of 
LRRK2, as well as the  autosomal dom inant p a tte rn  of 
inheritance, also point toward a gain-of-function pathology.
T h e  cellu lar function  of LRRK2 is still unknow n. It is 
essen tia lly  a cytoplasm ic pro tein  th a t may associa te  w ith 
in tracellu la r m em branes, such as the  o u te r  m itochondria  
m em brane, Golgi apparatus, and endop lasm ic re ticu lum  
(14). A lthough LRRK2 is not found to  in te rac t w ith 
e i th e r  a-synuclein  or tau, th e  id en tifica tio n  of 
a-synuclein -positive Lewy body pathology or tau-positive 
neurofibrillary tangle pathology in LRR K2 p a tien ts  
suggests a possible com m on role o f  LRRK2 in the  
phosphorylation and processing o f th e se  tw o proteins 
(16]. M ore recently, LRRK2 was show n to be 
a phosphory late m oesin as well as ez rin  and  radixin at 
a previously know n phosphorylation  s ite  encom passing 
T h f ° K (17]. T h e  phosphorylation o f th is  site  regulated 
th e  b ind ing  o f m oesin to  actin . T h e  G T P ase , 6 -term inal 
o f Roc, and  kinase dom ains as well as th e  W I>40 m otif and 
6 ’-te rm ina l tail o f LRRK2 w ere all found to  be essential 
for th is phosphory lation  (18].
Autosomal recessive Parkinson’s disease
Autosomal recessive Parkinsons disease (ARPD) occurs 
when both alleles o f a gene are m utated  resulting in the 
clinical manifestation o f Parkinsonism. DJ-1, parkin, P lN K l, 
and ATP13A2 are all associated with early onset ARPD and, 
interestingly, also all are linked to mitochondrial function.
Parkin (PARK2)
Kitada and colleagues (18] w ere the  first to find 
m uta tions in th e  parkin gene  in Japanese  ARPD fam ilies. 
Parkin was th en  found to  be th e  m ost com mon cause of 
early onse t A RPD , accoun ting  for alm ost 50% of cases (4 |.
Parkin is a 465 am ino acid F 2 -d e p e n d e n t E3 ub iqu itin  
ligase consisting  of an u b iq u itin -lik e  domain at th e  
A’-te rm in u s  and two really in te re s tin g  new  gene dom ains 
separated  by a linker region at th e  6 -te rm in u s  (4]. T h e  
main cellu lar role o f parkin is to  u b iq u itin a te  p ro teins, 
ta rge ting  th em  for proteasom al degradation. M ore 
recently, parkin has also been found to m ediate K63-linked 
polyubiquitination that targets the ubiqu itinated  protein 
for clearance by autophagy7 [19]. T h ere fo re , deregu lation
of parkin may lead to  dysfunction  of bo th  ub iqu itin  
proteasom al and autophagy pathways.
In contrast to  o the r forms of Parkinson’s disease, Ix w y  
bodies are typically not found in parkin-related Parkinson’s 
disease (4). N evertheless, relatively few postm ortem  
stud ies have been perform ed in parkin-related Parkinson’s 
disease to substan tia te  this assertion. A variety  of 
hom ozygous and com pound heterozygous m uta tions 
causing rearrangem ents and m issense m u ta tions in the  
parkin gene have been  found (4 |. O f these , m issense 
m uta tions w ere mainly found w ith in  th e  parkin 
6 -te rm in a l, really in te restin g  new  gene finger dom ain. 
M ost o f these  m uta tions w ere found to e i th e r  im pair its 
b ind ing  to pu ta tive substra tes  or render its ligase activity  
defective , thus resu lting  in loss-of-function (20]. T h is  
loss-of-function m echanism  is postu la ted  to  lead to 
neurodegeneration  and resu lt in Parkinson’s d isease w ith 
a lack o f Lewy bodies (4]. In one case, however, Lewy 
bodies w ere p resen t in a Parkinson’s d isease brain 
because o f com pound heterozvgote m uta tions th a t 
reduced  b u t did not abolish the  parkin activ ity  (4].
S tudies o f parkin knockout mice have suggested that parkin 
loss-of-function may lead to mitochondrial dysfunction and 
oxidative stress (4]. Parkin knockout mice have been shown 
to develop mitochondrial deficits (4] and parkin knockdown 
in cell lines renders cells more vulnerable to oxidative stress 
(21]. Parkins ubiquitin ligase activity was also shown to be 
modified by nitric oxide-m ediated oxidative stress, and
S-nitrosvlated parkin was found in insoluble inclusions in 
Parkinson’s disease brains [4,22]. Dopamine, another possible 
oxidative stressor especially in dopaminergic neurons, was 
shown to convalentlv modify7 parkin, resulting in the loss of 
its activity (22]. O ur laboratory7 has previously shown that 
endogenous parkin localizes to aggregates after exposure to 
dopam ine in neuroblastoma cells [23], Furthermore, oxidative 
stresses such as dopam ine and l-m ethvl-4-phenylpyridinium 
(M PP +  ) were shown to transcriptionally upregulate parkin 
in vitro [24]. Parkin-associated endothelin-receptor-like 
receptor, an endoplasmic reticulum-associated substrate of 
parkin, was found to be aggregated when overexpressed, 
leading to endoplasmic reticulum-stress and dopaminergic 
neuronal cell death [25]. T his was shown to be alleviated by 
the overexpression of parkin [25] and, interestingly, also by 
the introduction of dopam ine synthesis inhibitor [26], 
strongly implicating dopam ine’s involvement in the 
aggregation process. 'Diercfore, parkin may play an important 
role in cell protection against oxidative stresses.
PTEN-induced kinase 1 (PARK6)
P lN K l was first identified in cancer cell expression profile 
experim ents and was shown to be transcriptionally activated 
by P TE N , thus its name PTEN -induced kinase 1 [4]. 
M u ta tions in P lN K l w ere su b seq u en tly  discovered in 
th ree  large consanguineous fam ilies w ith  A R PD  -  one
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Spanish and two Italian [27]. P lN K l is an eigh t-exon  
gene th a t encodes for a 581 am ino  acid long protein . 
T h ro u g h  seq u en ce  com parisons w ith  o th e r  p roteins, it 
was found to  consist o f an A -term ina l m itochondrial 
ta rge ting  m otif, a 6 -term inal au to regu lato ry  dom ain and a 
highly conserved serin e /th reo n in e  k inase dom ain [4,27]. 
Recently, th is has been  corroborated  using  a baculovirus- 
in fec ted  insect cell system  show ing th a t P lN K l prefer­
en tially  phosphory lates se rin e /th reo n in e  residues on basic 
su b stra tes  com pared  w ith acidic su b tra te s , and not 
tyrosine residues [28]. T h is  phosphory lation  was further 
show n to  be regulated  and se le c te d  by P IN K l’s
6 -te rm in a l dom ain  [28].
Several m u ta tio n s  of the  P lN K l g en e  have been  found 
th a t are m ostly  d is trib u ted  around th e  kinase dom ain 
[4 ,27,29]. As such, d isruption  o f k inase ac tiv ity  is deem ed  
to  be  th e  m ost probable d isease m echanism . Som e 
stu d ies , using  th e  m easure o f m itochondria l m em brane 
p o ten tia ls , have been  perform ed, w hich  suggest th a t th e  
loss o f P lN K l function  adversely a ffec ts  m itochondrial 
function  the reby  also increases ce llu lar suscep tib ility  to 
stress [27]. M ore defin itive  s tu d ie s , however, have yet 
been  perform ed to support th is hypo thesis . N onethe less, 
th e  iden tifica tion  o f T N F  recep to r-assoc ia ted  pro tein  1 
(TR A P1) (also know n as h ea t shock  pro tein  75) as 
a substra te  o f P lN K l, O m i/H trA 2  as an in teractor w ith 
P lN K l, as well as th e ir  association  w ith  m itochondrial 
p ro tec tio n  s tren g th en s th e  above hypo thesis.
'I'R A Pl is a mitochondrial molecular chaperone associated 
with an antiapoptotic function preventing oxidative-stress- 
induccd mitochondrial cytochrome c release. T h is protective 
function was found to be dependent on T R A P l’s phosphor­
ylation by' P lN K l [30]. Pathogenic P lN K l mutations such as 
G309I), IA47R and W437X were shown to have an impaired 
phosphorylation ability on TRAP1 [30].
Omi/Htr.A2 is a m itochondrial, an tiapopto tic , serine 
p ro tease. It was show n th a t phosphorylation of O m i/ 
HtrA2 du ring  stress m o d u la ted  its proteolytic activity and 
th a t th is p38 p a th w ay -m ed ia ted  phosphorylation was 
d e p e n d e n t upon th e  p rese n ce  o f P lN K l [31]. T h is  was 
especially  show ed w hen  brains o f Parkinson’s d isease 
p a tien ts  w ith P lN K l m u ta tio n s  w ere found to have less 
phosphory lated  O m i/H trA 2 com pared  w ith idiopathic 
p a tien ts . IT e  d irect in te rac tio n  betw een  P lN K l and 
O m i/H trA 2, however, has no t b een  shown [31].
O n account of the association o f P lN K l and its interactors 
and DJ-1 w ith the  m itochondria, this strengthened the 
hypothesis that m itochondrial dysfunction may play a role 
in Parkinson’s disease pathogenesis. T h is  idea, although 
having been  around for som e tim e because of 
post-m ortem  stud ies  show ing m itochondrial im pairm ent 
and oxidative dam age, was overshadow ed by ano ther
theory' given rise by a-synuclein  and parkin, 
w hich focused on pro tein  aggregation and proteasom al 
dysfunction  [4]. T h e  findings tha t th e  ph en o ty p es in 
D rosophila w ith  P lN K l loss-of-function m uta tion  could 
be rescued  by using transgenic expression o f Parkin, thus 
show ing th a t Parkin and P lN K l may act in a com m on 
pathway, have show n th a t the  two theories m ight, in fact, 
act to g e th er in th e  pathogenesis o f Parkinson’s disease 
[32,33]. Both P lN K l and parkin m u ta n t D rosophila 
m odels have sim ilar pheno types -  m ale sterility, m uscle 
and dopam inergic neuronal degeneration , and increased 
sensitiv ity  to oxidative stresses. F urtherm ore, double 
knockouts o f bo th  genes resu lted  in an identical 
pheno type to th e  single m u tan ts  suggesting  a linear 
rela tionsh ip  b e tw een  th em  [32,33]. Parkin has been  
suggested  to  act dow nstream  from P lN K l in this
pathway, as som e o f th e  d isease ph en o ty p es seen  in
P lN K l knockdow n D rosophila m odels could be rescued  
by th e  in troduction  of bo th  w ild-type D rosophila parkin 
and hum an parkin b u t not vice versa [33]. Interestingly , 
overexpressing parkin could restore normal m itochondrial 
morphology, D N A  and pro tein  c o n ten t, bu t did
no t alleviate th e  P lN K l m u tan t D rosophila from its
sensitiv ity  to  stressors, suggesting  th a t th e  pathway 
involving P lN K l and parkin may only be involved in 
th e  m ain tenance o f m itochondrial in teg rity  [32]. T h e  
relevance o f the  D rosophila m odel to Parkinson’s disease 
was questionab le  as P lN K l knockout m ice failed to 
display any nigrostriatal neu rodegeneration  [34], 
however, Kxner et al. [35] later show ed, using hum an cell 
lines including prim ary cell lines from p a tien ts  w ith two 
d iffe ren t P lN K l m utations, th a t P lN K l knockout 
or m u ta tion  resu lted  in m itochondrial m orphology 
abnorm alities th a t could only be reverted  by enhanced  
expression of parkin or th e  re in troduc tion  o f w ild-tvpe 
P lN K l. After this discovery that P lN K l and parkin act 
through the same pathway, it would be especially interesting 
to identify substrates that, when phosphorylated by P lN K l 
in the  mitochondria, lead to the regulation o f parkin, which 
predominantly resides in the cytoplasm.
DJ-1 (PARK7)
Parkinson’s d isease causing DJ-1 m uta tions is rare and 
accoun t for only about 1-2% of early onse t A RPD  cases. 
Its cellu lar and subcellular localization is unclear, b u t it 
has been  show n to be en riched  in the  brain and peripheral 
tissues and is primarily cytoplasm ically localized, w ith 
a small pool associated w ith th e  m itochondria [36]. DJ-1 
is a m em ber of the  T H iJ /P fp l/D Jl superfam ily  and is 
th o u g h t to be involved in th e  oxidative stress response by 
ac ting  as a redox -dependen t chaperone [37]. It is capable 
o f such a role because o f the  presence o f sev eral cyste ine  
residues, which undergo an acidic sh ift in p i value w hen 
exposed  to reactive oxidative species, thus po ten tia lly  
m opping  them  up [4,29], As the quenching ability of DJ-1 
is modest, however, it is suspected that o ther pathways are 
involved, of which much evidence points toward the
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involvement of regulation of apoptosls through the phos- 
phoinositide-3 kinase -  AKT pathway [4,6]. This hypothesis 
is supported by evidence showing that RNAi knockdown of 
DJ-1 a  in Drosophila increased its sensitivity to oxidative 
stress that was reduced with increased PI3K/Akt-signaling 
capacity [6]. T he mechanism of interaction between DJ-1 
and the PI3K/Akt pathway, however, remains unknown.
ATP13A2 (PARK9)
ATP13A2 encodes for a m em ber of the P s-ATPases of the 
P-type ATPase superfamily. P-type ATPases generally 
make use of ATP to maintain an ion gradient across the 
cell m em brane. As each step  in this process is reversible, 
they, in turn, use the m em brane po tential to produce 
ATP [38]. T h e  substrate specificities and functions of 
the P.s-ATPases are still relatively unknow n, bu t because 
of the ir close homology to P r ATPases and P4-ATPases,
they are most probably ion pumps. It has been shown that 
ATP13A2 is expressed in most tissues in mice, but is 
especially abundant in the brain [39]. M utations in 
ATP13A2 have been identified recently as the  underlying 
cause of an autosomal recessive form of early onset 
parkinsonism with pyramidal degeneration and dem entia, 
Kufor-Rakeb syndrome [40]. Much is unknown about 
how these loss-of-function m utations lead to the genesis 
of this parkinsonian syndrome and w hether there is any 
interaction between this protein and the other Parkinson’s 
disease-associated genes. In-vitro models, however, have 
shown that, although wild-type ATP13A2 is localized to the 
lvsosomes, the m utated proteins were retained in the 
endoplasmic reticulum and degraded by the proteasome 
[40], it is suspected that an overload of such retained 
proteins may thus lead to neurodegeneration as seen in 
Kufor-Rakeb syndrome because of proteasomal dysfunc­
tion. Another theory is that such loss of functional
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ATP13A2 from the  lvsosomes may lead to lysosomal 
dysfunction, which may, in turn , im pair cellular autophagy. 
Currently, there  is increasing evidence in th e  im portance of 
autophagy im pairm ent in Parkinson’s disease.
Afterword
Parkinson’s disease involves multiple causations that lead to 
a very’ similar outcom e -  death of dopam inergic neurons. 
Research at a molecular level may identify' the link, 
association, or commonality betw een each cause. Such 
studies, as outlined above, are critical to  gain the  better 
understanding of the disease. Several potential pathways 
have been now uncovered -  ubiquitin proteasomal dysfunc­
tion pathw ay mitochondrial dysfunction pathway, and the 
autophagy im pairm ent pathway' (Fig. 1), each of that reveals 
a little more on the intricacies involved in the  interactions 
am ong the  known Parkinson’s disease-associated genes, the 
environm ent, and cellular functions.
In the  short-term  future, delinea ting  th e  functions of all 
these  Parkinson’s disease-associated genes and identifying 
their substra tes are of u tm ost im portance in getting  
a clearer p ic ture as well as to enable us to  fill in the  gaps 
currently  p resen t in the pathways.
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Abstract
Following a mutation screen of NR4A2 (also known as NURR1) in 409 Parkinson’s 
disease (PD) patients we identified a novel single base substitution in the 5’UTR of 
the gene (C.-309OT). Several mutations of the NR4A2 5’UTR have been previously 
described in PD, but pathogenecity remains controversial, partly due to low 
prevalence and partly due to a lack of functional data in human central nervous tissue. 
Here, we provide in vitro and in vivo expression data on the C.-309OT mutation. In 
vitro data on NR4A2 expression and the transactivation of downstream targets was 
corroborated, respectively, by allele specific real-time PCR from brain tissue and the 
assessment for enrichment of functional categories by modelling the hypergeometric 
distributions of data from a whole genome expression study. We also provide 
evidence from in vitro studies that show the C.-309OT mutation increases neuronal 
vulnerability to stress.
Our findings indicate the c.-309C>T mutation reduces NR4A2 expression resulting in 
the downregulation of genes involved in the development and maintenance of the 
nervous system and synaptic transmission. These downregulated pathways contained 
genes known to be transactivated by NR4A2 and were not disrupted in idiopathic PD 
brain suggesting causality of the c.-309C>T mutation in that patients parkinsonism.
EGR regulation of a-synuclein
Early growth response family of transcription factors 
mediate a-synuclein promoter up-regulation in response to 
oxidative stress
Yan Xiang Yang,1 David S. Latchman1,2
7Medical Molecular Biology Unit, Institute o f Child Health, University College 
London, London, WC1N I EH, U. K.; 2Birkbeck College, University o f London, 
London WC1E 7HX, U. K.
Correspondence: Yan Xiang Yang (yyang@ich.ucl.ac.uk)
EGR regulation of a-synuclein
Abstract
Parkinson’s disease is a highly prevalent neurodegenerative disorder. Several factors 
may contribute to its onset, including: susceptibility genes, environmental stress and 
aging, a-synuclein is one of several genes shown to be mutated in cases of familial 
Parkinson’s disease It has also been suggested that variations in the expression of the 
wild type genes may also lead to Parkinson’s disease. We show that a-synuclein is 
up-regulated when neuroblastoma cells were exposed to stresses such as dopamine 
and l-methyl-4-phenylpyridinium (MPP+). Moreover, we identify a novel interaction 
between the a-synuclein promoter and dopamine-induced early growth response 
transcription factor family members in these oxidative stress conditions. This work 
confirms and extends previous reports that oxidative stresses are implicated in 
Parkinson’s disease, and enhances our understanding of the effect of oxidative stress 
on a Parkinson’s disease-associated gene.
